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General introduction
Magnesium (Mg2+), a ubiquitous ion in nature, is a crucial mineral in the human body. 
The blood Mg2+ concentration is closely regulated by several transport systems, and 
abnormal concentrations of Mg2+ are associated with numerous diseases. Conversely, 
various disorders can result in abnormal Mg2+ concentrations. This thesis focuses 
on Mg2+ in type 2 diabetes mellitus (T2D).  
Body magnesium homeostasis
Blood Mg2+ levels are maintained within the physiological range between 0.70 and 
1.05 mmol/L (1). Only 1% of the body’s Mg2+ is present in the circulating blood, while 
46% is stored in soft tissue and 53% in bone (2).  In blood, 27% of Mg2+ is bound to 
albumin, 8% to anions and 65% is ionized, which is the biologically active form of 
Mg2+ (3). Measurement of the blood Mg2+ concentration is the quickest and least 
invasive method of determining a patient’s Mg2+ status and is widely used in clinical 
practice.
 Hypomagnesemia (blood Mg2+ <0.7 mmol/L) can be a result of insufficient 
dietary intake, malabsorption in the intestine or excessive urinary Mg2+ loss (Figure 1) (4). 
Foods containing high amounts of Mg2+ include green leaf vegetables, grains, nuts, 
seeds and fish, whereas the Mg2+ content of processed foods is low (5). As the 
Western diet contains high amounts of processed foods and less unrefined grains 
and fresh vegetables dietary intake of Mg2+ in developed countries is reduced (6). 
Several oral Mg2+ supplementations are available to increase blood Mg2+ levels, but 
their effectiveness is hindered by the fact that high dose oral Mg2+ can result in 
diarrhea (7). Mg-citrate was found to be one of the most bioavailable Mg2+ 
preparations, while Mg-oxide is poorly reabsorbed (8, 9). Acute hypomagnesemia 
can also be treated by intravenous administration of a Mg-sulfate solution.
 Three organs, namely the intestines, kidneys and bones, are involved in the 
regulation of the body’s Mg2+ balance (6). The intestines regulate dietary Mg2+ uptake, 
the kidneys adjust the urinary excretion and the bones serve as dynamic storage 
compartments.
Physiological regulation of blood magnesium levels
Intestines 
Approximately 30% of the variation in blood Mg2+ levels can be explained by dietary 
intake (10). Only 30-50% of dietary Mg2+ intake is absorbed in the intestines, which 
can vary based on the dietary Mg2+ availability (11, 12). Major causes for intestinal 
Mg2+ loss are the use of proton pump inhibitors or diarrhea, which can be caused by 
metformin use or diabetic neuropathy (4, 13-15). When dietary Mg2+ is high, the bulk 
of Mg2+ absorption takes place in the small intestine via the paracellular route by tight 
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junction proteins, known as claudins (16). The rate of absorption in this segment is 
determined by the luminal concentration of Mg2+ (16). Little is known regarding the 
exact mechanisms and proteins involved in the transport of Mg2+ in this segment. 
Transcellular Mg2+ absorption takes place in the distal colon via the apical divalent 
cation channels transient receptor potential melastatin 6 and 7 (TRPM6 and TRPM7) 
and the basolateral transporter cyclin M4 (CNNM4) (17, 18). Intestine-specific Trpm6 
knockout mice develop severe hypomagnesemia, highlighting the essential role of 
colonic Trpm6 in maintaining the body’s Mg2+ homeostasis (19).
Kidneys
The kidneys are the key regulators of the body’s Mg2+ homeostasis, as they can 
adjust the urinary excretion of Mg2+ based on changes in the blood Mg2+ 
concentration (20, 21). Each day the kidneys filter 2.4 g of Mg2+, equivalent to 10% of 
Figure 1 | Causes of hypomagnesemia
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the total body Mg2+ content (6). Approximately 95% (2.4 g) of the filtered Mg2+ is 
reabsorbed, resulting in a total daily urinary excretion of 100 mg Mg2+ (22). Therefore, 
minor defects in renal Mg2+ reabsorption can already have large consequences on 
the body’s Mg2+ balance.
  In the proximal tubule, 10-25% of filtered Mg2+ is reabsorbed (23, 24). The 
reabsorption in this segment takes place via passive paracellular transport and is 
dependent on the active reabsorption of sodium (Na+) salts and water (25, 26). Mg2+ 
reabsorption in the proximal tubule is increased when the osmolality or the Mg2+ 
concentration of the pro-urine rises (27). Downstream nephron segments can 
compensate for insufficient Mg2+ reabsorption in the proximal tubule. Therefore, 
changes in the reabsorption of Mg2+ in the proximal tubule do, in general, not affect 
the final urinary Mg2+ excretion. 
  The bulk of Mg2+ reabsorption in the nephron takes place in the thick ascending 
limb of Henle’s loop (TAL, 55-70%) (28, 29). Also in this segment the reabsorption 
takes place via the paracellular route, facilitated by cation-specific tight junction 
proteins known as claudin 16 (CLDN16) and 19 (CLDN19) (30, 31). On the other hand, 
Mg2+ reabsorption in the TAL is negatively regulated by claudin 10 (CLDN10), as 
deletions in CLDN10 result in hypermagnesemia (32). The transepithelial voltage 
gradient required for the paracellular transport of Mg2+ in the TAL is achieved by the 
activity of the Na-K-2Cl cotransporter 2 (NKCC2), which reabsorbs one molecule of 
Na+ and potassium (K+) and two molecules of chloride (Cl-) transcellular. 
  Fine-tuning of urinary Mg2+ excretion takes place in the distal convoluted tubule 
(DCT, 5-10%), the final tubular segment where Mg2+ can be reabsorbed, as the 
connecting tubule (CNT) and collecting duct (CD) are impermeable for Mg2+ (28, 33). 
In the DCT, Mg2+ is transported transcellularly via TRPM6 (34, 35). Reabsorption of 
Mg2+ by TRPM6 is dependent on the apical thiazide-sensitive sodium-chloride 
cotransporter (NCC), encoded by the gene SLC12A3 (36). This is emphasized by the 
fact that hypomagnesemia is one of the main side effects of thiazide diuretics (37). 
Moreover, loss-of-function mutations in SLC12A3 or genes regulating NCC activity 
(Gitelman syndrome) also cause hypomagnesemia (22, 38, 39). In which manner 
Na+ reabsorption via NCC contributes to TRPM6-mediated Mg2+ uptake remains to 
be elucidated. Mutations in TRPM6 lead to the recessive autosomal disease known 
as familial hypomagnesemia with secondary hypocalcemia (HSH). This disease is 
characterized by extreme hypomagnesemia (serum Mg2+ 0.1-0.3 mmol/L), 
underlining the critical importance of the DCT in Mg2+ homeostasis (17, 40). TRPM6 
mRNA expression, membrane trafficking and activity are strongly regulated by 
several mechanisms, including epidermal growth factor (EGF), intracellular ATP 
levels and blood Mg2+ levels (6, 41, 42). Moreover, the activity of both TRPM6 and 
NCC is stimulated by insulin, but the exact mechanism and physiological relevance 
remain largely unknown (43, 44).
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Hypomagnesemia in disease
A mild hypomagnesemia (blood Mg2+ 0.5-0.7 mmol/L) can result in symptoms such 
as fatigue, muscle ache and headache (45). As these complaints are aspecific, it is 
often difficult for physicians to attribute them to reduced blood Mg2+ levels. Therefore, 
hypomagnesemia is often overlooked in the clinic. The complications of hypo-
magnesemia get more pronounced in the case of severe hypomagnesemia (blood Mg2+ 
<0.5 mmol/L), where dangerous manifestations can arise including tetany, seizures, 
depression, cardiac arrhythmia, coma and potentially death (22). In the clinic, Mg2+ 
deficiencies are frequently observed in patients with metabolic disorders such as the 
metabolic syndrome and T2D (46, 47). 
Type 2 diabetes
Diabetes, defined as a chronically elevated blood glucose concentration, is a global 
pandemic, with an estimated 422 million adults suffering from diabetes in 2014 (48). 
Since 1980 the prevalence of diabetes in adults has risen from 4.7% to 8.5% (49). 
T2D, also known as non-insulin-dependent diabetes, consists of the large majority 
(± 90%) of diabetes cases (49, 50). In T2D, the pancreatic β-cells can no longer meet 
the increased demand for insulin due to insulin resistance, resulting in increased 
blood glucose levels. The major risk factors for T2D include obesity, sedentary 
lifestyle, on top of genetic susceptibility. The therapy of T2D consists of lifestyle 
changes, medication, of which metformin is the first-line treatment, and if necessary, 
insulin is added (51). Severe complications can occur when blood glucose levels 
remain poorly regulated. Cardiovascular disease, including hypertension, stroke, 
heart failure and coronary artery disease, is one of the major complications in T2D 
(52). Moreover, microvascular defects can lead to food ulcers, blindness and diabetic 
neuropathy. Neuronal dysfunction can hamper the enteric nervous system resulting 
in obstipation or diarrhea. Diabetic nephropathy is the main cause of end-stage renal 
disease (ESRD) in the developed world (53). These complications need specific 
individual treatments, making polypharmacy and drug-drug interactions a huge 
issue in the treatment of T2D (54). 
Hypomagnesemia in type 2 diabetes  
Hypomagnesemia is a common phenomenon in T2D patients, but remains poorly 
recognized in the clinics. The first study that suggested a relationship between Mg2+ 
and T2D stems from the 1920s, in which electrolyte changes in response to insulin 
usage and diabetic keto-acidosis were investigated (55). The direct reduction in 
serum Mg2+ and potassium (K+) in response to insulin was discovered in the 1940s 
(56). In this article the authors advise Mg2+ salt supplementation when treating 
diabetes (57). The high prevalence of hypomagnesemia in diabetes patients first 
came to light in a cohort published in 1979, involving 582 diabetes patients and 140 
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control subjects (58). After this initial cohort study, more cohort studies showed 
hypomagnesemia specifically in T2D patients, with prevalence numbers ranging 
from 11% to 65% (Table 1). It remains unclear if hypomagnesemia is a cause or a 
consequence of T2D (59). Importantly, the definition of hypomagnesemia differs 
substantially among these population studies.
Table 1 | Prevalence of hypomagnesemia in cohorts of diabetes patients
First author Year Hypomagnesemia 
prevalence
Definition of 
hypomagnesemia
Patient population
Mather  
et al. (58)
1979 25% Plasma Mg2+  
<0.69 mmol/L
582 Diabetes patients
McNair  
et al. (60)
1982 39% Serum Mg2+ 
<normal mean 
minus 2x SD
215 Insulin-treated 
diabetic outpatients
De Lordes Lima 
et al. (61)
1998 48% Plasma Mg2+  
<0.70 mmol/L
128 T2D patients
Wälti  
et al. (62)
2003 38% Undefined 109 T2D patients
Corica  
et al. (46)
2006 49% Serum ionized Mg2+ 
<0.46 mmol/L
290 T2D patients
Dasgupta  
et al. (63)
2012 11% Serum Mg2+  
<0.66 mmol/L
150 Non-critically ill T2D 
patients
Rasheed  
et al. (64)
2012 65% Serum Mg2+  
<0.70 mmol/L
219 Diabetes patients 
between 40-60 years old
Peters  
et al. (65)
2013 19% Serum Mg2+  
<0.70 mmol/L
920 Non-insulin-treated 
T2D patients
Ramadass  
et al. (66)
2015 62% Serum Mg2+  
<0.74 mmol/L
50 T2D patients in  
tertiary care
Umer Siddiqui  
et al. (67)
2016 36% Serum Mg2+  
<0.60 mmol/L
323 Uncontrolled T2D 
patients on oral 
hypoglycemic agents
Odusan  
et al. (68)
2017 23% Serum Mg2+  
<0.66 mmol/L
125 T2D patients, of 
which 62 with hypertension
Pokharel  
et al. (69)
2017 50% Serum Mg2+  
<0.70 mmol/L
150 T2D patients
When only ‘diabetes’ is mentioned, the article does not discriminate between types of diabetes.
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Cause-effect relationship between hypomagnesemia and  
type 2 diabetes
From Table 1 it is clear that hypomagnesemia is a prominent issue in T2D patients. 
However, to better understand its clinical relevance, it is essential to understand 
the etiology of hypomagnesemia in T2D. The major question that arises is whether 
hypomagnesemia is merely a consequence of T2D, or if hypomagnesemia also 
contributes to the onset and development of T2D. The arguments for either side will 
be further elaborated in the following paragraphs.
Type 2 diabetes affects magnesium homeostasis
T2D has been shown to be an independent risk factor for hypomagnesemia (70). 
Besides the poor dietary habits of many T2D patients reducing their Mg2+ intake, 
several other mechanisms have been hypothesized on how T2D-related factors can 
induce hypomagnesemia (71). Firstly, high-dose insulin shots shift Mg2+ from the 
blood towards the intracellular compartment, thereby inducing a short-term decrease 
in the blood Mg2+ concentration (72-74). This is illustrated by the occurrence of a 
severe hypomagnesemia in a patient who took an insulin overdose (74). Secondly, 
other commonly used medications in T2D patients are known to cause hypo-
magnesemia, such as proton pump inhibitors (PPIs) and thiazides (6). Thirdly, as 
insulin stimulates TRPM6 activity, chronic insulin resistance can cause a reduction in 
renal and intestinal Mg2+ (re)absorption (75). Fourthly, metformin medication and 
diabetic neuropathy can cause diarrhea, leading to intestinal malabsorption (15, 
76-78). Lastly, severe glucosuria and osmotic diuresis are hypothesized to result in 
renal Mg2+ loss (71). However, this hypothesis is in contradiction with the fact that 
SGLT2 inhibitors cause massive glucosuria and osmotic diuresis, but lead to an 
increase in blood Mg2+ levels (79). The contribution of each of these factors towards 
a decrease in blood Mg2+ levels, or if there are other unknown mechanisms that alter 
blood Mg2+, remains unclear. 
Hypomagnesemia as a risk factor for the development of 
type 2 diabetes
Hypomagnesemia may also be a causative factor for T2D. In large population studies, 
lower serum Mg2+ levels have been shown to increase the risk of developing 
pre-diabetes and T2D (80, 81). This increased risk is partially mediated through 
insulin resistance and may be conveyed by SNPs in important Mg2+-regulating 
genes (80). Moreover, reduced Mg2+ levels are an independent predictor for the 
development of ESRD in diabetic nephropathy and are associated with albuminuria, 
a marker of renal damage (82, 83) In contrast, higher dietary Mg2+ intake improves 
glucose and insulin metabolism and reduces the risk to develop T2D (84-87). 
Elevating dietary Mg2+ intake could be an attractive method of reducing T2D 
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incidence in the general population. Oral Mg2+ supplementation has been shown to 
be a promising and low-priced treatment strategy for improving insulin sensitivity, 
β-cell function, metabolic control and lipid profile in T2D patients (88-91). However, 
the number of patients included in the clinical trials studying the beneficial effects of 
oral Mg2+ homeostasis on T2D-related parameters is limited, and the outcomes are 
contradicting (Table 2). In most studies no increase of blood Mg2+ levels by the sup-
plementation was realized. Most of the beneficial effects are achieved in the trials 
enrolling hypomagnesemic patients and in which an increase in blood Mg2+ levels by 
the oral Mg2+ supplementation is realized (Table 2). The effect of dietary Mg2+ on the 
risk for developing T2D, and the consequences of dietary Mg2+ on metabolism and 
energy homeostasis remain unknown.
The role of magnesium in energy metabolism
These data implicate that a reduced dietary Mg2+ intake and lower blood Mg2+ levels 
could contribute to the development of T2D and its related complications. Moreover, 
Mg2+ supplementation potentially reduces the chance of developing T2D (Table 2). 
Little is known regarding the underlying molecular mechanism by which Mg2+ could 
influence glucose and energy homeostasis, which could contribute to T2D 
progression.  However, a potential role for Mg2+ has been implicated in the regulation 
of glucose concentrations, insulin signaling and secretion, mitochondrial function 
and lipid metabolism.
Glucose homeostasis
Mg2+ plays an important role in the regulation of blood glucose levels. The enzymes 
in the glycolysis pathway require MgATP2- to function. Hexokinase, glucokinase, 
phosphofructokinase, and pyruvate kinase are the four main regulatory enzymes of 
the glycolysis pathway and require MgATP2-. The Km value for Mg2+ of some these 
glycolytic enzymes fall into the physiological range.
 Hexokinase, the enzyme performing the first step in glycolysis, has a Km for 
Mg2+ at 1.0-2.3 mmol/L and for MgATP2- at 1-2 mmol/L (108). Pyruvate kinase, 
catalyzing the last step in glycolysis, requires one K+ and two Mg2+ ions for its 
catalytic function and has a Km for Mg2+ of 1 mmol/L (108-110). However, in isolated 
human erythrocytes only extremely low intracellular Mg2+ levels (<0.2 mmol/L) 
negatively affect glycolysis rate. How a mild hypomagnesemia affects glycolysis rate 
or the functioning of enzymes involved in glycolysis remains unknown. Both in 
patients with T2D and subject with the metabolic syndrome, fasting blood glucose 
levels are inversely correlated with blood Mg2+ concentrations (58, 60, 111-113). 
Moreover, a higher dietary Mg2+ intake and oral Mg2+ supplementation have the 
potential to reduce fasting glucose levels (114-116).
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Table 2 |  Clinical trials that investigated the beneficial effect of oral Mg2+ supplementation  
on diabetes-related parameters  
First author Year Study design Patients Intervention Intervention  
increased blood 
Mg2+?
Improved  
fasting glucose 
from baseline?
Other effects
Gullestad  
et al. (92)
1994 Randomized double-blind 
placebo-controlled trial
56 T2D patients with >1 year disease 
duration
Mg-lactatecitrate equivalent to 
approximately 266 g elemental 
Mg2+ daily for 4 months
No No No improvement on 
HbA1c, lipid profile and 
blood pressure
Eriksson  
et al. (93)
1995 Randomized double-blind  
cross-over trial
56 Diabetes patients 600 mg oral Mg2+ (unclear which 
form) or 2 g ascorbic acid daily for 
two 90-day periods
Not reported No No improvement on lipid 
profile and blood pressure 
in the T2D patients
Eibl  
et al. (94)
1995 Randomized double-blind 
placebo-controlled trial
40 T2D patients with hypomagnesemia 
(undefined), treated with diet and oral
hypoglycemic agents, (HbA1c <8%)
Mg-citrate equivalent to 560 mg 
elemental Mg2+ daily for 3 months
Yes, serum Mg2+ from 
0.73 to 0.81 mmol/L
No No improvement on insulin 
resistance, HbA1c and 
lipid profile
De Lourdes Lima  
et al. (95)
1998 Randomized double-blind 
placebo-controlled trial
128 T2D patients treated by diet or diet 
plus oral antidiabetic drugs
Mg-oxide equivalent to 500 mg  
or 1 g elemental Mg2+ daily for  
30 days
No No No effect on glycemia and 
HbA1c
Rodriguez-Moran  
et al. (96)
2003 Randomized double-blind 
placebo-controlled trial
63 T2D patients with hypomagnesemia 
(serum Mg2+ <0.74 mmol/L) treated by 
glibenclamide 
2.5 g oral MgCl2, equivalent to 
450 mg elemental Mg2+ in 50 ml 
solution daily for 16 weeks
Yes, serum Mg2+ from 
0.64 to 0.74 mmol/L
Yes, from 10.3  
to 8.0 mmol/L
Improved HOMA-IR and 
HbA1c, no effect on blood 
pressure
Barragán-Rodríguez  
et al. (97)
2008 Randomized active control 
equivalent trial
23 Elderly (>60 years) T2D patients 
with hypomagnesemia (<0.74 mmol/L) 
and newly diagnosed depression
2.5 g oral MgCl2, equivalent to 
450 mg elemental Mg2+, or 50 mg 
Imipramine in 50 ml solution daily 
for 12 weeks 
Yes, serum Mg2+ from 
0.53 to 0.86 mmol/L
No Improved triglyceride 
levels. No effect on HbA1c 
and blood pressure.
Lee  
et al. (98)
2009 Randomized double-blind 
placebo-controlled trial
155 Participants with a BMI ≥23 kg/m2 12.3 mmol Mg-oxide,
equivalent to 300 mg of elemental 
Mg2+ daily for 12 weeks
No No No effect on blood 
pressure, lipid profile and 
HOMA-IR
Barbagallo  
et al. (99)
2010 Placebo-controlled clinical trial
(no randomization or blinding)
60 Elderly (≥ 65 years) diabetes patients 2.25 g oral Mg-pidolate twice 
a day, equivalent to 368 mg of 
elemental Mg2+ daily for 1 month
Serum ionized fraction 
increased significantly 
but not the total level
No No improvement on blood 
pressure
Chacko  
et al. (100)
2011 Randomized double-blind 
placebo-controlled crossover trial
14 Healthy overweight volunteers 
(BMI> 25 kg/m2) 
Mg-citrate equivalent to 500 mg 
elemental Mg2+ daily for 4 weeks 
(1-month washout period)
Increased by 0.1 
mmol/L from baseline 
but not significantly 
different from placebo
No No improvement on 
HbA1c and triglycerides 
concentrations but lower 
c-peptide levels
Mooren  
et al. (101)
2011 Randomized double-blind 
placebo-controlled trial
47 Non-diabetic subjects with BMI ≥25 
kg/m2 and decreased insulin sensitivity
Mg-aspartate hydrochloride 
equivalent to 365 mg elemental 
Mg2+ daily for 6 months
Serum ionized fraction 
increased significantly 
but not the total level
No, from 5.07  
to 4.75 (p=0.07)
Improved insulin 
sensitivity. Diastolic blood 
pressure borderline 
improved (p=0.06) but 
no effect on OGTT or lipid 
profile
Lima de Souza e Silva  
et al. (102)
2014 Randomized double-blind 
placebo-controlled trial
62 Patients with the metabolic 
syndrome as defined by the 
International Diabetes Federation
400 mg of chelated 
Mg2+ (unspecified to which 
molecule) per day 12-week divided 
into 2 daily dosages
No No Improved blood pressure 
but no effects on lipid 
profile and HOMA-IR
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Insulin secretion 
Blood glucose levels are strongly regulated by the islets of Langerhans in the 
pancreas, which secrete glucagon and insulin into the bloodstream (117). Limited 
studies have focused on the role of Mg2+ in insulin production and secretion. In 
small-scale human studies Mg2+ has been shown to be beneficial for insulin release 
and beta cell function (89, 118). These data are in contrast with in vitro data using in-
sulin-producing cells, in which Mg2+-deficient medium stimulated insulin secretion 
(119). Moreover, in ex vivo studies in which rat or dog pancreases were perfused with 
increasing concentrations of Mg2+, glucose-induced insulin secretion was 
suppressed, also contradicting the results observed in human studies (120, 121). 
Therefore, it is unknown what effect changes in blood Mg2+ concentrations have on 
insulin secretion in T2D patients.
Table 2 |  Continued  
First author Year Study design Patients Intervention Intervention  
increased blood 
Mg2+?
Improved  
fasting glucose 
from baseline?
Other effects
Navarrete-Cortes  
et al. (103)
2014 Randomized double-blind 
placebo-controlled crossover trial
56 T2D patients with 
normomagnesemia (serum Mg2+  
>0.74 mmol/L)
Two tablets of 1.5 g Mg-lactate 
twice daily, equivalent to 360 mg 
elemental Mg2+ daily for 3 months 
(3-month washout period)
No No No effect on HbA1c, 
HOMA-IR and lipid profile
Cosaro  
et al. (104)
2014 Randomized double-blind 
placebo-controlled crossover trial
16 Healthy male subjects with positive 
family history of metabolic syndrome 
and/or T2D in at least one first-degree 
relative 
Mg-pidolate twice a day,  
equivalent to 368 mg of  
elementary Mg2+ per day for  
8 weeks (4-week washout period)
No No No effect on lipid profile 
and HOMA-IR
Rodríguez-Moran  
et al. (105)
2014 Randomized double-blind 
placebo-controlled trial
47 Normal-weight individuals (BMI 
20-25 kg/m2) with hypomagnesemia 
(serum Mg2+ <0.74 mmol/L) and 
a fasting hyperglycemia, insulin 
resistance, hypertriglyceridemia and/or 
hypertension
30 mL 5% MgCl2 orally,  
equivalent to 450 mg elemental 
Mg2+ daily for 16 weeks
Yes, serum Mg2+ from 
0.55 to 0.76 mmol/L
Yes, from 6.1 to 
5.3 mmol/L
Improved triglycerides, 
blood pressure and 
HOMA-IR
Simental-Mendía  
et al. (106)
2014 Randomized double-blind 
placebo-controlled trial
62 Patients with newly-diagnosed 
prediabetes and hypomagnesemia 
(serum Mg2+ <0.74 mmol/L)
30 mL 5% MgCl2 orally,  
equivalent to 450 mg elemental 
Mg2+ daily for 3 months
Yes, serum Mg2+ from 
0.65 to 0.86 mmol/L
Yes, from 6.0 to 
5.5 mmol/L
Improved C-reactive 
protein. No effect on blood 
pressure
Razzaghi  
et al.  (107)
2018 Randomized double-blind 
placebo-controlled trial
70 Diabetic patients with grade 3 
diabetic foot ulcer
250 mg Mg-oxide orally,  
equivalent to 150 mg elemental 
Mg2+, daily for 12 weeks
Yes, serum Mg2+ from 
0.86 to 0.95 mmol/L
Yes, from 12.6 to 
10.1 mmol/L
Improved serum insulin, 
triglycerides and 
C-reactive protein
Articles were included if the study used oral Mg2+ treatment, specified the intervention, patient population and 
study design, and measured fasting glucose levels. BMI, body mass index; HbA1c, glycated hemoglobin; 
HOMA-IR, homeostatic model assessment of insulin resistance; MgCl2, magnesium chloride, OGTT, oral glucose 
tolerance test.
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Insulin receptor sensitivity
When insulin is secreted by the pancreas and enters the bloodstream, it binds to the 
insulin receptor, which is expressed in almost all tissues (122). Insulin receptor 
activation stimulates cellular glucose uptake and/or breakdown (123, 124). Both 
dietary Mg2+ intake as well as oral Mg2+ supplementation have been shown to 
improve insulin sensitivity (96, 101, 125). In rats with streptozotocin-induced type 1 
diabetes, oral Mg2+-sulfate supplementation improved the intraperitoneal glucose 
tolerance test (IPGTT), while blood insulin levels were equal, showing an improved 
insulin sensitivity (126). Moreover, hypomagnesemic rats have increased insulin 
resistance (127). Insulin receptor signal transduction begins with the tyrosine kinase 
autophosphorylating tyrosine residues of the beta-subunit of the insulin receptor. 
Tyrosine kinase activity has been shown to be strongly Mg2+-dependent, which 
Table 2 |  Continued  
First author Year Study design Patients Intervention Intervention  
increased blood 
Mg2+?
Improved  
fasting glucose 
from baseline?
Other effects
Navarrete-Cortes  
et al. (103)
2014 Randomized double-blind 
placebo-controlled crossover trial
56 T2D patients with 
normomagnesemia (serum Mg2+  
>0.74 mmol/L)
Two tablets of 1.5 g Mg-lactate 
twice daily, equivalent to 360 mg 
elemental Mg2+ daily for 3 months 
(3-month washout period)
No No No effect on HbA1c, 
HOMA-IR and lipid profile
Cosaro  
et al. (104)
2014 Randomized double-blind 
placebo-controlled crossover trial
16 Healthy male subjects with positive 
family history of metabolic syndrome 
and/or T2D in at least one first-degree 
relative 
Mg-pidolate twice a day,  
equivalent to 368 mg of  
elementary Mg2+ per day for  
8 weeks (4-week washout period)
No No No effect on lipid profile 
and HOMA-IR
Rodríguez-Moran  
et al. (105)
2014 Randomized double-blind 
placebo-controlled trial
47 Normal-weight individuals (BMI 
20-25 kg/m2) with hypomagnesemia 
(serum Mg2+ <0.74 mmol/L) and 
a fasting hyperglycemia, insulin 
resistance, hypertriglyceridemia and/or 
hypertension
30 mL 5% MgCl2 orally,  
equivalent to 450 mg elemental 
Mg2+ daily for 16 weeks
Yes, serum Mg2+ from 
0.55 to 0.76 mmol/L
Yes, from 6.1 to 
5.3 mmol/L
Improved triglycerides, 
blood pressure and 
HOMA-IR
Simental-Mendía  
et al. (106)
2014 Randomized double-blind 
placebo-controlled trial
62 Patients with newly-diagnosed 
prediabetes and hypomagnesemia 
(serum Mg2+ <0.74 mmol/L)
30 mL 5% MgCl2 orally,  
equivalent to 450 mg elemental 
Mg2+ daily for 3 months
Yes, serum Mg2+ from 
0.65 to 0.86 mmol/L
Yes, from 6.0 to 
5.5 mmol/L
Improved C-reactive 
protein. No effect on blood 
pressure
Razzaghi  
et al.  (107)
2018 Randomized double-blind 
placebo-controlled trial
70 Diabetic patients with grade 3 
diabetic foot ulcer
250 mg Mg-oxide orally,  
equivalent to 150 mg elemental 
Mg2+, daily for 12 weeks
Yes, serum Mg2+ from 
0.86 to 0.95 mmol/L
Yes, from 12.6 to 
10.1 mmol/L
Improved serum insulin, 
triglycerides and 
C-reactive protein
Articles were included if the study used oral Mg2+ treatment, specified the intervention, patient population and 
study design, and measured fasting glucose levels. BMI, body mass index; HbA1c, glycated hemoglobin; 
HOMA-IR, homeostatic model assessment of insulin resistance; MgCl2, magnesium chloride, OGTT, oral glucose 
tolerance test.
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could be the underlying mechanism of the increased insulin sensitivity by Mg2+ 
(127-130). The most important downstream effect of the insulin receptor is the 
shuttling of vesicles, containing glucose transporter 4 (GLUT4), from the cytosol into 
the cell membrane, increasing cellular glucose uptake. In animal studies oral Mg2+ 
enhances Glut4 mRNA expression levels, which could increase the effects induced 
by insulin (126, 131). It remains largely unknown how intracellular Mg2+ affects 
downstream insulin receptor signaling, finally leading to changes in GLUT4 membrane 
expression. 
 
Lipid homeostasis 
Besides serving as an important energy source, lipids are also components of the 
cell membrane and can act as signaling molecules (132). Dietary lipids are absorbed 
by the intestine in the form of free fatty acids (FFA) (133). In the blood, fatty acids are 
transported in two forms: as triacylglycerols, also known as triglycerides, the main 
component of lipoprotein particles or as FFAs (also known as non-esterified fatty 
acids). Due to the poor solubility of FFAs they require carrier proteins, predominantly 
albumin, to become soluble (134). FFAs are stored in soft tissue, mainly liver and 
white adipose tissue, in the form of triglycerides. When the energy demand increases, 
FFAs can be released from triglycerides in these tissues by lipolysis and subsequently 
secreted into the bloodstream for other tissues, e.g. skeletal muscle, to consume. 
Hyperlipidemia is present in over 75% of T2D patients (135). Low blood Mg2+ levels in T2D 
patients correlate with hyperlipidemia (136). Moreover, oral Mg2+ supplementation 
has beneficial effects on the lipid profile (91, 137, 138). Hypomagnesemia in rats 
increases blood triglyceride and cholesterol levels, and negatively influences the fatty 
acid composition in lipoprotein particles (139, 140). These findings demonstrate the 
detrimental effects of low Mg2+ levels on lipid homeostasis.
Mitochondrial function
Mitochondria are key organelles in regulating cellular energy homeostasis by 
producing ATP via aerobic respiration. Mitochondria are hypothesized to be stores for 
cellular Mg2+, shown by fluorescent imaging (141). Culturing mitochondria in balanced 
deep-sea water with increasing Mg2+ concentrations enhances mitochondrial activity, 
indicated by higher mRNA expression of carnitine palmitoyltransferase 1 (CPT1-L), 
medium chain acyl dehydrogenase (MCAD) and Cytochrome C (CYCS) (142). This 
data is strengthened by the fact that chelating extracellular Mg2+ from mitochondria 
using EDTA reduced ATP production due to a disrupted utilization of octanoylcarnitine 
and palmitoylcarnitine, which could be rescued by re-administration of Mg2+ (19). 
More knowledge is needed regarding the effects of hypomagnesemia on mitochondrial 
function in T2D patients.
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In summary, Mg2+ plays an important role in human physiology in general and energy 
metabolism in particular. Ample cohort studies have revealed that hypomagnesemia 
is a prominent issue in T2D patients. However, most of the current data is based on 
association studies, providing no insight into the causality and molecular mechanisms. 
This thesis aims to unravel the cause of the bidirectional relationship between T2D 
and hypomagnesemia, from molecule to population. On one hand, the effect of Mg2+ 
on energy homeostasis, glucose handling and lipid metabolism is investigated. On 
the other hand, this thesis will explore how T2D can lead to hypomagnesemia. 
Figure 2 | The complex interconnection between hypomagnesemia and T2D
Hypomagnesemia could attribute to the onset of T2D by increasing insulin resistance and blood lipid 
levels. On the other hand, T2D could induce reductions in blood Mg2+ levels via insulin resistance 
and hyperlipidemia.
Insulin resistance
Hyperlipidemia
Type 2 diabetes Hypomagnesemia
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Outline of this thesis
This thesis aims to further disclose the causal relationship between hypomagnesemia 
and T2D (Figure 2). In Chapter 2 the prevalence of hypomagnesemia and the extent 
of urinary Mg2+ wasting was studied in a cohort of patients with advanced T2D. 
Clinical and laboratory factors were associated to changes in plasma Mg2+ levels. 
Chapter 3 aimed to study the metabolic consequences induced by hypomagnesemia 
in a T2D mouse model, using a Mg2+ deficient high fat diet. In Chapter 4 the same 
dietary intervention was used to study the effects of a high fat diet on Mg2+ 
homeostasis. This chapter also studied the consequences of hypomagnesemia on 
the kidney. In Chapter 5 we investigated the effect of metformin treatment on Mg2+ 
homeostasis in genetically modified mice (db/db mice), which suffer from T2D. The 
rationale for this study was based on the association between plasma Mg2+ and the 
use of metformin in T2D patients of the PARELSNOER cohort. In Chapter 6 serum 
Mg2+ levels were correlated to alterations in the lipid profile of overweight individuals. 
This chapter further studied the binding of Mg2+ to negatively charged FFA molecules 
to unravel the inverse relationship between triglycerides and Mg2+. Acute increases 
in blood lipid levels were achieved using oral loading of olive oil and cream in mice 
and human subjects, respectively. The main results of this thesis are summarized in 
Chapter 7. In Chapter 8 the main findings are put into perspective. In this chapter we 
also discuss the clinical translation of the results and formulate recommendations for 
clinical practice. Finally, potential directions for further research are provided.
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Abstract
Hypomagnesemia (plasma magnesium (Mg2+) concentration <0.7 mmol/L) has 
been described in patients with type 2 diabetes (T2D). Polypharmacy is inevitable 
when treating a complex disease such as T2D and could explain disturbances in the 
plasma Mg2+ concentration.  
  In this study, we aimed to establish the extent of hypomagnesemia in a cohort of 
395 T2D patients and to identify determinants of plasma Mg2+ levels. Using Pearson 
correlation analyses, variables were correlated to plasma Mg2+ levels. After excluding 
confounding variables, all parameters correlating (p<0.1) with plasma Mg2+ were 
included in a stepwise backward regression model. The mean plasma Mg2+ 
concentration in this cohort was 0.74 ± 0.10 mmol/L. In total, 121 patients (30.6%) 
suffered from hypomagnesemia. Both plasma triglyceride (r=-0.273, p<0.001) and 
glucose levels (r=-0.231, p<0.001) negatively correlated with the plasma Mg2+ 
concentration. Patients using metformin (n=251, 62%), proton pump inhibitors 
(n=179, 45%) or β-adrenergic receptor agonists (n=31, 8%) displayed reduced 
plasma Mg2+ levels. Insulin use (n=299, 76%) positively correlated with plasma Mg2+ 
levels. The model predicted (R2) 20% of all variance in the plasma Mg2+ 
concentration.  
  Hypomagnesemia is highly prevalent in T2D patients. Plasma triglycerides and 
glucose levels are major determinants of the plasma Mg2+ concentration, whereas 
only a minor part (<10%) of hypomagnesemia can be explained by drug intake, 
excluding polypharmacy as a major cause for hypomagnesemia in T2D.
Keywords: Glucose; hypomagnesemia; magnesium; medication; triglyceride; type 2 
diabetes.
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Introduction
Over the last decades, evidence is accumulating that hypomagnesemia (plasma 
M2+ concentration <0.7 mmol/L) is frequently present in patients with T2D [1]. Since 
its first report in the 1940s, hypomagnesemia has been shown in several cohort 
studies [2-4]. Although plasma Mg2+ levels are not regularly monitored in T2D 
patients, the presence of hypomagnesemia is of significant clinical importance [5]
Oral Mg2+ supplementation has been shown to reduce the progression from 
pre-diabetes to diabetes and improve insulin sensitivity and glucose handling [3, 6-8]. 
Moreover, in T2D patients, hypomagnesemia results in a faster renal decline and is 
associated with a worse disease progression and outcome [9, 10]. Mg2+ also plays 
a key role in common comorbidities of T2D such as chronic kidney disease, athero-
sclerosis and hypertension [11-14].
  Hypomagnesemia can have many underlying causes, related or unrelated to 
T2D [1, 15]. Firstly, hypomagnesemia can result from mutations in magnesiotropic 
genes, which has been extensively reviewed by Viering et al. [16]. Secondly, the 
processing of food leads to a marked depletion of Mg2+ in the Western diet, resulting 
in a reduced dietary Mg2+ intake [17]. Thirdly, hypomagnesemia can be a result of 
impaired intestinal Mg2+ uptake due to diarrhea that could be induced by diabetic 
autonomic neuropathy or metformin use [18-20]. Fourthly, the use of certain medication 
(i.e. diuretics, immunosuppressive drugs, proton pump inhibitors (PPIs)) has been 
associated with hypomagnesemia [21]. Lastly, metabolic acidosis and insulin resistance 
can decrease the expression of the renal Mg2+ channel transient receptor potential 
melastatin 6 (TRPM6), increasing urinary Mg2+ loss and thereby reducing the plasma 
Mg2+ concentration [22, 23].
 The origin of hypomagnesemia in T2D is currently unknown. The contributing 
factors to disturbed Mg2+ homeostasis may be multiple and have been poorly 
studied. T2D patients suffer from a wide-range of clinical disturbances including 
increased plasma glucose concentrations, dyslipidemia (high triglyceride and low 
HDL-cholesterol) and insulin resistance [24].
 In order to maintain proper glucose levels and blood pressure, polypharmacy is 
an inevitable consequence of effectively treating T2D. However, it also constitutes 
a growing risk factor as each drug carries its own side effects and drug-drug 
interactions [25]. Potentially, the use of medication can contribute to hypomagnesemia. 
Several regularly prescribed drugs in T2D are known to reduce the plasma Mg2+ 
levels, including PPIs and thiazide diuretics [26-30]. However, it is unclear to what 
extent the hypomagnesemia in T2D patients can be explained by the extensive use 
of medication.
 In this study, we aimed to determine the prevalence of hypomagnesemia in a 
carefully phenotyped cohort of 402 T2D patients. Subsequently, the determinants of 
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plasma Mg2+ levels were analyzed using laboratory parameters and an extensive 
screening of drug use.
Results
Study population
In total, 395 T2D patients were included in the study cohort. Clinical characteristics 
and laboratory results are provided in Table 1. 
This is a group of patients with longstanding T2D, mostly on insulin treatment with an 
extensive use of medication (Table 2). The average plasma Mg2+ concentration in the 
cohort was 0.74 ± 0.10 mmol/L, and a total of 121 patients (30.6%) had levels below 
0.70 mmol/L, indicating hypomagnesemia (Fig. 1A). Hypermagnesemia was found in 
1 patient. Plasma sodium (Na+) and (K+) levels were normally distributed in the 
reference range (Fig. 1B,C). 
Table 1 | Characteristics of T2D patients
Variable Mean ± SD Range Reference value
Demographics
Gender (m:f, %)
BMI (Kg/m2)
Age (years)
Duration diabetes (years)
Waist circumference (m:f, cm)
SBP (mmHg)
DBP (mmHg)
Heart rate (beats/min)
Alcohol consumption (no:yes, %)
59:41
32.6 ± 6.5 
67 ± 10
15.8 ± 9.5
110 ± 16
143 ± 20
77 ± 11.
73 ± 12
52:48
-
17 − 61
34 − 90
0 − 56
65 − 152
84 − 207
51 − 117
45 – 116
-
-
18.5-25
-
-
<102:<88
90 − 140
60 − 90
60 – 100
-
Laboratory analyses
Total cholesterol (mmol/L)
Triglycerides (mmol/L)
HbA1c (mmol/mol)
Glucose (mmol/L)
LDL (mmol/L)
HDL (m:f, mmol/L)
4.5 ± 1.5
2.5 ± 4.1
63.1 ± 14.2
9.4 ± 3.4
2.3 ± 0.8
1.1 ± 0.3
2.0 − 20.0
0.4 − 50.7
33.3 − 118.6
2.3 − 24.9
0.6 − 4.9
0.5 − 2.2
<5.2
<1.7 
<42
3.9 − 5.5
<2.6
>1.1:>1.3 
m; male, f; female.
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Determinants of the plasma Mg2+ concentration
Using univariate regression analyses, a correlation between plasma Mg2+ concentration 
and several clinical characteristics was demonstrated: BMI (r=-0.162, p=0.001), 
waist circumference (r=-0.158, p=0.002), diastolic blood pressure (DBP, r=-0.144, 
p=0.004), heart rate (r=-0.104, p=0.039), eGFR (r=-0.168, p=0.001), HbA1c (r=-0.123, 
p=0.015), and plasma levels of triglycerides (r=-0.273, p<0.001) and glucose 
(r=-0.231, p<0.001) negatively correlated with the plasma Mg2+ concentration. In 
contrast, the duration of diabetes (r=0.139, p=0.008) and the plasma level of HDL 
(r=0.156, p=0.002) and Na+ (r=0.108, p=0.032) were correlated with an increased 
plasma Mg2+ concentration (Table 3). The effect of drug use was specifically 
analyzed. The use of metformin (r=-0.268, p<0.001) or β-adrenergic receptor 
agonists (r=-0.103, p=0.041) negatively correlated with plasma Mg2+, whereas use 
of insulin (r=0.109, p=0.030) was associated with higher plasma Mg2+ levels. 
Confounding factors were identified using partial correlation analyses and excluded 
from subsequent analysis (Supplementary Tables 1-3). After correction for 
confounding, all parameters correlating (p<0.1) with plasma Mg2+ univariately, were 
included in the stepwise backward regression analysis model (Table 4). In this model, 
parameters with a p-value >0.1 were eliminated (BMI, DBP and angiotensin-converting- 
enzyme (ACE) inhibitors).
 In the final model, plasma levels of glucose and triglycerides, as well as the use 
of PPIs, metformin or β-adrenergic receptor agonists negatively predicted plasma 
Mg2+ levels. Interestingly, patients on insulin had a trend (p=0.053) towards having 
higher plasma Mg2+ levels than people not on insulin. Altogether, the model predicted 
(R2) 20% of the plasma Mg2+ concentration.
Table 2 | Medication use of T2D patients
Medication Number of patients 
(n=395)
Percentage
ACE inhibitor
ANGIIR antagonist
β-adrenergic agonist
β-adrenergic antagonist
Calcium channel blocker
Insulin
K+-saving diuretic
Loop diuretic 
Metformin
Nitrate
PPI
Statin
Sulfonylureum
Thiazide diuretic
 187
 95
 31
 209
 88
 299
 48
 75
 251
 54
 179
 293
 77
 128
 47.3
24.1
7.8
52.9
22.3
75.7
12.2
19.0
63.5
13.7
45.3
74.2
19.5
32.4
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Increased urinary Mg2+ excretion
To investigate whether the hypomagnesemia is explained by renal Mg2+ loss, the 
fractional excretion of Mg2+ (FEMg) was determined. The mean FEMg in the cohort 
was 3.9 ± 2.7%. In total, 148 patients (40.8%) suffered from renal Mg2+ wasting, 
defined as FEMg >4%. Nevertheless, FEMg was not significantly different (p=0.75) 
between normomagnesemic patients (3.9 ± 2.8%) and hypomagnesemic patients 
(3.9 ± 2.5%) (Fig. 2A,B).  
Figure 1 | Hypomagnesemia in T2D patients
The plasma (A) Mg2+, (B) Na+ and (C) K+ concentration was determined in 395 type 2 diabetes 
patients. Hypomagnesemia was observed in 30.6% of the patients. Bars represent the number 
of patients. Dotted vertical lines indicate the normal range (Mg2+ 0.7-1.1 mmol/L, Na+ 135-145 
mmol/L, K+ 3.5-5.5 mmol/L).
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Table 3 |  Univariate analyses for correlation of patient characteristics on the plasma  
Mg2+ concentration
Variable Pearson’s 
correlation 
coefficient
p-value n
Demographics
Gender 
BMI (Kg/m2) 
Age (years) 
Duration diabetes (years) 
Waist circumference (cm) 
SBP (mmHg) 
DBP (mmHg) 
Heart rate (beats/min) 
Alcohol consumption (no/yes)
0.007
-0.162
0.089
0.139
-0.158
-0.056
-0.144
-0.104
-0.004
0.897
0.001
0.076
0.008
0.002
0.269
0.004
0.039
0.680
395 
394 
395 
365 
392 
395 
395 
395 
390
Laboratory analyses
eGFR (ml/min) 
Log10 HDL (mmol/L) 
Log10 Total cholesterol (mmol/L) 
Log10 HbA1c (mmol/mol) 
Log10 Triglycerides (mmol/L) 
Log10 Glucose (mmol/L) 
Log10 LDL (mmol/L) 
Plasma Na+ (mmol/L) 
Plasma K+ (mmol/L)
-0.168
0.156
-0.059
-0.123
-0.273
-0.231
0.077
0.108
0.081
0.001
0.002
0.247
0.015
<0.001
<0.001
0.145
0.032
0.110
371 
387 
388 
391 
387 
383 
365 
391 
394
Medication
ACE inhibitor  
ANGIIR antagonist 
β-adrenergic agonist 
β-blocker 
Calcium channel blocker 
Insulin 
K+-saving diuretic 
Loop diuretic 
Metformin 
Nitrate 
PPI 
Statin 
Sulfonylureum 
Thiazide diuretic
-0.094
0.037
-0.103
-0.056
-0.072
0.109
-0.023
0.072
-0.268
-0.043
-0.084
0.002
-0.044
-0.084
0.063
0.469
0.041
0.270
0.155
0.030
0.685
0.153
<0.001
0.389
0.094
0.962
0.382
0.104
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Figure 2 | Increased FEMg in T2D patients 
The fractional excretion of Mg2+ (FEMg) was determined in 369 type 2 diabetes patients, of which 259 
were normomagnesemic (A) and 110 were hypomagnesemic (B). Bars represent the percentage of 
the population. Dotted vertical lines indicate the threshold for urinary Mg2+ wasting (FEMg > 4%).
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Table 4 | Stepwise backward regression analysis on the plasma Mg2+ concentration
Variable Coefficient p-value Range
Log10 triglycerides (mmol/L)
Log10 glucose (mmol/L)
eGFR (mL/min) 
PPI*  
Metformin*  
Insulin*  
β-adrenergic agonist* 
-0.073
-0.149
0.000
-0.023
-0.044
0.023
-0.047
<0.001
<0.001
0.022
0.022
<0.001
0.053
0.009
-0.113 
-0.216 
-0.001 
-0.043 
-0.065 
0.000 
-0.082 
−
−
−
−
−
–
−
-0.033
-0.082
0.000
-0.003
-0.023
0.046
-0.012
All variables with a p>0.1 were excluded from the model. *No; 0, Yes; 1.
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Discussion
The present study further substantiates the high prevalence of hypomagnesemia in 
T2D. A negative correlation between plasma Mg2+ concentration and the plasma 
glucose and triglycerides levels was demonstrated. In addition, polypharmacy could 
be excluded as the main cause of hypomagnesemia in T2D patients, since only less 
than ten percent of changes in plasma Mg2+ could be attributed to medication use. 
These findings suggest that hypomagnesemia in T2D patients is intrinsic to the disease.
 Hypomagnesemia was observed in 30.6% of the patients, corresponding to 
incidence numbers of 13.5-47.7% observed in previous cohort studies [3, 4, 31, 32]. 
In comparison, in a large study of 5179 subjects aged 55 and older the incidence of 
hypomagnesemia was only two percent, highlighting the extensive amount of 
hypomagnesemia in T2D patients [10]. Given that hypomagnesemia is related to a 
faster disease progression and an increased risk of diabetes-related complications, 
such as renal failure and cardiovascular disease, it is of great clinical importance to 
identify the factors that determine plasma Mg2+ concentrations [1, 9, 13, 33]. 
Therefore, we constructed a statistical model that included the factors influencing 
plasma Mg2+ levels. Twenty percent of the variation in the plasma Mg2+ concentration 
is explained by our model containing eGFR, the plasma concentrations of glucose 
and triglycerides and the use of PPIs, insulin, metformin and β-adrenergic receptor 
agonists. Although this is only a modest part of the total variation, it is comparable to 
the effect of dietary Mg2+ intake and higher than current genetic models, which 
explain 25-30% and 1-5% of changes in the plasma Mg2+ concentration respectively 
[34-36]. The finding that in our model most of the variance in plasma Mg2+ can be 
explained by factors that determine metabolic control underlines the importance of 
glucose and lipid homeostasis in the regulation of plasma Mg2+ levels. 
  Plasma glucose and triglyceride levels were the main determinants of plasma 
Mg2+ concentrations in our model. This correlation was independent of obesity-relat-
ed factors such as waist circumference, BMI and cholesterol. Previous studies 
investigating the metabolic syndrome have shown an association between 
triglycerides and Mg2+ levels [37, 38]. However, these studies did not investigate the 
collinearity between triglycerides and HDL or were not based on the plasma Mg2+ 
concentration. Mg2+ supplementation is generally considered to improve the lipid 
profile in patients, however, studies addressing the effect of Mg2+ on plasma 
triglyceride concentrations are inconsistent [39, 40]. As Mg2+ increases the affinity of 
the insulin receptor tyrosine kinase for ATP, the decreased plasma Mg2+ levels could 
exacerbate insulin resistance in T2D patients, and thereby increase plasma glucose 
and triglyceride concentrations [41, 42].  
  Medication could only explain a minor part of the changes in plasma Mg2+ 
concentration in T2D patients (<10%), showing that polypharmacy is not the primary 
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cause of hypomagnesemia in T2D patients. Known hypomagnesemia-causing drugs 
β-adrenergic receptor agonists and PPIs, negatively correlated with the plasma Mg2+ 
concentration, although with minor effect sizes (<2%) [30, 43-45]. Of all drugs, the 
use of metformin was most strongly correlated (r=-0.268, p<0.001) with the plasma 
Mg2+ concentration, irrespective of eGFR or fasting glucose levels. Our study is the 
first large cohort study to identify the association between the use of metformin and 
plasma Mg2+ levels. A few studies with limited patient numbers from the 70s and 80s 
suggested that treating patients with metformin reduces plasma Mg2+ levels [4, 46]. 
How metformin affects Mg2+ handling remains to be elucidated. In contrast, patients 
taking insulin had a trend (p=0.053) towards higher plasma Mg2+ levels than those 
that did not require insulin treatment. This is in concordance with experimental studies 
showing that insulin stimulates the renal Mg2+ channel TRPM6, resulting in increased 
renal Mg2+ reabsorption [23]. Therefore, despite their worse glycemic control, 
patients on insulin treatment have slightly better plasma Mg2+ values than met-
formin-treated patients. These results suggest that the positive renal effect of insulin 
on the reabsorption of Mg2+ overrides the negative effect of poor glycemic control of 
insulin-dependent patients on their Mg2+ levels.
  We observed that high renal Mg2+ excretion is prevalent among T2D patients, 
with 41% of the patients in the cohort having a FEMg >4%. While these findings 
suggest that impaired renal Mg2+ reabsorption contributes to hypomagnesemia in 
T2D patients, renal Mg2+ wasting was equally frequent in hypomagnesemic and nor-
momagnesemic patients. Hypomagnesemia only arises when body Mg2+ stores, 
such as bone, are depleted [47]. Therefore, hypomagnesemia may only develop after 
several years, despite increased renal Mg2+ excretion. Our findings of overall high 
Mg2+ excretion may thus indicate that the complete diabetic population is at risk to 
develop hypomagnesemia. FEMg was not related to fasting glucose levels (data not 
shown), showing that T2D disease severity does not influence the amount of urinary 
Mg2+ loss.
 The strength of our study is the thorough and extensive phenotyping of the T2D 
patients, allowing systematic investigation of the contribution of polypharmacy and 
metabolism-related parameters to changes in the plasma Mg2+ concentration of T2D 
patients. By carefully collecting data on drug use, this is the first cohort study that 
determined the contribution of medication usage to changes in plasma Mg2+ 
concentrations. The availability of urine samples enabled the determination of the 
FEMg in a large cohort of severe T2D patients for the first time. However, several 
limitations have to be considered. Firstly, data on the dietary habits of the participants 
was not collected, excluding the potential effects of diet from our analyses. However, 
the influence of diet on plasma Mg2+ levels will be minor, as samples were collected 
after an overnight fast. Secondly, all the samples were collected at a single point and 
no follow-up data are available. Therefore, the observed correlations will not provide 
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information about causality. A final limitation is the fact that the extent of insulin 
resistance was not directly determined. However, several studies have proposed that 
the product of fasting glucose and triglycerides can be used as a measure to estimate 
insulin resistance [48, 49]. The strong correlation of plasma Mg2+ with glucose and 
triglycerides in our study therefore provides an indirect link with insulin resistance. 
  In conclusion, this study shows that hypomagnesemia is a prominent feature of 
T2D, and is supported by excessive urinary Mg2+ loss. We excluded polypharmacy 
as the major cause of changes in plasma Mg2+ concentration in T2D patients. Given 
that metabolic factors such as glucose and triglyceride concentrations are main 
determinants of the plasma Mg2+ concentration, Mg2+ disturbances should be 
considered and, if required, corrected in T2D patients.
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Materials and methods
Subjects
Patients data and samples were taken from the Nijmegen-part of the Diabetes Pearl 
cohort [50]. In short, 402 T2D patients were included between June 2009 and 
February 2012 at the Radboud university medical center in Nijmegen, the Netherlands. 
Inclusion criteria were based on the WHO standards: a venous fasting plasma 
glucose concentration higher than 7.0 mmol/L, or a casual venous plasma glucose 
concentration higher than 11.1 mmol/L [51]. Personal information was obtained by 
dedicated patient questionnaires. This cohort consisted of patients under chronic 
secondary and tertiary care including many patients at an advanced disease stage.  
  BMI was calculated as the weight in kilograms divided by square of the height in 
meters. Blood pressure and heart rate were measured in triplicate, and the average 
value was used in subsequent analyses. Waist circumference was measured in 
duplicate after normal exhalation and if the difference between these two 
measurements was >1.0 cm, the measurement was repeated for a third time. Plasma 
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and urine samples were taken after an overnight fasting period. The samples were 
analyzed for laboratory parameters (glycated hemoglobin (HbA1c), plasma glucose, 
creatinine, total cholesterol, high density lipoprotein (HDL), low density lipoprotein 
(LDL) and triglycerides) and immediately stored at -80˚C for further analyses. A detailed 
description of the patient characteristics is reported in Table 1.
  Participants were requested to bring all their medication on the day of the visit or 
lists from pharmacists to score their medication use accurately. Medication was 
classed into groups according to the Anatomical Therapeutic Chemical Classification 
System (ATC) for statistical analysis (Table 2). The study was performed according to 
the declaration of Helsinki. All patients provided written informed consent and all 
study investigators had access to the study data.
Measures 
This study was designed as an observational cohort study using samples from the 
existing Diabetes Pearl cohort biobank [50]. Laboratory values (fasting) and use of 
medication of 402 patients were examined at the inclusion date. Seven patients 
were excluded because of insufficient sample availability. Mg2+, but also Na+ and 
potassium K+ concentrations were measured in the stored plasma and urine samples 
from the biobank. Fasting plasma Mg2+ concentrations were determined using a 
spectrophotometric assay (Roche/Hitachi, Tokyo, Japan), and measured at 600 nm 
on a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad laboratories, 
Hercules, USA), according to the manufacturer’s protocol. Fasting plasma Na+, K+ 
and creatinine, and urinary Mg2+, Na+, K+ and creatinine concentrations were measured 
at the clinical chemistry department using standardized methods. The fractional 
excretion of Mg2+ (FEMg) was calculated according to the formula (UMg × Screa)/
(Ucrea × SMg × 0.7) × 100 [52]. GFR was estimated (eGFR) using the ‘Modification of 
Diet in Renal Disease (MDRD) formula: 186 × plasma creatinine-1.154 × age-0.203 × 
1.210 (if black) × 0.742 (if female) [53]. Patients with an eGFR <30 mL/min were 
excluded from subsequent urinary analyses. 
Statistical analyses
Data are presented as mean ± standard deviation (SD). Pearson’s correlation tests 
were performed to determine the association between plasma Mg2+ concentration 
and clinical and anthropomorphic parameters. HbA1c and plasma values of triglycerides, 
glucose, LDL, HDL and total cholesterol were log10 transformed prior to use in statistical 
analyses. All variables with a p-value <0.1 in the Pearson’s correlation analyses, not 
corrected for multiple testing, were checked for confounding by performing partial 
regression analyses. Variables that correlated to plasma Mg2+ concentration with 
p<0.1, after correcting for confounding, were included in the stepwise multivariate 
backward elimination model. In this model variables with p>0.1 were eliminated. All 
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statistical analyses were performed using SPSS for Windows (V22.0.0.1 IBM, Armonk, 
NY). A p-value of <0.05 was considered statistically significant. 
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Supplementary data
Supplementary table 1 | Stepwise backward regression analysis to investigate collinearity 
between correlating variables related to obesity and diabetes, with plasma Mg2+ as dependent 
variable
Variable Coefficient p-value
BMI (kg/m2)
Waist circumference (cm)
Log10 glucose (mmol/L)
Log10 triglycerides (mmol/L)
Log10 HbA1c (mmol/mol)
Log10 HDL (mmol/L)
-0.002
<0.001
-0.133
-0.067
0.025
0.036
0.300
0.847
0.001
0.006
0.686
0.505
BMI (kg/m2)
Log10 glucose (mmol/L)
Log10 triglycerides (mmol/L)
Log10 HbA1c (mmol/mol)
Log10 HDL (mmol/L)
-0.001
-0.132
-0.067
0.025
0.033
0.094
0.001
0.006
0.684
0.523
BMI (kg/m2)
Log10 glucose (mmol/L)
Log10 triglycerides (mmol/L)
Log10 HDL (mmol/L)
-0.001
-0.125
-0.067
0.034
0.102
<0.001
0.007
0.511
BMI (kg/m2)
Log10 glucose (mmol/L)
Log10 triglycerides (mmol/L)
-0.001
-0.122
-0.074
0.077
<0.001
0.001
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Supplementary table 2 | Stepwise backward regression analysis to investigate collinearity 
between correlating variables related to blood pressure, with plasma Mg2+ as dependent variable
Variable Coefficient p-value
BMI (kg/m2)
DBP (mm Hg)
Heart rate (beats/min)
Plasma Na+ (mmol/L)
Plasma K+ (mmol/L)
eGFR (mL/min)
ACE inhibitor*
Log10 glucose (mmol/L)
-0.003
-0.001
<0.001
0.002
0.017
<0.001
-0.021
-0.147
0.002
0.082
0.693
0.421
0.168
0.085
0.048
<0.001
BMI (kg/m2)
DBP (mm Hg)
Plasma Na+ (mmol/L)
Plasma K+ (mmol/L)
eGFR (mL/min)
ACE inhibitor*
Log10 glucose (mmol/L)
-0.003
-0.001
0.002
0.017
<0.001
-0.020
-0.148
0.001
0.049
0.423
0.169
0.084
0.050
<0.001
BMI (kg/m2)
DBP (mm Hg)
Plasma K+ (mmol/L)
eGFR (mL/min)
ACE inhibitor*
Log10 glucose (mmol/L)
-0.003
-0.001
0.016
<0.001
-0.021
-0.157
0.002
0.051
0.180
0.063
0.043
<0.001
BMI (kg/m2)
DBP (mm Hg)
eGFR (mL/min)
ACE inhibitor*
Log10 glucose (mmol/L)
-0.003
-0.001
<0.001
-0.020
-0.151
0.002
0.040
0.022
0.048
<0.001
*No; 0, Yes; 1.
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Supplementary table 3 | Stepwise backward regression analysis to investigate collinearity 
between the use of metformin and the duration of diabetes.
Variable Coefficient p-value
Duration diabetes (years)
Metformin*
<0.001
-0.055
0.154
<0.001
Metformin* -0.059 <0.001
*No; 0, Yes; 1.
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Abstract
Hypomagnesemia (blood Mg2+ <0.7 mmol/L) is a common phenomenon in 
individuals with type 2 diabetes (T2D). However, it remains unknown how a low blood 
Mg2+ concentration affects lipid and energy metabolism. Therefore, the importance 
of Mg2+ in obesity and T2D has been largely neglected to date. This study aims to 
determine the effects of hypomagnesemia on energy homeostasis and lipid 
metabolism. To this aim, mice were fed either a low-fat diet (LFD) or a high-fat diet 
(HFD) in combination with a normal- or low-Mg2+ content for 17 weeks. 
  In this study, we show that low dietary Mg2+ intake ameliorates HFD-induced 
obesity in mice. Consequently, fasting serum glucose levels decreased and insulin 
sensitivity improved in low Mg2+-HFD-fed mice. Moreover, HFD-induced liver 
steatosis was absent in the low Mg2+ group. In hypomagnesaemic HFD-fed mice, 
mRNA expression of key lipolysis genes was increased in epididymal white adipose 
tissue (eWAT), corresponding to reduced lipid storage and high blood lipid levels. 
Low Mg2+-HFD-fed mice had increased brown adipose tissue (BAT) Ucp1 mRNA 
expression and a higher body temperature. No difference was observed in energy 
expenditure between the two HFD groups.
  In conclusion, Mg2+-deficiency abrogates HFD-induced obesity in mice through 
enhanced eWAT lipolysis and BAT activity. 
Keywords: β-Adrenergic receptor; brown adipose tissue; energy homeostasis; 
hypo magnesaemia; lipid metabolism; lipolysis; magnesium; obesity; white adipose 
tissue. 
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Introduction
Hypomagnesemia (blood Mg2+ concentration <0.7 mmol/L) affects approximately 
30% of individuals with T2D (1, 2). Hypomagnesemia is an important risk factor for the 
development and progression of T2D (3-5). Low dietary Mg2+ intake and reduced 
serum Mg2+ have also been associated with obesity, although with conflicting results 
(1, 6-8). Moreover, reduced blood Mg2+ levels have been correlated with elevated 
glucose and triglyceride concentrations in individuals with T2D, suggesting that 
hypomagnesemia is associated with insulin resistance and dyslipidaemia (1). 
  Mg2+ fulfils many roles including cell growth, membrane stability, enzyme activity 
and energy metabolism (9). It is a cofactor for numerous enzymes, primarily because 
it stabilises ATP and facilitates phosphate transfer reactions (10, 11). Mg2+ is essential 
for glycolysis and the citric acid cycle (12, 13). Because Mg2+ is critical for insulin 
receptor tyrosine kinase activity, hypomagnesemia has also been implicated in 
insulin resistance (14-16). Recently, hypomagnesemia in mice was shown to 
contribute to enhanced catabolism, but no in-depth metabolic phenotype analysis 
was performed (17). 
  In T2D, restoring serum Mg2+ values by oral Mg2+ supplementation improves 
insulin sensitivity, decreases fasting glucose levels (18) and corrects the lipid profile 
(19-21). Although Mg2+ is essential for key enzymes in lipid metabolism, including 
hepatic lipase and lecithin-cholesterol acyltransferase (22, 23), the effects of chronic 
Mg2+ deficiency on adipocyte function and lipid metabolism remain largely unknown. 
In this study, we explored the role of Mg2+ in energy homeostasis, insulin sensitivity 
and lipid metabolism, by feeding mice a low-fat diet (LFD) or a high-fat diet (HFD) 
combined with low or normal Mg2+ for 17 weeks. The resulting metabolic effects were 
extensively characterised. Data were confirmed by an independent replication 
experiment.
Results
Low dietary Mg2+ intake reduces diet-induced obesity in mice
The mice were fed a LFD or HFD containing either a low (0.03% wt/wt) or normal 
(0.21% wt/wt) Mg2+ concentration for 17 weeks (Fig. 1A). There was no difference in 
body weight between low and normal Mg2+ groups on the LFD, but mice on the 
LowMg-HFD gained significantly less weight (58% less) than those on the normal 
Mg2+ (NormMg)-HFD (47.00 ± 1.53 g vs 38.62 ± 1.51 g in mice given a NormMg-HFD 
and LowMg-HFD, respectively, p<0.05, Fig. 1A,B). The lower body weight of the 
LowMg-HFD group could not be explained by differences in dietary intake, as shown 
by similar food intake and faeces production between the two HFD groups (Fig. 1C,D). 
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Figure 1 | Low dietary Mg2+ intake reduces diet-induced obesity in mice
(A) Body weight of mice during the experiment and (B) at week 17 (end of experiment). Arrows 
indicate experimental interventions: metabolic cage (MC), ITT, GTT. (C) Food intake, (D) total faeces 
weight, (E) water intake (two-way ANOVA for dietary fat effect p<0.05) and (F) urinary production 
determined over a period of 24 h, using metabolic cages, at week 16. (G) Serum Mg2+ levels at 
death. NormMg-LFD (white circles), LowMg-LFD (grey circles), NormMg-HFD (white squares), 
LowMg-HFD (grey squares). Data are mean ± SEM. *p<0.05 for the comparisons shown.
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There was also no difference in water intake or urinary volume between the HFD groups 
(Fig. 1E,F). Hypomagnesemia was detected in both the LowMg groups, but was 
significantly more pronounced in mice that were concomitantly fed a HFD (Fig. 1G).
Reduced diet-induced obesity in Mg2+-deficient mice is accompanied 
by improved insulin sensitivity  
To explore glucose metabolism in more detail, beta cell function and insulin sensitivity 
were determined by an intraperitoneal (IP) glucose tolerance test (GTT) and IP insulin 
tolerance test (ITT). In the IPGTT (a measure for beta cell dysfunction and insulin 
resistance), glucose clearance was reduced in both HFD groups (Fig. 2A). Glucose 
clearance was not significantly different between NormMg-HFD-fed mice and 
LowMg-HFD-fed mice (2.58 ± 0.08 vs 2.26 ± 0.13 mol/L× min in NormMg-HFD- and 
LowMg-HFD-fed mice, respectively, p=0.07, Fig. 2C). LowMg-HFD-fed mice required 
significantly less insulin than NormMg-HFD-fed mice to clear the glucose, consistent 
with LowMg-HFD-fed mice being more insulin sensitive (Fig. 2B). Fasting blood 
glucose and insulin concentrations were significantly increased in the HFD-fed mice, 
in accordance with the increased body weight (Fig. 2D,E). Compared with the 
NormMg-HFD-fed mice, fasting blood glucose was lower in the LowMg-HFD-fed 
mice (Fig. 2D). The effect of dietary Mg2+ on fasting insulin was not statistically 
significant (Fig. 2E, two-way ANOVA for dietary Mg2+ effect, p=0.07).  
  Both HFD-fed groups demonstrated increased insulin resistance in the ITT 
compared with their respective controls (Fig. 2F,G). Low dietary Mg2+ content 
resulted in a significantly lower AUC of the ITT (Fig. 2G, two-way ANOVA for dietary 
Mg2+ effect p<0.05). In the LowMg-HFD group compared to the NormMg-HFD-fed 
mice, the AUC of the ITT was not significantly different (0.91 ± 0.05 vs 0.72 ± 0.05 
mol/L × min in NormMg-HFD-fed and LowMg-HFD-fed mice, respectively, Tukey’s 
test p=0.07, Fig. 2F,G). 
  Insulin resistance is often accompanied by hyperlipidemia, in particular, high 
triglyceride and FFA levels. As expected, the HFD-fed mice had higher serum 
triglyceride and FFA levels than LFD-fed mice (Fig. 2H,I). Interestingly, despite their 
lower body weight and increased insulin sensitivity, LowMg-HFD-fed mice also had 
high serum triglyceride and FFA (Fig. 2H,I). In contrast, serum leptin levels correlated 
with body weight; hence, reduced leptin levels were observed in the LowMg-HFD-fed 
mice compared with NormMg-HFD-fed mice (Fig. 2J). No difference between the 
two HFD groups was observed in serum adiponectin and cholesterol (Supplementary 
Fig. 1 A,B).
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Figure 2 | Reduced diet-induced obesity in Mg2+-deficient mice is accompanied by high 
triglyceride levels and improved insulin sensitivity
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Mg2+ deficiency prevents diet-induced hepatic lipid storage
Liver function is often impaired in T2D as a consequence of insulin resistance and 
hepatic steatosis (28). Feeding mice a NormMg-HFD resulted in a significantly 
heavier liver. However, this effect was abrogated in mice fed a LowMg-HFD (Fig. 3A). 
In Mg2+-deficient mice, the HFD did not increase liver triglyceride content (Fig. 3B). 
In line with the triglyceride measurements, H&E and Oil Red O staining showed 
reduced hepatic lipid accumulation in the Mg2+-deficient HFD-fed mice (Fig. 3C,D, 
respectively). Hepatic mRNA expression of Cd36, a long-chain fatty acid transporter, 
was reduced in the LowMg-HFD-fed mice compared with the NormMg-HFD-fed 
mice (Supplementary Fig. 2A). 
 Low dietary Mg2+ increased hepatic mRNA expression of sterol regulatory 
element- binding protein 1c (Srebp1c), which is involved in cholesterol and fatty acid 
metabolism, and phosphoenolpyruvate carboxykinase 1 (Pepck1), essential for 
gluco neogenesis, glyceroneogenesis and fatty acid re-esterification (Suppelementary 
Fig. 2B,C two-way ANOVA for dietary Mg2+ effect p<0.05). No differences were 
observed between the two HFD-fed groups in the expression of key genes involved 
in hepatic glycolysis, ketogenesis and beta-oxidation (Supplementary Fig. 2D-L).
Reduced adipose tissue mass in Mg2+-deficient HFD-fed mice is 
associated with increased mRNA expression of lipolysis genes 
Our results show that mice fed a LowMg-HFD diet exhibit reduced body weight and 
high triglyceride levels compared with their NormMg-HFD-fed littermates. Interestingly, 
the LowMg-HFD group had decreased mass of epididymal and inguinal white 
adipose tissue (eWAT and iWAT, respectively) (Fig. 4A,B), which may point towards 
defective lipid handling in WAT. The HFD increased adipocyte size (Fig. 4C,D), but no 
significant difference was observed between the two HFD groups (Fig. 4C,D). 
Nevertheless, quantitative PCR showed that mRNA expression ofSrebp1c, Pepck1 
and genes involved in beta-oxidation was increased in the eWAT of the LowMg-HFD 
group compared with the NormMg-HFD group (Supplementary Fig. 3A-F). 
Figure 2 | Continued.
(A) Glucose clearance determined by IPGTT at week 15. (B) Serum insulin measured at 0, 15 and 
120 mins of the GTT. (C) AUC determined between 0 and 120 min. (D) Fasting blood glucose and 
(E) serum insulin measured during the GTT. (F) Blood glucose measured during an intraperitoneal 
ITT at week 14. (G) AUC determined between 0 and 120 min (two-way ANOVA for dietary Mg2+ 
effect, p<0.05). Non-fasted serum (H) triglyceride, (I) FFA and (J) leptin concentrations at killing. 
NormMg-LFD (white circles), LowMg-LFD (grey circles), NormMg-HFD (white squares), LowMg-
HFD (grey squares). Data are mean ± SEM. *p<0.05 for the comparisons shown.
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To determine the consequences of low Mg2+ on lipid metabolism, we performed 
RNA sequencing on eWAT. A principal component analysis using the log2 transformed 
expression values shows that the samples from both LFD groups cluster closely 
together, indicating the absence of a strong Mg2+ effect, whereas there is a clear 
separation of NormMg-HFD vs LowMg-HFD gene expression profiles (Fig. 4E). To 
investigate the effect of Mg2+ on specific biological pathways, the fold changes for 
groups of genes belonging to the same gene ontology were analysed. Gene ontology 
term analysis indicated that processes associated with adiposity (e.g. inflammation) 
were downregulated in LowMg-HFD-fed vs NormMg-HFD-fed mice, in accordance 
with decreased adipose tissue mass (Supplementary Table 1). Interestingly, despite 
the increased insulin sensitivity of the LowMg-HFD-fed mice, several key genes 
involved in the triglyceride catabolism pathway (lipolysis) were upregulated in the 
LowMg-HFD vs the NormMg-HFD group, which may explain the reduced lipid 
Figure 3 | Mg2+ deficiency prevents diet-induced hepatic lipid storage
Liver (A) weight and (B) triglyceride content at death. Representative images of livers stained with 
(C) H&E or (D) Oil Red O. Scale bars, 100 μm. NormMg-LFD (white circles), LowMg-LFD (grey 
circles), NormMg-HFD (white squares), LowMg-HFD (grey squares). Data are mean ± SEM. 
*p<0.05 for the comparisons shown.
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Figure 4 | Reduced adipose tissue mass in Mg2+-deficient HFD-fed mice is associated
with increased mRNA expression of lipolysis genes in eWAT
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storage as well as the high serum FFA levels (Fig. 4F). A modest increase in acyl-CoA 
dehydrogenase dependent beta-oxidation was observed in the LowMg-HFD-fed 
mice vs the NormMg-HFD-fed mice (Fig. 4G). The metabolic effects of Mg2+ in eWAT 
appear to be specific to lipid homeostasis, as there was no clear effect on glycolysis 
(Supplementary Fig. 3G). Although serum cholesterol levels were not different 
between the experimental groups, cholesterol biosynthesis was greatly reduced in 
the LowMg-HFD-fed vs the NormMg-HFD-fed mice (Supplementary Fig. 3H). 
  To investigate whether hypomagnesemia has a direct effect on lipolysis in eWAT, 
we examined the effect of Mg2+ on lipolysis in differentiated 3T3-L1 cells in vitro. 
Unstimulated lipolysis was not different at 0 or 1 mmol/L Mg2+, indicating that Mg2+ 
deficiency does not directly induce lipolysis in adipocytes (Supplementary Fig. 4). 
mRNA expression of the β3-adrenergic receptor is increased in 
LowMg-HFD mice
β3-Adrenergic receptors (ADRB3) are essential regulators of lipid metabolism, 
increasing brown adipose tissue (BAT) activity and reducing WAT lipid storage via 
activation of lipolysis (29-32). We therefore explored whether enhanced β-adrenergic 
signalling could explain the high triglyceride levels, increased lipolysis and reduced 
body weight of Mg2+-deficient HFD-fed mice. Expression of Adrb3 was significantly 
increased by 2.5-fold in the eWAT of LowMg-HFD-fed compared with NormMg- 
HFD-fed mice (Fig. 5A). Additionally, both HFD-fed groups showed elevated mRNA 
expression of Adrb3 in BAT, but this upregulation was more pronounced in the 
LowMg-HFD group (Fig. 5B). No significant difference was observed in the serum 
level of the dopamine metabolite 3-methoxytyramine (Fig. 5C). 
Figure 4 | Continued.
Weight of (A) eWAT and (B) iWAT, and (C) eWAT cell size at killing. NormMg-LFD (white circles), 
LowMg-LFD (grey circles), NormMg-HFD (white squares), LowMg-HFD (grey squares). Data are 
mean ± SEM. (D) Representative images of H&E stained eWAT. Scale bars, 100 μm. (E) Principal 
component (PC) analysis of RNA sequencing on eWAT. The percentages on the x-axis and 
y-axis indicate the total percentage of variance explained by the first two principal components 
respectively. GO-term analyses of the pathways (F) ‘triglyceride catabolic process’ and (G) 
‘β-oxidation using acyl-CoA dehydrogenase’; and ‘positive regulation of fatty acid β-oxidation’. 
Gene expression changes are presented as log2 fold changes with the NormMg2+ diet as 
reference, so that a negative value (in red) indicates a decrease in expression in the NormMg2+ 
vs LowMg2+ groups. *p<0.05 for the comparisons shown.
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Figure 5 | mRNA expression of the β3-adrenergic receptor is increased in eWAT of LowMg- HFD-
fed mice
Relative mRNA expression of Adrb3 in (A) eWAT and (B) BAT, normalised to Gapdh expression, 
relative to NormMg-LFD. (C) Serum 3-methoxytyramine concentration at death. eWAT mRNA 
expression of genes essential for lipolysis, (D) Hsl, (E) Atgl and (F) Mgll, and BAT mRNA 
expression of (G) Ucp1, (H) Cpt1-m and (I) Atgl. NormMg-LFD (white circles), LowMg-LFD (grey 
circles), NormMg-HFD (white squares), LowMg-HFD (grey squares). Data are mean ± SEM. 
*p<0.05 for the comparisons shown.
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Gene expression of the lipolysis genes adipose triglyceride lipase (Atgl), hormone- 
sensitive lipase (Hsl) and monoglyceride lipase (Mgll) was significantly increased 
in eWAT of Mg2+-deficient HFD-fed mice compared with the NormMg-HFD group 
(Fig. 5D-F). 
  Expression of Ucp1 in BAT, which is essential for non-shivering thermogenesis, 
was upregulated in NormMg-HFD-fed mice compared with NormMg-LFD-fed mice 
(Fig. 5G). In line with increased β3-adrenergic signalling, Ucp1 expression was further 
increased in BAT of LowMg-HFD-fed mice. BAT thermogenesis is strongly regulated 
by fatty acid availability (33). Indeed, essential genes involved in FFA metabolism of 
BAT are upregulated (Fig. 5H,I). 
LowMg-HFD-fed mice have increased body temperature but equal 
energy expenditure 
  To investigate the energy metabolism in Mg2+-deficient HFD-fed mice, the dietary 
intervention study was repeated with respiratory cages. Respiration, body temperature 
and activity were measured at week 8, which was when the weight differences developed 
in our first experiment. In line with the previous experiment, the Mg2+-deficient 
HFD-fed mice had reduced body weight compared with the NormMg-HFD-fed mice 
(Fig. 6A). Lean body mass was not different between the two HFD groups, indicating 
that the weight difference depends on adipose tissue mass (Fig. 6B). As with our 
previous experiment, the HFD caused a reduction in serum Mg2+ levels (Fig. 6C). 
A significant increase was observed in serum triglyceride when animals were killed 
(after 9 weeks) in the LowMg-HFD group compared with the NormMg-HFD group 
(Fig. 6D). Low dietary Mg2+-fed mice had decreased non-fasted serum glucose (Fig. 6E; 
two-way ANOVA for dietary Mg2+ effect p<0.05), while the difference between the 
two HFD-fed groups was not significant (NormMg-HFD vs LowMg-HFD, Tukey’s test 
p=0.07). Hypomagnesemia and HFD decreased core body temperature (Fig. 6F). 
In contrast, the body temperature of LowMg-HFD-fed mice was higher than 
NormMg-HFD-fed mice (Fig. 6F; 35.8 ± 0.1 vs 36.4 ± 0.2 °C in NormMg-HFD and 
LowMg-HFD, p<0.05), in line with increased BAT activity. Moreover, mice fed a 
Mg2+-deficient diet showed increased locomotor activity (Supplementary Fig. 6A,B; 
two-way ANOVA for dietary Mg2+ effect p<0.05). However, energy expenditure was 
not different between the two HFD-fed groups (Fig. 6G,H). In both HFD groups, the 
respiratory exchange ratio (RER) was approximately 0.7, indicating that fatty acids are 
the main energy source (Fig. 6I,J). Interestingly, in the LFD groups, hypomagnesemia 
resulted in a reduction of the RER (Fig. 6I,J), suggesting an increased use of fatty 
acids as an energy substrate over glucose. However, this reduction was not statistically 
significant (Fig. 6J; 0.82 ± 0.01 vs 0.79 ± 0.01 average RER in NormMg-LFD and 
LowMg-LFD, respectively; p=0.10).
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Figure 6 | LowMg-HFD-fed mice have increased body temperature but equal energy expenditure
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Discussion
Hypomagnesemia has been repeatedly reported in T2D or the metabolic syndrome 
(1, 2, 14), but the role of Mg2+ in lipid metabolism has been largely overlooked. 
Here, we demonstrate that low dietary Mg2+ intake ameliorates HFD-induced obesity. 
The lower body weight results in beneficial metabolic effects including improved 
insulin sensitivity, reduced hepatic steatosis and lower WAT inflammation. Nevertheless, 
serum triglyceride and FFA concentrations were increased in the low Mg2+ HFD group, 
corresponding to increased eWAT mRNA expression of lipolysis genes. These findings 
establish Mg2+ as an important regulator of body weight and lipid metabolism. 
  In this study, a Mg2+-deficient diet ameliorated HFD-induced weight gain in 
mice. This was the result of reduced adiposity, because lean body mass was similar 
between the two HFD groups and both eWAT and iWAT weight were lower in mice fed 
a LowMg-HFD compared with a NormMg-HFD. The reduced body weight was 
associated with favourable metabolic effects. IPGTT, IPITT and fasting glucose levels 
indicated enhanced insulin sensitivity. Moreover, the reduced body weight of the 
LowMg-HFD mice led to a complete absence of hepatic steatosis and RNA 
sequencing of the eWAT demonstrated downregulation of pro-inflammatory 
pathways. Despite these beneficial effects, blood lipid levels remained high. In line 
with our data, others have demonstrated that low dietary Mg2+ intake reduced body 
weight in several rat models of Mg2+ deficiency (34-37). However, these studies did 
not address the underlying cause or investigate the effects on lipid metabolism. 
  Our animal data is strengthened by the results of Chubanov et al (17) where 
severe hypomagnesemia via Trpm6 knockout also resulted in a catabolic phenotype 
and improved insulin sensitivity (17). The catabolic phenotype of Mg2+-deficient mice 
leads to hyperlipidemia, which has considerable adverse effects in individuals with 
Figure 6 | Continued.
A replication animal study was performed for a duration of 9 weeks. (A) Body weight and (B) 
lean body weight of the animals at death. Non-fasted serum (C) Mg2+, (D) triglyceride and (E) 
glucose concentrations at killing (serum glucose two-way ANOVA for dietary Mg2+ effect 
p<0.05; NormMg-HFD vs LowMg-HFD Tukey’s test p=0.07). (F) Body temperature, (G) energy 
expenditure averaged per hour and corrected for lean weight, (H) from which the AUC is 
calculated, measured after 8 weeks of dietary intervention. (I) RER averaged per hour, 
measured after 8 weeks of dietary intervention. RER is determined by dividing the CO2 
production by the O2 intake. (J) Average RER over the entire duration of the measurement 
(from 18:30 to 09:30 hours). NormMg-LFD (white circles), LowMg-LFD (grey circles), 
NormMg-HFD (white squares), LowMg-HFD (grey squares). Data are mean ± SEM. *p<0.05 
for the comparisons shown.
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T2D (38, 39). Nevertheless, the low Mg2+ HFD does not completely mimic the human 
situation because the hypomagnesemia induced in mice is more severe (1). Moreover, 
an unhealthy human diet consists of both high fat and sugar, whereas the HFD in 
mice purely depends on palm oil. Indeed, Mg2+-deficiency in high-fructose diets 
has adversely affected insulin sensitivity and lipid homeostasis in rats. This shows 
the considerable differences in the role of Mg2+ in the metabolism of lipids vs 
carbohydrates (40, 41). Future studies should investigate the role of Mg2+ in combined 
fat and sugar diets. These differences may explain why, in humans, higher oral Mg2+ 
intake and Mg2+ supplementation have beneficial effects on metabolic variables, 
which apparently contrasts with our animal data (18-20).
  In our study, the reduced WAT mass of LowMg-HFD-fed mice was associated 
with enhanced lipolysis gene expression, causing high serum FFA and triglyceride 
levels. These findings suggest that LowMg-HFD-fed mice depend more on 
mitochondrial beta-oxidation, rather than glycolysis, for energy production. However, 
our energy metabolism experiments demonstrated neither differences in energy 
expenditure nor in RER between the NormMg-HFD and LowMg-HFD groups. It should be 
noted, however, that both HFD groups mainly depend on lipids for energy metabolism, 
masking potential RER differences between these groups. Moreover, despite equal 
energy expenditure, the NormMg-HFD-fed mice are considerably heavier than 
LowMg-HFD-fed mice and therefore have a higher energy demand. Several studies 
have discussed the considerable difficulties associated with the interpretation of 
energy expenditure data and emphasised that body weight differences complicate 
interpretation (42, 43). Increased thermogenesis may explain why energy expenditure 
does not differ between LowMg-HFD-fed and the heavier NormMg-HFD-fed mice. 
Although the effects are modest, the LowMg-HFD-fed mice had a significantly higher 
body temperature and increased Ucp1 expression in BAT, indicative of higher 
thermogenesis. Cold-exposure studies are necessary to further investigate the role of 
Mg2+ status in BAT activation, WAT browning and thermogenesis.
  The increased lipolysis and brown adipose tissue activity were associated with 
higher β3-adrenergic receptor expression in eWAT and BAT of LowMg-HFD-fed mice. 
β3-receptor knockout mice have increased lipid stores and impaired WAT browning 
(44, 45). Activation of the β3-adrenergic receptors in mice using agonist CL316243 
decreases adipose tissue mass, improves insulin sensitivity, increases uncoupling 
protein-1 (UCP1)-dependent thermogenesis and activates a cycle of concomitant 
lipolysis and de novo lipogenesis (46, 47). Interestingly, this is exactly the phenotype 
that was observed in the LowMg-HFD-fed mice, although to a lesser extent. A link 
between Mg2+, β-adrenergic signalling and lipolysis is not without precedent. Use of 
β-adrenergic agonists, which stimulate lipolysis, have been associated with decreased 
blood Mg2+ levels (1, 48, 49). Mg2+ has also been shown to reduce catecholamine 
release from the adrenal medulla (50) and Mg2+ deficiency is associated with higher 
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urinary levels of adrenaline and noradrenaline (norepinephrine) (37). Moreover, Mg2+ 
supplementation has been suggested to regulate lipolysis, as it prevents hyperlipidemia 
in diabetic rats and reduces serum triglyceride levels in individuals with T2D (20, 51). 
Further research is required to determine exactly how hypomagnesemia increases 
β-adrenergic signalling and how β-adrenergic signalling can induce hypomagnesemia.
  A strength of this study is that the model used to induce T2D and low dietary 
Mg2+ intake closely resembles the human situation. The Western diet contains high 
amounts of processed foods consisting of high energy and low Mg2+. Moreover, the 
extensive phenotyping of the animals in this study provides new avenues for research 
into the pivotal role of Mg2+ in metabolism. The data obtained in this study are robust, 
as a replicate animal experiment was performed in a separate institution, confirming 
our results.
  Our study has limitations. First, because of the large weight differences induced 
by the Mg2+ deficient diet, it is difficult to specifically attribute the metabolic changes 
of the mice to their lower body weight or their Mg2+ deficiency. In addition, our study 
design did not allow us to study in more depth the contribution of disturbed 
β-adrenergic signalling to the differences in body weight, eWAT lipolysis, BAT activity 
and hyperlipidemia. Although our data and previous studies support a role for Mg2+ 
in β-adrenergic signalling (37, 50), further studies are required to establish the exact 
role of Mg2+ in catecholamine secretion and signalling. 
  In conclusion, our results demonstrate that hypomagnesemia in mice prevents 
HFD-induced weight gain by enhanced BAT activity and increased eWAT lipolysis 
gene expression. Consequently, this led to improved insulin sensitivity and absent 
hepatic steatosis. These results underline the pivotal function of Mg2+ in maintaining 
a healthy energy metabolism. 
Materials and methods
17-week mouse study – Radboud university medical center
This study was approved by the animal ethics board of the Radboud University 
Nijmegen (RU DEC 2015-0073) and the Dutch Central Commission for Animal 
Experiments (CCD, AVD103002015239). To study the effect of dietary Mg2+ on 
HFD-induced obesity, 48 male C57BL6/J mice (Charles River, Germany), age 9-10 
weeks, were randomly allocated into four experimental groups of n=12 mice. Mice 
were acclimatized for two weeks in a temperature- and light-controlled room, six per 
cage (Eurostandard Type III), and had ad libitum access to acidified tap water and 
standard pellet chow (Ssniff Spezialdiäten, GmbH, Germany). Experimental diets 
consisted of both 10 or 60 kcal% palm oil and 0.03 or 0.21 w/w% magnesiumoxide 
(Ssniff Spezialdiäten, NormalMg-LFD #S9074-E0277, LowMg-LFD #S9074-E0287, 
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NormalMg-HFD #S9074-E0297, LowMg-HFD #S9074-E0317). Researchers and 
animal caretakers were blinded for the Mg2+ content of the experimental diets 
throughout the experiment. At day -1, 84 and 112, mice were housed individually in 
metabolic cages for 24 hours for the collection of urine and faeces and determining 
food and water intake. Mice were weighed twice weekly and blood was collected via 
cheek puncture at day -1, 28, 56 and 84. At week 14 and 15 insulin and glucose 
tolerance tests, respectively, were performed. One mouse died unrelated to the 
dietary intervention and was excluded from future analyses. After 17 weeks on the 
diets, mice were anaesthetized by 4 v/v% isoflurane and exsanguinated via orbital 
sinus bleeding. Death was confirmed by cervical dislocation. Tissues were stored in 
10 v/v% formalin or snap frozen in liquid nitrogen.  
Intraperitoneal insulin and glucose tolerance tests
After 14 weeks on the diets, three mice per group per day underwent an intraperito-
neal insulin tolerance test (IPITT), over a period of four days (n=9 mice/group). After 
6 hours of fasting from 08:00 AM, mice were injected with 0.75 U/kg bodyweight 
human insulin (Novorapid, Novo Nordisk, Denmark) dissolved in phosphate buffered 
saline (PBS). Blood glucose levels were measured at 0, 20, 40, 60, 90 and 120 
minutes after the insulin injection. Blood was taken via a tail cut and glucose levels 
were measured using a StatStrip® Xpress glucose meter (Nova Biomedical, USA). 
Three mice developed severe hypoglycaemia and were injected with D-glucose 
(Invitrogen, The Netherlands) between 15 and 30 minutes post insulin-injection. For 
the subsequent time points, these mice were given the same glucose values as the 
lowest values within that group. After 15 weeks on the diets, three mice per group per 
day underwent an intraperitoneal glucose tolerance test (IPGTT), over a period of four 
days (n=12 mice/group). After an overnight fast (from 18:00 to 09:00), mice were 
injected with 2 g/kg body weight D-glucose (Invitrogen, The Netherlands) dissolved 
in PBS, with an injection volume of 50ul/10g body weight. Blood glucose levels were 
measured at 0, 15, 30, 60 and 120 minutes after the glucose injection.
Quantitative real-time PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen, Paisley, UK), subjected to 
DNase (Promega, Fitchburg, WI, USA) treatment and measured using the Nanodrop 
2000c spectrophotometer (Thermo Scientific, Waltham, MA, USA). RNA was reverse 
transcribed using Moloney murine leukaemia virus (M-MLV) reverse transcriptase 
(Invitrogen, Bleiswijk, the Netherlands). Gene expression levels were quantified by 
SYBR-Green (Bio-Rad, Veenendaal, the Netherlands) on a CFX96 real-time PCR 
detection system (Bio-Rad, Veenendaal, the Netherlands) and normalised for Gapdh. 
Primer sequences are provided in Table 2.
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Histology
Epididymal fat and liver tissues were fixed in 10% vol./vol. neutral-buffered formalin 
(KLINIPATH, Duiven, the Netherlands) in PBS. Samples were dehydrated through 
alcohol, embedded in paraffin and cut into 4 μm sections. Sections were stained with 
H&E using standard procedures. The average cell size of 100-300 cells per mouse 
was determined manually using ImageJ software (v1.48, NIH, USA, RRID:SCR_003070). 
Liver samples were snap frozen in liquid nitrogen, cut into 10 μm sections, stained with 
Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) and counterstained with haematoxylin. 
RNA-Sequencing
Total RNA was extracted from epididymal white adipose tissue using TRIzol reagent 
(Invitrogen, UK) according to manufacturer’s protocol. RNA integrity was validated by 
investigating the 18S/28S bands on a 2 w/v% agarose gel. Five randomly selected 
Table 1 | RT-qPCR Primer sequences
Gene Forward primer (5’  3’) Reverse primer (5’  3’)
Adrb3
Atgl
Cact
Cd36
Cpt1-l
Cpt1-m
Cpt2
Fbp1
G6pase
Gapdh
Glut1
Glut2
Glut4
Gs
Gyk
Hmgcs1
Hsl
Mgll
Pepck1
Pk-lr
Ppar-α 
Ppar-γ
Srebp1
Ucp1
TCCGTCGTCTTCTGTGTAGC
GAGGAATGGCCTACTGAACCAAC
CGATTCCAGACTGCACCTCC
TGCATGAATTAGAACCGGGC
GTGAGCCTGGCCTCGCC
CTGGGCTATCTGTGTCCGTC
GTATCTGCAGCACAGCATCG
CCCAGCTGCTGAATTCGCTC
TTGGACAACGCCCGTATTGG
TAACATCAAATGGGGTGAGG
GGGTCTTAAGTGCGTCAGGG
AGAAGACAAGATCACCGGAACC
CTTATTGCAGCGCCTGAGTC
TGACTGAGCTCAAACGAAATGATTC
GTTGTCCCCTCTGGCTCTTC
TCCCCTTTGGCTCTTTCACC
AGGGAGGGCCTCAGCG
CGGAACAAGTCGGAGGGTTC
CCTAGTGCCTGTGGGAAGAC
CAGTATGGAAGGGCCAGCAG
GTGGTGCATTTGGGCGTATC
CTGACGGGGTCTCGGTTG
CAGCCACACTTCATCAAGGC
TGGCCTCTTTAACCCTGCTG
GCCATCAAACCTGTTGAGCG
AGGCTGCAATTGATCCTCCTC
CGCGGATCATGACTGCATTG
TCTCCTCGTGCAGCAGAATC
TGAGTGGTGACCGAGTCTGC
GGGACAGGAAGCTTAGGCAG
GTTTAGGGATAGGCAGCCTGG
AGCGATACCATAGAGCTGTGC
GGACTTCCTGGTCCGGTCTC
GGTTCACACCCATCACAAAC
TCACCTTCTTGCTGCTGGG
TCACACCGATGTCATAGCCG
GTTCCCCATCGTCAGAGCC
TGCATCAGGGTGTGGATCTG
AGGCCTGTCTTGGACTTGAC
TCCCACATCTTTTGGCCAGC
TGTCTTCTGCGAGTGTCACC
TGTTTTGTCCTGACTCCGGG
AGCCCTTAAGTTGCCTTGGG
CAGGAAGGTGTCCGCCATAG
TGAACTTCAACTTGGCTCTCC
CAACCATGGTAATTTCAGTAAAGGGCC
ACTCACCAGGGTCTGC
GATTAGGGGTCGTCCCTTTCC
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samples of each group were RNA-sequenced (RNA-Seq). Quality control and 
RNA-Seq were performed by Beijing Genomics Institute (BGI), Hong Kong). Quality 
control was performed by using Agilent 2100 Bioanalyzer and ABI StepOnePlus 
Real-Time PCR System to qualify and quantify the sample library. One sample from the 
NormalMg-LFD group failed the quality control, and was excluded from subsequent 
sequencing and analyses. One sample from the LowMg-HFD group showed a small 
contamination with pancreatic tissue and was excluded from subsequent analyses. 
13 million reads were sequenced using the Hiseq 4000 platform (Illumina, USA) using 
a 50 bp single-end module. Clean reads were mapped to Mus Musculus transcriptome 
(GRCm38/mm10) using HISAT/Bowtie2 tool (24, 25). RSEM software v1.2.31 was 
used to quantify gene expression levels (FPKM values)(26). FPKM values were log2 
transformed and further analysed in R (www.r-project.org, RRID:SCR_001905). In 
order to filter non-expressed transcripts from the data, only transcripts that showed 
an average expression level of 8 within a group and for which the transcript levels 
were above 8 in at least four replicates from an experimental group were retained, 
yielding a total of 8808 transcripts. To calculate the differences between expression 
levels for genes belonging to the same Gene Ontology group, the fold change 
between the LowMg and NormalMg condition for both the HFD and LFD groups were 
collected for each gene in the group. Subsequently a t-test was used to test for the 
hypothesis of equal means. The procedure was repeated for all GO terms and the 
p-values for the tests were corrected for multiple testing using the Benjamini-Hoch-
berg method as implemented in the p.adjust method in R. Heatmaps for individual 
GO terms were created using the ggplot2 library (RRID:SCR_014601) (27).
Analytical procedures 
Serum Mg2+ was determined using a spectrophotometric assay at 600 nm (Roche/
Hitachi, Tokyo, Japan) according to the manufacturer’s protocol. Liver samples were 
weighed and lysed in lysis buffer (10% wt/vol.) containing 50 mmol/L Tris-HCl pH 7.5, 
1 mmol/L EGTA, 1 mmol/L EDTA, 1% vol./vol. Triton X-100, 10 mmol/L glycerophosphate, 
1 mmol/L sodium orthovanadate, 50 mmol/L sodium fluoride, 10 mmol/L sodium 
pyrophosphate and 150 mmol/L sodium chloride. Triglyceride concentrations in 
serum and liver lysate were assayed using an enzymatic kit (Roche Molecular 
Biochemicals, Indianapolis, IN, USA), according to the manufacturer’s protocol. 
Serum FFA (NEFA-C kit, WAKO Diagnostics, Delfzijl, the Netherlands), cholesterol 
(Human Diagnostics, Wiesbaden, Germany), glucose (Instruchemie, Delfzijl, the 
Netherlands), leptin (R&D Systems, Minneapolis, MN, USA) and adiponectin (R&D 
Systems, Minneapolis, MN, USA) concentrations were determined according to 
manufacturers’ protocols. 3-Methoxytyramine and normetadrenaline (normetanephrine) 
were analysed by a 6490 LC-MS/MS (Agilent Technologies, Amstelveen, the Netherlands) 
after solid phase extraction (SPE) Oasis WCX μElution sample cleanup (Waters, 
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Etten-Leur, the Netherlands). A calibration curve was used with 3-methoxytyramine-HCl 
(Sigma-Aldrich, St. Louis, MO, USA) as calibrator. 3-Methoxytyramine-d4-HCl 
(Medical Isotopes, Pelham, NH, USA) was used as internal standard. An ethylene 
bridged hybrid (BEH) Amide 1.7 μm 100A, 2.1 x 100 mm column (Waters, Etten-Leur, 
the Netherlands) was used as an analytical column.
9-Week replication mouse study – MRC Harwell Institute
All experimental procedures were conducted in compliance with the UK Animals 
Scientific Procedures Act (1986) and University of Oxford ethical guidelines. 39 male 
C57BL6/J mice (MRC Harwell, UK) were randomly allocated into 4 groups of n=10 
mice (n=9 in the LowMg-LFD group) housed with five per cage (1284L and 1285L 
IVC, Tecniplast, Italy). Mice had ad libitum access to demineralized chlorinated tap 
water and standard pellet chow. At 8 weeks old, mice were put on experimental diets 
identical to the first animal experiment at the Radboudumc, for a period of 9 weeks. 
At day 14, mice were housed individually in metabolic cages (Tecniplast, Italy) for 24 
hours for the collection of urine and faeces and determining food and water intake. 
Mice were weighed twice weekly and blood was collected via tail bleed at day -1 and 
14. Respiration metabolic cages (TSE Phenomaster Cages, Germany) were used at 
day 28 and 56 of the experiment and body temperatures were measured by rectal 
probe (ATP-instrumentation, UK). Data were averaged per hour and plotted from 6:30 
PM to 9:30 AM. After 9 weeks on the diets, mice were anaesthetized by 4 vol./vol.% 
isoflurane and exsanguinated via orbital sinus bleeding. Death was confirmed by 
cervical dislocation. Tissues were stored in 10 v/v% formalin or snap frozen in liquid 
nitrogen.
Lipolysis in 3T3-L1 adipocytes
3T3-L1 fibroblasts (ATCC, mycoplasma-free) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Lonza Westburg, Leusden, the Netherlands) containing 2 
mg/ml ciproxin (Fresenius Kabi, Zeist, The Netherlands), 200 mmol/L L-glutamine 
(GE healthcare Life Sciences, Logan, UT, USA) and 10 vol./vol.% fetal bovine serum 
(FBS, Greiner Bio One), at 37 °C, in 5 vol./vol.% CO2. 3T3-L1 cells between passages 
10 and 20 were differentiated according to ATCC’s protocol. In short, cells were 
seeded in PLL (Sigma-Aldrich) coated 6-well plates in DMEM and upon confluence 
medium was refreshed. Two days post-confluence the induction process was initiated 
by changing the medium to induction medium containing 1 μg/mL bovine insulin 
(Sigma-Aldrich, St. Louis, MO, USA), 0.5 mmol/L IBMX (Sigma-Aldrich), and 1 μmol/L 
dexamethasone (Sigma-Aldrich) for 48 hours. The cells were then washed (PBS) and 
DMEM containing 1 μg/mL insulin was added. Hereafter, the medium was refreshed 
every two days until >90% of the cells were completely differentiated into adipocytes. 
To determine the effect of Mg2+ on lipolysis, differentiated 3T3-L1 cells were incubated 
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for 20 hours in DMEM without added insulin, containing 1.0 or 0 mmol/L MgCl2, 
followed by 2 hours serum-starvation. Hereafter, cells were incubated for 4 hours in 
700 μl KRPH buffer (20 mmol/L HEPES pH 7.4, 5 mmol/L KH2PO4, 1 mmol/L CaCl2, 
136 mmol/L NaCl, 4.7 mmol/L KCl at 37 °C) containing 1.0 or 0 mmol/L MgCl2, 0.1 wt/
vol.% glucose (Merck Millipore, Amsterdam, the Netherlands) and 3.5 wt/vol.% fatty 
acid free BSA (Sigma-Aldrich). 50 μL aliquots of the medium were taken every hour 
and heated for 8 minutes at 65 °C. The concentration of FFAs was assessed using the 
WAKO NEFA-C kit (Instruchemie, Delfzijl, the Netherlands) according to the 
manufacturer’s protocol.  
Statistics
For the animal experiments, a two-way ANOVA was used to look for a significant 
interaction effect between the two main variables (dietary fat and Mg2+ content). If 
there was none, significant differences between the groups were assessed using a 
two-way ANOVA approach with a Tukey’s multiple comparisons test. If the two-way 
ANOVA demonstrated a significant interaction effect between the two main variables, 
an unpaired multiple t test approach using the Holm–Sidak method for multiple 
comparisons was used. Statistical significance was determined using Graphpad 
Prism v7 (California, USA, RRID: SCR_002798). For the lipolysis assays, an unpaired 
Student’s t test was used.  Differences with a p-value of <0.05 were considered 
statistically significant. Results are presented as mean ± SEM.
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Supplementary data
Supplementary figure 1 | Changes in dietary Mg2+ do not affect serum adiponectin and 
cholesterol concentrations
Non-fasted serum concentrations of (A) adiponectin and (B) cholesterol at killing. NormMg-
LFD (white circles), LowMg-LFD (grey circles), NormMg-HFD (white squares), LowMg-HFD 
(grey squares). Data are mean ± SEM. *p<0.05 for the comparisons shown.
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Supplementary figure 2 | Hepatic mRNA expression of key genes involved in energy metabolism
Hepatic mRNA expression of (A) Cd36, (B) Srebp1c (two-way ANOVA for dietary Mg2+ effect 
p<0.05), (C) Pepck1 (two-way ANOVA for dietary Mg2+ effect p<0.05; NormMg-HFD vs. LowMgHFD 
Tukey’s test p=0.06), (D) Glut2, (E) Pparα, (F) G6pase, (G) Fbp1, (H) Pk-lr, (I) Cpt1-l (two-way ANOVA 
dietary fat effect p<0.05), (J) Gyk, (K) Gs and (L) Hmgcs1 normalized to Gapdh expression, relative 
to NormMg-LFD. NormMg-LFD (white circles), LowMg-LFD (grey circles), NormMg-HFD (white 
squares), LowMg-HFD (grey squares). Data are mean ± SEM. * Indicates p<0.05.
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Supplementary figure 3 | Increased mRNA expression of key genes involved in gluconeogenesis 
and beta-oxidation in the eWAT of LowMg-HFD mice and heatmaps of eWAT RNA-Seq GO-Term 
glycolysis and cholesterol biosynthesis pathways
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Supplementary figure 3 | Continued.
Epididymal white adipose tissue (eWAT) mRNA expression of (A) Pparγ, (B) Srebp1c, (C) Pepck1, 
(D) Cpt1-l, (E) Cpt2 and (F) Cact, normalized to Gapdh expression, relative to NormalMg-LFD. 
GO-Term Analyses of the Pathways (G) ‘Glycolytic Process’ and (H) ‘Cholesterol Biosynthesis’. 
Gene expression changes are presented as log2 fold changes with the NormalMg2+ diet as 
reference, so that a negative value (in red) indicates a decrease in expression in the NormalMg2+ 
versus LowMg2+ groups. NormalMg-LFD (white circles), LowMg-LFD (grey circles), NormalMg-
HFD (white squares), LowMg-HFD (grey squares). Data are mean ± SEM. * Indicates p<0.05.
Supplementary figure 4 | Extracellular Mg2+ deficiency does not directly induce lipolysis in 
3T3-1L adipocytes
3T3-1L cells were differentiated into adipocytes and cultured in 0 (open circles) or 1 (closed 
circles) mmol/L extracellular MgCl2 for 22 hours. As a measure of the rate of lipolysis, the free 
fatty acid concentration in the medium was measured over a period of 4 hours (n=3 wells per 
time point per condition). A figure of a representative experiment is shown. The experiment was 
repeated with similar results. Data are mean ± SEM.
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Supplementary figure 5 | Mice on a low dietary Mg2+ content have increased locomotor activity
(A) Distance walked by mice, averaged per hour from 18:30 to 09:30, measured after 8 weeks 
of dietary intervention, (B) from which the total distance walked during this period is calculated 
(two-way ANOVA for dietary Mg2+ effect p<0.05). NormalMg-LFD (white circles), LowMg-LFD 
(grey circles), NormalMg-HFD (white squares), LowMg-HFD (grey squares). Data are mean ± SEM. 
* Indicates p<0.05.
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Supplementary table 1 | List of differentially regulated GO-terms from the RNA-Seq on white 
adipose tissue between NormalMg-HFD and LowMg-HFD. A negative log2 fold change indicates 
a higher expression in the NormalMg-HFD group compared to the LowMg-HFD.
GO-Term; 10 lowest p-values Corrected 
p-value
Log2 Fold 
change
Translational initiation 
Protein transport
SRP-dependent cotranslational protein targeting to membrane
Intracellular protein transport
RRNA processing
Viral transcription
Cell division
Cytoplasmic translation
Nuclear-transcribed mRNA catabolic process,  
nonsense-mediated decay
Cell proliferation
3.5E-06
6.5E-06
9.2E-06
1.1E-05
1.4E-05
7.1E-05
7.7E-05
7.7E-05
7.7E-05
8.2E-05
-0.26
-0.12
-0.30
-0.15
-0.21
-0.31
-0.15
-0.21
-0.24
-0.17
GO-Term; 10 largest positive fold change (decreased in 
NormalMg-HFD compared to LowMg-HFD)
Corrected 
p-value
Log2 Fold 
change
Positive regulation of cholesterol esterification
Positive regulation of heat generation
Negative regulation of neurotrophin TRK receptor signalling pathway
Positive regulation of double-strand break repair
L-glutamate import
Positive regulation of renal sodium excretion
Drug metabolic process
DNA dealkylation involved in DNA repair
Angiotensin mediated vasoconstriction involved in regulation of 
systemic arterial blood pressure
Desmosome assembly
0.57
0.55
0.74
0.74
0.62
0.65
0.40
0.76
0.76
0.36
1.00
0.68
0.67
0.67
0.65
0.63
0.62
0.61
0.61
0.61
GO-Term; 10 largest negative fold change (increased in 
NormalMg-HFD compared to LowMg-HFD)
Corrected 
p-value
Log2 Fold 
change
Positive regulation of T cell differentiation in thymus
Negative regulation of B cell receptor signalling pathway
Positive regulation of type III hypersensitivity
Cell activation
Mast cell degranulation
Antigen processing and presentation of exogenous peptide  
antigen via MHC class I
Positive regulation of type I hypersensitivity
Sphingosine metabolic process
Positive regulation of CD4-positive, alpha-beta T cell differentiation
Positive regulation of type IIa hypersensitivity
0.51
0.21
0.05
0.70
0.49
0.11
0.16
0.67
0.24
0.26
-1.11
-1.09
-1.07
-1.06
-1.06
-1.02
-1.02
-1.02
-0.99
-0.95
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“There is a god in man
And in nature
He who sits in the dark
The bringer of light”
– Gorgoroth | The Sign of an Open Eye
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Abstract
In T2D patients, reduced blood Mg2+ levels are associated with an increased decline 
in renal function, independent of glycemic control and hypertension. To study the 
underlying mechanism of this phenomenon, we investigated the renal effects of 
hypomagnesemia in a diet-induced mouse model of T2D.
In mice fed a low dietary Mg2+, the HFD resulted in severe hypomagnesemia within 4 
weeks. Renal or intestinal Mg2+ wasting was not observed after 16 weeks on the 
diets. Despite the absence of urinary or fecal Mg2+ loss, the HFD induced a reduction 
in the mRNA expression Trpm6 in both the kidney and colon. mRNA expression of 
distal convoluted tubule (DCT)-specific genes was down-regulated by the 
LowMg-HFD, indicating atrophy of the DCT. The low dietary Mg2+ resulted in severe 
HFD-induced proximal tubule phospholipidosis, which was absent in mice on a 
NormalMg-HFD. This was accompanied by alterations in renal energy metabolism 
including enhanced gluconeogenesis and cholesterol synthesis. 
  In conclusion, this study shows that hypomagnesemia is a consequence of T2D. 
Moreover, hypomagnesemia induces major structural changes in the diabetic kidney, 
including proximal tubular phospholipidosis, providing a novel mechanism for the 
increased renal decline in hypomagnesemic T2D patients. 
Keywords: Hypomagnesemia; type 2 diabetes; proximal tubule; phospholipidosis; 
distal convoluted tubule.
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Introduction
Hypomagnesemia (blood magnesium (Mg2+) concentration <0.7 mmol/L) is present 
in approximately 30% of patients with type 2 diabetes mellitus (T2D), compared to 
2.5% in the general population (1, 2). Hypomagnesemia in T2D patients has a number 
of clinical implications. Besides general complaints such as fatigue and headache, 
hypomagnesemia increases T2D disease progression and leads to more diabe-
tes-related complications, such as renal failure, hypertension and cardiovascular 
events (3-6). Mg2+ deficiency has been shown to inversely correlate with blood 
glucose and lipid levels, which could underlie the increased risk of cardiovascular 
events and the more rapid renal function decline in hypomagnesemic T2D patients 
(1, 4, 7, 8). In the developed world, diabetic nephropathy accounts for approximately 
50% of end-stage renal disease cases, making it the main cause of end-stage renal 
disease (9). How Mg2+ deficiency contributes to a more rapid renal function decline 
in T2D patients remains unclear.
  In the physiological situation, blood Mg2+ levels are tightly regulated between 
0.7-1.05 mmol/L by the interplay of intestine, bone and kidney (10). In the kidney, 
paracellular reabsorption of Mg2+ takes place in the proximal tubule (10-25%) and in 
the thick ascending limb (TAL, 50-70%), where Mg2+ reabsorption is dependent on 
tight junction permeability (11, 12). Despite the bulk of Mg2+ uptake occurring in the 
TAL, inhibiting Mg2+ reabsorption in this segment by furosemide does not lead to 
severe hypomagnesemia, indicating the immense compensatory capacity of the 
distal convoluted tubule (DCT) (13). Therefore, fine-tuning of urinary Mg2+ excretion 
is determined by transcellular reabsorption in the DCT (10%, but fluctuant) (14). Mg2+ 
reabsorption in the DCT is regulated by hormones such as epidermal growth factor 
(EGF) and insulin (15, 16). When blood Mg2+ levels decrease, renal Mg2+ reabsorption 
in the DCT is enhanced by upregulating the gene expression and activity of the 
epithelial Mg2+ channel, transient receptor potential melastatin type 6 (TRPM6), and 
of Mg2+-transport regulators, such as Cyclin M2 (CNNM2) (17, 18). Over 40% of T2D 
patients have excessive urinary Mg2+ wasting; however, the exact origin of this renal 
Mg2+ leak remains to be elucidated (1). 
  This study investigates the effects on mineral and lipid metabolism that are 
induced in the kidney by feeding mice a Mg2+-deficient high fat diet (HFD). Repeated 
blood samples were taken to monitor Mg2+ levels over time and metabolic cages 
were used to determine urinary and fecal Mg2+ excretion. After 17 weeks, kidney 
tissue was analyzed by immunohistochemistry, electron microscopy and real-time 
qPCR (RT-qPCR). 
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Results
High fat diet feeding induces severe hypomagnesemia
To investigate the effect of T2D on Mg2+ homeostasis, mice were fed a low-fat diet 
(LFD) or a HFD combined with a normal or low dietary Mg2+ content. Both low Mg2+ 
diet groups showed decreased serum Mg2+ levels after 17 weeks on the diet (Fig. 1A,B). 
Interestingly, the LowMg-HFD mice developed an almost two-fold larger decrease in 
serum Mg2+ compared to LowMg-LFD mice (Fig. 1A,B, 0.39 ± 0.21 vs. 0.74 ± 0.12 
mmol/L decrease in NormMg-HFD vs. LowMg-HFD, respectively, p≤0.05). After 16 weeks 
on the diet, urinary Mg2+ excretion was minimal in both LowMg groups (Fig. 1C). 
Renal loss of Mg2+ was lower in NormalMg-HFD mice compared to NormalMg-LFD 
mice (Fig. 1C). The fecal Mg2+ excretion matched the results observed in the urine 
(Fig. 1D). Moreover, serum calcium (Ca2+) levels were reduced in mice fed a 
LowMg-HFD compared to a NormalMg-HFD (Fig. 1E). Serum sodium (Na+) and 
potassium (K+) concentrations were not different among all groups (Fig. 1F,G). Both 
LowMg-fed groups showed reduced renal Ca2+ excretion, while the HFD did not 
affect urinary Ca2+ excretion (Fig. 1H). In line with the serum levels, no changes were 
observed on urinary K+ and Na+ excretion between the two HFD-fed groups (Fig. 1I,J). 
A Mg2+ deficient HFD reduces mRNA expression of DCT-specific genes
Mice on the LowMg-LFD had increased mRNA expression of Trpm6 compared to 
NormalMg-LFD mice (Fig. 2A). Despite the severe hypomagnesemia of the LowMg-HFD 
mice, Trpm6 mRNA levels were not upregulated compared to NormalMg-HFD mice 
(Fig. 2A). The mRNA expression of Cnnm2, a DCT and connecting tubule (CNT) 
specific Mg2+-regulating gene, was also reduced in the LowMg-HFD fed mice 
compared to NormalMg-HFD (Fig. 2B). To investigate if a similar expression pattern 
was observed for other DCT-specific genes involved in electrolyte transport, the 
mRNA levels of parvalbumin (Pvalb) and Na+-Cl− cotransporter (Slc12a3) were 
examined. Indeed, the mRNA expression of Pvalb and Slc12a3 was decreased in the 
LowMg-HFD versus the NormalMg-HFD mice (Fig. 2C,D). Interestingly, the mRNA 
transcript of Kallikrein 1 (Klk1), a DCT/CNT-specific gene that is not directly involved in 
electrolyte transport, was also reduced in the LowMg-HFD mice (Fig. 2E). The renal 
mRNA expression of the ubiquitous Mg2+-channel Trpm7 remained unchanged 
between all mice groups (Fig. 2F). Dedifferentiation of DCT cells as a cause of lower 
mRNA expression of DCT-specific genes was ruled out based on distinct apical 
localization of NCC (Fig. 3A). To study whether there was a reduction in DCT-length, 
immunohistological stainings were performed (Fig. 3B). Based on an NCC-staining, 
the total DCT-area was 26% lower in LowMg-HFD-fed mice than NormMg-HFD mice, 
however, this did not attain statistical significance (Fig. 3B,C 2.3 ± 0.3 vs. 1.7 ± 0.3 % 
DCT-area in NormalMg-HFD vs. LowMg-HFD, respectively, p>0.05).  
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Figure 1 | Feeding mice a HFD induces hypomagnesemia within 4 weeks
(A) Serum Mg2+ levels over time. NormalMg-LFD (open triangle), LowMg-HFD (inverted open 
triangle), NormalMg-HFD (closed triangle), LowMg-HFD (inverted closed triangle). (B) Decrease 
in the serum Mg2+ concentration at 17 weeks compared to 0 weeks of dietary intervention. (C-
D) 24-Hour excretion of (C) urinary and (D) fecal Mg2+ determined using metabolic cages at 16 
weeks. (E-G) Serum (E) Ca2+, (F) K+ and (G) Na+ concentrations at sacrifice. (H-J) 24-Hour 
urinary excretion of (H) Ca2+, (I) K+ and (J) Na+ (urinary Na+ at 16 weeks, two-way ANOVA for 
dietary calorie effect, p≤0.05) determined using metabolic cages at 16 weeks. Open bars, LFD. 
Filled bars, HFD. Data are mean ± SEM, * indicates p≤0.05.
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No significant changes were observed between the two HFD groups in other genes 
involved in renal Mg2+ handling, including solute carrier family 41 member 1 (Slc41a1), 
claudin 10 (Cldn10), Cldn14, Cldn16, Cldn19, hepatocyte nuclear factor 1 homeobox B 
(Hnf1b), Egf and Mg2+ transporter MRS2 homolog (Mrs2) (Supplementary Fig. 1A-H).
A HFD reduces mRNA expression of Trpm6 in distal colon 
When blood Mg2+ levels decrease, the colon compensates by increasing the uptake 
of Mg2+ from the diet (19). Indeed, in mice fed a low dietary Mg2+ content colonic 
Trpm6 mRNA expression was upregulated (Fig. 4A). Interestingly, despite a lower 
serum Mg2+ concentration in the LowMg-HFD fed mice, colonic Trpm6 mRNA 
expression was reduced compared to LowMg-LFD mice (Fig. 4A). The colonic mRNA 
expression of Trpm7, Cnnm2 and Cnnm4 remained unchanged (Fig. 4B-D). In the 
HFD-fed mice, low dietary Mg2+ content reduced mRNA expression of Slc41a1, 
however did this not attain statistical significance (Fig. 4E, 1.23 ± 0.07 vs. 0.87 ± 0.09 
relative fold change in NormalMg-HFD vs. LowMg-HFD, respectively, p=0.06).
Figure 2 | A Mg2+ deficient HFD reduces mRNA expression of DCT-specific genes
(A-F) Renal mRNA expression of (A) Trpm6, (B) Cnnm2, (C) Pvalb, (D) Slc12a3, (E) Klk1 and 
(F) Trpm7 normalized to Gapdh expression, relative to NormalMg-LFD. Open bars, LFD. Filled 
bars, HFD. Data are mean ± SEM, * indicates p≤0.05.
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Figure 3 | Characterizing the effects of the dietary interventions on DCT differentiation and length
(A) Representative images of NCC-stained kidney slices indicating apical expression of NCC 
(scale bars, 50 μm). NCC: green, DAPI: blue. (B) Representative images of NCC- and BCRP-stained 
whole-kidney slices (left) and the image after automatic segmentation of the NCC-channel 
in the cortex area (right, scale bars, 1 mm). NCC: green, BCRP: red, DAPI: blue. (C) Total 
percentage of NCC-stained area corrected for total kidney cortex area. Data are mean ± SEM.
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Magnesium deficient high-fat-diet-fed mice develop proximal tubule 
phospholipidosis 
To further assess the impact of the dietary interventions on the kidney, several 
histological stainings were performed. H&E staining of the kidneys revealed massive 
vesicle-like structures in the proximal tubules of the LowMg-HFD mice (Fig. 5A). This 
phenomenon was not observed in the other animal groups. To further characterize 
these vesicle accumulations, kidneys were stained with Oil Red O, staining neutral 
lipids and with periodic acid-Schiff, which stains polysaccharides (Supplementary 
Fig. 2A,B). However, both detections were negative. Toluidine blue staining revealed 
the presence of acidic components in the proximal tubule of the LowMg-HFD fed 
mice (Fig. 5B). Electron microscopy (EM) demonstrated multi-lamellar onion-like 
structures, located specifically in the proximal tubule cells, which exceeded the size 
of mitochondria, indicative of advanced proximal tubule phospholipidosis (Fig. 5C). 
In Mg2+-deficient HFD mice kidney injury molecule 1 (Kim1) mRNA expression was 
upregulated compared to LowMg-LFD mice (Supplementary Fig. 3A).
 We hypothesized that the accumulation of phospholipids could be due to a 
disturbed breakdown of phospholipids or sphingolipids. LowMg-HFD mice had 
lower mRNA expression of phospholipase C isoform beta 1 (Plcb1, Fig. 6A), essential 
Figure 4 | A HFD reduces mRNA expression of Trpm6 in distal colon
(A-E) Colonic mRNA expression of (A) Trpm6, (B) Trpm7, (C) Cnnm2, (D) Cnnm4 and (E) 
Slc41a1 normalized to Gapdh expression, relative to NormalMg-LFD. Open bars, LFD. Filled 
bars, HFD. Data are mean ± SEM, * indicates p≤0.05. 
A
0
0.5
1.0
1.5
2.0
C
ol
on
ic
 T
rp
m
6 
m
R
N
A
ex
pr
es
si
on
 (f
ol
d 
ch
an
ge
)
* *
*
0
0.5
1.0
1.5
C
ol
on
ic
 T
rp
m
7 
m
R
N
A
ex
pr
es
si
on
 (f
ol
d 
ch
an
ge
)
0
0.5
1.0
1.5
C
ol
on
ic
 C
nn
m
4 
m
R
N
A
ex
pr
es
si
on
 (f
ol
d 
ch
an
ge
)
B C
0
0.5
1.0
1.5
C
ol
on
ic
 C
nn
m
2 
m
R
N
A
ex
pr
es
si
on
 (f
ol
d 
ch
an
ge
)
0
0.5
1.0
1.5
 C
ol
on
ic
 S
lc
41
a1
 m
R
N
A
ex
pr
es
si
on
 (f
ol
d 
ch
an
ge
)
D E
No
rm
Mg
-LF
D
Lo
wM
g-L
FD
No
rm
Mg
-H
FD
Lo
wM
g-H
FD
No
rm
Mg
-LF
D
Lo
wM
g-L
FD
No
rm
Mg
-H
FD
Lo
wM
g-H
FD
No
rm
Mg
-LF
D
Lo
wM
g-L
FD
No
rm
Mg
-H
FD
Lo
wM
g-H
FD
No
rm
Mg
-LF
D
Lo
wM
g-L
FD
No
rm
Mg
-H
FD
Lo
wM
g-H
FD
No
rm
Mg
-LF
D
Lo
wM
g-L
FD
No
rm
Mg
-H
FD
Lo
wM
g-H
FD
Renal phospholipidosis and impaired magnesium handling in diabetic mice | 93
4
for phospholipid breakdown, compared to NormalMg-HFD mice. There was no 
significant reduction in phospholipase C isoforms gamma 1 and 2 (Plcg1 and Plcg2, 
Supplementary Fig. 3B-C). Moreover, there were no differences in expression of enzymes 
that catabolize sphingomyelin, sphingomyelin phosphodiesterase 1 (Smpd1), Smpd2 
and Smpdl3a, nor in the expression of the enzyme that catabolizes ceramides, alpha 
galactosidase (Gla, Supplementary Fig. 3D-G). 
Magnesium deficiency alters renal energy metabolism
As LowMg-HFD mice developed renal phospholipidosis, we examined whether this 
was associated with changes in renal energy metabolism. In both low Mg2+ fed groups 
a striking increase was observed in mRNA expression of phosphoenolpyruvate 
Figure 5 | LowMg-HFD fed mice develop proximal tubule phospholipidosis
(A) Representative images of H&E stained kidney slides (scale bars, 50 μm). (B) Representative 
images of Toluidine-blue stained kidney slides (scale bars, 50 μm). (C) Representative images 
of the proximal tubule cells by electron microscopy (scale bars, 5 μm). Black arrows indicate 
the vesicles.
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carboxykinase 1 (Pepck1), the rate-limiting enzyme in gluconeogenesis, which is 
predominantly expressed in the proximal tubule (Fig. 6B) (20). mRNA levels of 
lipoprotein lipase (Lpl), which hydrolyses triglycerides in lipoprotein particles, was 
elevated in LowMg-HFD compared to NormalMg-HFD fed mice (Fig. 6C). Moreover, 
mRNA expression of HMG-CoA reductase (Hmgcr), the rate-limiting enzyme in 
cholesterol synthesis and the target of statin drugs, was also enhanced (Fig. 6D). 
Mitochondrial long chain fatty acid oxidation was equal between all groups, indicated by 
similar mRNA expression of carnitine palmitoyltransferase 1 (Cpt1-l), the rate-controlling 
enzyme in this process (Fig. 6E). 
Discussion
Hypomagnesemia is a commonly observed electrolyte disorder in T2D patients. In 
this study we demonstrate that HFD-feeding causes severe hypomagnesemia when 
dietary Mg2+ intake is low. The LowMg-HFD reduced colonic and renal Trpm6 mRNA 
expression and resulted in a diminished mRNA expression of DCT-specific genes. 
Moreover, the Mg2+-deficient HFD caused severe proximal tubule phospholipidosis. 
Figure 6 | Mg2+ deficiency induces renal metabolic changes on mRNA level
(A-E) Renal mRNA expression of (A) Plcb1, (B) Pepck1, (C) Lpl, (D) Hmgcr and (E) Cpt1-l. Open 
bars, LFD. Filled bars, HFD. Data are mean ± SEM, * indicates p≤0.05. 
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This was accompanied by alterations in renal energy metabolism, including enhanced 
gluconeogenesis and cholesterol synthesis.
  In mice on a low Mg2+ diet, HFD feeding induced hypomagnesemia, which was 
observed within 4 weeks on the diet, indicating that hypomagnesemia is a 
consequence of T2D-related factors. Importantly, the HFD did not affect serum or 
urinary Na+ and K+ levels, which corresponds with the normal plasma distribution of 
these cations in T2D patients (1). The HFD induced hypomagnesemia in the mice on 
a Mg2+-deficient diet, but not in a normomagnesemic diet. The Mg2+ content of the 
normal Mg2+ diet (0.21% w/w) is much higher than the minimal dietary Mg2+ 
requirement for mice (0.05% w/w) (21). Therefore, it is likely that high dietary Mg2+ 
intake in these animals prevents the HFD-induced hypomagnesemia. 
  HFD-induced hypomagnesemia has been previously reported, but the molecular 
basis for this Mg2+ deficiency was not further explored (22). In our study, despite the 
absence of fecal or urinary Mg2+ wasting, colonic and renal Trpm6 mRNA expression 
were reduced in LowMg-HFD-fed mice. Moreover, in kidneys of the LowMg-HFD 
mice a lower mRNA expression of other DCT-specific genes such as Slc12a3, Pvalb 
and Klk1, was observed (20). Klk1 is a serine protease that is not directly involved in 
Mg2+ or Ca2+ handling, thus the reduced expression of Klk1 suggests dedifferentia-
tion or shortening of the DCT segment. As NCC was normally present on the apical 
membrane, dedifferentiation of DCT cell was ruled out. Immunohistochemistry on 
whole-kidney slides indicated a non-significant reduction in DCT-area.  Atrophy of the 
DCT segment has been previously described after thiazide use, which blocks NCC 
activity and also results in hypomagnesemia (23). However, we are the first to show 
effects on the DCT in response to LowMg-HFD feeding. 
  The hypomagnesemia observed in the HFD-fed mice is irrespective of urinary 
Mg2+ wasting, which differs from the excessive urinary Mg2+ wasting in T2D patients 
(1, 24, 25). In our study the urinary measurements were performed after 16 weeks on 
the diets. Possibly, the urinary Mg2+ wasting occurred during the initial phase. 
Moreover, the reduced 24h urinary Mg2+ loss after is also partially explained by the 
lower serum Mg2+ levels of the HFD-fed animals. 
  Feeding mice a Mg2+-deficient HFD resulted in proximal tubule phospholipidosis, 
a lysosomal storage disorder. In humans, phospholipidosis can be caused by the 
use of cationic amphiphilic drugs or it can be inherited, such as in Niemann-Pick or 
Fabry’s disease (26-28). In these diseases the breakdown of sphingolipids is disturbed, 
leading to an excessive accumulation of lipids in the lysosomes. EM pictures of renal 
cells in models of these diseases appear identical to the EM pictures of our 
LowMg-HFD fed mice (Fig. 5C) (28, 29). On mRNA expression level, no differences 
were observed in the key genes underlying these diseases. Possibly, reduced Plcb1 
expression in the kidneys of LowMg-HFD mice could underlie the phospholipid 
accumulation. Inhibition of phospholipase C by cationic amphiphilic drugs, has been 
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shown to induce renal cortical phospholipidosis (30). Interestingly, phospholipase C 
requires Mg2+ to function (31, 32). Moreover, hypomagnesemic Trpm6 knockout 
mice have elevated serum and liver sphingolipid levels (19). How hypomagnesemia 
affects phospholipid and sphingolipid metabolism requires further investigation.
  Numerous studies have investigated HFD-induced histological changes in the 
kidney. The reported histological findings include, but are not limited to, glomerulo-
sclerosis, thickened basal membrane, neutral lipid accumulation and macrophage 
infiltration (33-35). Interestingly, only one study observes HFD-induced proximal 
tubule phospholipidosis (35). In our study, renal phospholipidosis by HFD-feeding 
exclusively occurs in the Mg2+-deficient mice and not in the normomagnesemic 
mice, indicating a key role for Mg2+ in preventing the onset of renal phospholipidosis. 
Possibly, differences in dietary Mg2+ content explain the discrepancy between 
different studies in the observation of HFD-induced renal phospholipidosis. 
  Lower blood Mg2+ levels in T2D patients leads to a more rapid renal decline, but 
the underlying mechanism remains unclear (4). The increased renal decline was 
shown to be independent of glycemic control and blood pressure, which are currently 
the main targets in the treatment of diabetic nephropathy (4, 36, 37). Renal lipid 
accumulation could be a new possible mechanism explaining the more rapid decline 
in renal function caused by lower blood Mg2+ levels. Future studies should focus on 
unraveling the consequences of Mg2+ deficiency on renal energy metabolism in T2D 
patients.
  In conclusion, we showed that when dietary Mg2+ intake is low, feeding mice a 
HFD induces severe hypomagnesemia in the absence of urinary or fecal Mg2+ 
wasting. The Mg2+ deficiency lead to renal phospholipidosis in HFD-fed mice, 
whereas the HFD did not induce these effects in normomagnesemic conditions. 
Renal lipid accumulation should be explored as a potential novel factor influencing 
renal function in hypomagnesemic T2D patients. T2D patients are at risk for 
hypomagnesemia, and in the hypomagnesemic T2D patients, correcting blood Mg2+ 
levels could be beneficial to preserve kidney function. 
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Materials and methods
Mouse study
This study was approved by the animal ethics board of the Radboud University 
Nijmegen (RU DEC 2015-0073) and by the Dutch Central Commission for Animal 
Experiments (CCD, AVD103002015239). 48 male C57BL6/J mice (Charles River, 
Germany) were allocated randomly into four groups of mice (n=12 per group) (38). 
Mice, obtained at 9-10 weeks of age, were acclimatized for two weeks in a temperature 
and light controlled room, six mice per cage (Eurostandard Type III). Mice had access 
to acidified drinking water and standard pellet chow ad libitum (Ssniff Spezialdiäten, 
GmbH, Germany). Experimental diets consisted of 10 or 60 kcal% palm oil and 0.03 or 
0.21% (wt./wt.) magnesiumoxide (Ssniff Spezialdiäten, NormalMg-LFD #S9074-E0277, 
LowMg-LFD #S9074-E0287, NormalMg-HFD #S9074-E0297, LowMg-HFD #S9074-E0317). 
Researchers and animal caretakers were blinded for the content of Mg2+ in the 
experimental diets throughout the entire duration of the experiment. At day -1, 84 and 
112 mice were housed individually in metabolic cages for 24 hours for the collection 
of urine and feces and the determination of food and water intake. Blood was 
collected via sub-mandibular vein puncture at day -1, 28, 56 and 84 and collected in 
Microvette tubes (Sarstedt, Germany). After coagulation samples were spun down at 
3,500 g for 5 minutes and serum was collected. One mouse died unrelated to the 
dietary intervention and was excluded from future analyses. After 17 weeks on the 
diets, mice were anaesthetized by 4% v/v isoflurane and exsanguinated via orbital 
sinus bleeding. Death was confirmed by cervical dislocation. Colon was cleaned with 
PBS and cut into a proximal, transversal and distal part. The renal capsule was 
removed and colon and kidney were subsequently stored in 10% (vol./vol.) formalin 
or snap frozen in liquid nitrogen for future analyses.  
RT-qPCR
Total RNA was extracted from half of the kidney and from the distal part of the colon 
using TRIzol reagent (Invitrogen, UK) according to manufacturer’s protocol. The 
isolated RNA underwent DNase (Promega, USA) treatment and subsequently RNA 
concentrations were determined using the Nanodrop 2000c spectrophotometer 
(Thermo Scientific, USA). RNA was reversed transcribed using Moloney murine 
leukemia virus (M-MLV) reverse transcriptase (Invitrogen, The Netherlands). Gene 
expression levels were quantified by SYBR-Green (BioRad, USA) on a CFX96 
real-time PCR detection system (BioRad, USA) and normalized for Gapdh expression. 
Primer sequences are provided in Table 1.
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Histology
Kidney tissue was fixed in 10% vol./vol. neutral-buffered formalin (KLINIPATH, the 
Netherlands) in PBS for 24 hours. Samples were dehydrated through alcohol, 
embedded in paraffin and cut into 4 μm sections. Sections were stained with H&E or 
Periodic acid Schiff (PAS) staining using standard procedures. For immunohisto-
chemistry of the kidney sections, deparaffinization and rehydration were performed, 
followed by antigen retrieval using a citrate buffer at pH 6.0. Sections were blocked 
by a 1% wt./vol. BSA in PBS and incubated overnight at 4 °C with the primary 
antibodies rabbit anti-NCC (1:200, Millipore) and rat anti-BCRP (1:100, Kamiya 
Table 1 | RT-qPCR primer sequences
Gene Forward primer (5’  3’) Reverse primer (5’  3’)
Cldn10b
Cldn14
Cldn16
Cldn19
Cpt1-l
Cnnm2v1
Cnnm4
Egf
Gapdh
Gla
Hnf1-β
Hmgcr
Kim-1
Klk1
Lpl
Mrs2
Slc12a3
Pepck1
Plcb1
Plcg1
Plcg2
Pvalb
Slc41a1
Smpd1
Smpd2
Smpdl3a
Trpm6
Trpm7
GGAGTTCCCCTCCATGCT
GTCCAGCTCCTAGGCTTCCT
GTTGCAGGGACCACATTAC
GGTTCCTTTCTCTGCTGCAC
GTGAGCCTGGCCTCGCC
GTCTCGCACCTTTGTTGTCA
TCTGGGCCAGTATGTCTCTG
GAGAATCTACTGGACAGACAGTGG
TAACATCAAATGGGGTGAGG
CTGATGCCTGCATAAGTGAGC
CAAGATGTCAGGAGTGCGCTAC
TGCGTAAGCGCAGTTCCTTC
GGAAGTAAAGGGGGTAGTGGG
ACCTCAAGCTCCTGCCTAATG
ATTTGCCCTAAGGACCCCTG
TCCTGTGCCCCCTGTGATGAC 
CTTCGGCCACTGGCATTCTG
CCTAGTGCCTGTGGGAAGAC
CTTGCAACTCAAGCCCGTG
GCAAATTGAGAGGTGGCTCC
GTATGATCCGATGCCCCTGG
CGCTGAGGACATCAAGAAGG
CATCCCACACGCCTTCCTGC 
AGAGCACTCCTGTCAATGGC
ACAGGGCAATAAGCCTGTGC
CTAAAGGCGCAAATGCCTCC
CTTCACAATGAAAACCTGCCC
GGTTCCTCCTGTGGTGCCTT
GCAAAAATGGAACCGAAAAA
CATCCACAGTCCCTTCAGGT
GAGGAGCGTTCGACGTAAAC
CGGGCAACTTAACAACAGG
TGAGTGGTGACCGAGTCTGC
GTCGCTCCGACTGAGAGAAT
CACAGCCATCGAAGGTAGG
CTCGAGATTCTCTCCTGGATG
GGTTCACACCCATCACAAAC
TGCCCTTTGAATCCCTCTCG
CTGGTCACCATGGCACTGTTAC
TCACAGTCCTGGATCCTCC
AAGCAGAAGATGGGCATTGC
GTGGGCCTCCGCACAAG
ATTCCCGTTACCGTCCATCC
TCCTTCCGGCCTGAGGCTGTT
GATGGCAAGGTAGGAGATGG
AGCCCTTAAGTTGCCTTGGG
TGGAGTCATCATCCCACTTGAC
TCGGAGGAAGCGCATATTGG
CGTGCACCAAGAACCTTGAC
AGCTTTCAGCCACCAGAGTG
CGGCTGGCCTGCACAGCCAC
AGCCCCCAATTCTTAGGGTG
GGGATGTCCCAGCAGTTGAG
ATGAGGTGGGCTATCCCCTG
AAAGCCATGCGAGTTATCAGC
CCCCATGTCGTCTCTGTCGT
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Biomedical Company). For detection, kidney sections were incubated for 2 hours at 
room temperature with Alexa-conjugated secondary antibody (1:300, Invitrogen - 
Molecular Probes). Images were taken using an AxioCam camera and ZEN lite 
software (Zeiss, Sliedrecht, the Netherlands). For the whole-slide immunohistochemistry, 
a Leica DMI6000 confocal microscope and LAS AF software were used. The NCC- 
stained area in the whole-kidney slices (Fig. 7A) was determined using a script. The 
analysis was performed on the annotated cortical area of the whole-kidney slices, 
with stain artifacts removed (Fig. 7B). First, the NCC-channel in the annotated cortical 
area was isolated from the picture (Fig. 7C). Otsu’s method was used to automatically 
determine a suitable NCC-channel intensity threshold (39). An empirically chosen 
intensity threshold of 67 was used in cases where the automatic threshold was 
determined to be insufficient based on visual inspection. A closing operation was 
performed on the thresholded image, using a square structuring element with size 
ten. Components with a pixel size smaller than 200 were removed, resulting in the 
final image (Fig. 7D). Finally, the percentage of NCC-stained area was determined by 
dividing the pixels in the final image by the pixels in the annotated area. The researcher 
performing these analyses was blinded for the mice groups during all the steps of 
Figure 7 | Approach for automated segmentation of the NCC-stained tubuli
(A) Representative images from immunohistochemistry stainings of whole-kidney (scale bars, 
1 mm). DAPI: blue, BCRP: red, NCC: green. (B) Immunohistochemistry stained image overlaid 
with handcrafted annotations. The area annotated with red (‘1: label’) was exclusively considered 
when calculating the NCC-stained area. (C) Image obtained by isolating the NCC-channel from 
the original RGB image. (D) Resulting segmentation of the green channel after applying the 
threshold, performing the closing operation and removing small (noisy) components.
A B C D
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analysis. The code for segmentation was written in Python (RRID:SCR_008394), 
utilizing the Scikit-image and OpenCV packages.
 For the Oil Red O staining, kidney samples were snap frozen in liquid nitrogen 
and cut into 10 μm sections, stained with Oil Red O (Sigma-Aldrich, Missouri, USA) 
and counterstained with hematoxylin. For electron microscopy, we used immersion 
fixation. Small fragments of cortex were fixed in 2.5% wt./vol. glutaraldehyde dissolved 
in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C and washed in the same 
buffer. The tissue fragments were postfixed in palade-buffered 2 w/v% OsO4 for 1 h, 
dehydrated, and embedded in Epon812, Luft’s procedure (Merck, Darmstadt, 
Germany). Semi-thin sections (1 μm) were stained with Toluidine blue 1% wt./vol. 
(metachromatic staining). Ultrathin sections were contrasted with 4% wt./vol. uranyl 
acetate for 45 min and subsequently with lead citrate for 5 min at room temperature. 
Sections were examined using a Jeol 1400 electron microscope (JEOL, Tokyo, Japan).
Analytical procedures
Serum, urinary and fecal Mg2+ concentrations were determined using a spectropho-
tometric assay (Roche/Hitachi, Tokyo, Japan) according to the manufacturer’s 
protocol. The Ca2+ concentration was measured by the o-cresophthalein complexone 
method. Absorbance was measured using a Bio-Rad Benchmark plus microplate 
spectrophotometer (Bio-Rad laboratories, California, USA). Serum and urinary Na+ 
and K+ concentrations were measured by the clinical chemistry department of the 
Radboudumc using standardized methods. 
Quantification and statistical analysis
To determine whether there was a significant interaction effect between the two main 
variables (dietary fat and Mg2+ content), a two-way ANOVA was used. If there was no 
significant interaction effect, significant differences between the groups were 
assessed using a two-way ANOVA approach with Tukey’s multiple comparisons test. 
If the two-way ANOVA demonstrated a significant interaction effect, a multiple t-test 
approach using the Holm-Sidak correction for multiple comparisons was used. To 
determine statistical significance in the NCC-stained area of whole-kidney slices, an 
unpaired Student’s t-test was used. Statistical significance was assessed using 
Graphpad Prism v7 (California, USA, RRID: SCR_002798). Differences with a p-value 
of ≤0.05 were considered statistically significant. Results are presented as mean ± 
standard error of the mean (SEM).
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Supplementary data
Supplementary figure 1 | No differences in renal mRNA expression of other magnesiotropic 
genes between any of the groups
(A-H) Renal mRNA expression of (A) Slc41a1, (B) Cldn10, (C) Cldn14, (D) Cldn16, (E) Cldn19, 
(F) Hnf1β, (G) Egf and (H) Mrs2 normalized to Gapdh expression, relative to NormalMg-LFD. 
Two-way ANOVA for Cldn10, Egf and Mrs2 indicates a significant dietary calorie effect, p≤0.05. 
Two-way ANOVA for Cldn16 indicates a significant dietary Mg2+ effect, p≤0.05. Open bars, LFD. 
Filled bars, HFD. Data are mean ± SEM, * indicates a p≤0.05.
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Supplementary figure 2 | Proximal tubule vesicles are negative for PAS and Oil Red O staining
(A) Representative images of Oil Red O stained kidney slides (scale bars, 100 μm). (B) Representative 
images of PAS stained kidney slides (scale bars, 50 μm).
A B
NormMg-LFD LowMg-LFD
NormMg-HFD LowMg-HFD
NormMg-LFD LowMg-LFD
NormMg-HFD LowMg-HFD
A B
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NormMg-LFD LowMg-LFD
NormMg-HFD LowMg-HFD
A
B
Supplementary figure 3 | Renal mRNA expression differences of genes involved in metabolism.
(A-G) Renal mRNA expression of (A) Kim-1, (B) Plcg1, (C) Plcg2, (D) Smpd1, (E) Smpd2, (F) 
Smpdl3a and (G) Gla. Two-way ANOVA for Plcg2 indicates a significant dietary Mg2+ and calorie 
effect, p≤0.05. Two-way ANOVA for Smpdl3a indicates a significant dietary calorie effect, p≤0.05. 
Open bars, LFD. Filled bars, HFD. Data are mean ± SEM, * indicates a p≤0.05.
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Abstract
In T2D patients, treatment with metformin is associated with reduced blood Mg2+ 
levels. However, the mechanism underlying this phenomenon remains to be elucidated. 
Therefore, we investigated how T2D and metformin affect Mg2+ homeostasis.  
  In this study, twenty diabetic db/db mice and twenty control db/m mice were 
treated with metformin or placebo for four weeks. Db/m mice had a considerably 
lower body weight than db/db mice, which was not affected by metformin-treatment. 
Metformin attenuated the glycosuria of the db/db mice. Db/db mice had significantly 
lower serum Mg2+ levels than db/m mice. Mild hypermagnesuria was observed in the 
db/db mice at two weeks, but not at four weeks. Metformin-treatment had no effect 
on the serum Mg2+ concentration and on the urinary Mg2+ excretion. Both in kidney 
and distal colon of db/db mice, there was a compensatory upregulation in the mRNA 
expression of magnesiotropic genes, such as transient receptor potential melastatin 
6 (Trpm6), whereas metformin treatment did not affect gene expression levels. 
  In conclusion, using genetically modified mice, we show that T2D causes 
hypomagnesemia. Moreover, metformin treatment has no effect on Mg2+ homeostasis 
in mice.  
Keywords: Colon; db/db; kidney; magnesium; metformin; type 2 diabetes.
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Introduction
Approximately 30% of patients with type 2 diabetes mellitus (T2D) have hypo-
magnesemia (blood magnesium (Mg2+) <0.7 mmol/L) (1, 2). Hypomagnesemia has 
serious clinical consequences as it increases the risk of complications such as 
retinopathy, nephropathy, micro and macrovascular disease and foot ulceration (3, 4). 
However, the etiology and underlying mechanisms of hypomagnesemia in T2D patients 
remains largely unknown (5).    
  As Mg2+ is necessary for the activity of over 600 enzymes, it plays numerous 
vital physiological functions including macromolecule synthesis, energy balance and 
DNA transcription (6). 
  The intestine and kidney collaboratively regulate Mg2+ balance and maintain its 
blood concentrations within a narrow range (7, 8). In the gut, the bulk of Mg2+ 
absorption occurs in the small intestine via paracellular (passive) transport (7). In the 
colon, the final absorption of Mg2+ takes place by an active transcellular mechanism 
through transient receptor potential melastatin type 6/7 (TRPM6/TRPM7) cation 
channels (6). In the kidney, 95-99% of filtered Mg2+ is reabsorbed under physiological 
circumstances (6). Approximately 85% of the filtered Mg2+ is reabsorbed paracellularly 
by the proximal tubule and the thick ascending loop of Henle (TAL), where transport 
relies on tight junction permeability (9, 10). Active transport in the distal convoluted 
tubule (DCT) determines the final urinary Mg2+ concentration, as this is the final segment 
where Mg2+ is reabsorbed (11). In physiological conditions, the DCT reclaims 5-10% 
of filtered Mg2+ transcellularly via TRPM6/7 channels (10, 12). The expression and/or 
the activity of TRPM6 is affected by SNPs, dietary Mg2+ intake, drugs and hormones, 
such as insulin and epidermal growth factor (EGF) (10, 13-16). SNPs in TRPM6 that 
impair its response to insulin have been associated with an increased risk of 
developing T2D and gestational diabetes (15, 17). 
  Metformin, the first-line pharmacotherapy in T2D (18), suppresses hepatic gluco-
neogenesis and improves insulin sensitivity (19). Therefore, its major clinical benefit 
is reducing blood glucose levels with only a minimal risk of hypoglycemia (20, 21). 
The most common side effects of metformin treatment are lactic acidosis, nausea 
and diarrhea (22). Recent cohort studies showed that metformin use in T2D patients 
is associated with reduced blood Mg2+ levels (1, 23). However, the mechanism that 
underlies this correlation has not yet been elucidated. To investigate how T2D and 
metformin affect Mg2+ homeostasis, control (db/m) and diabetic (db/db) mice were 
treated with placebo or metformin for four weeks. Serum and urinary electrolytes 
were measured and mRNA expression of magnesiotropic genes was evaluated in 
kidney and distal colon.
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Results
Metformin reduces food intake of db/db mice without affecting  
body weight
Db/db mice were significantly heavier than db/m mice (Fig. 1A,B; 27.0 ± 0.3 vs. 45.6 
± 0.6 gr. for db/m and db/db mice, respectively, at four weeks, p≤0.05). Metformin 
treatment had no effect on body weight in both db/m and db/db mice (Fig. 1A,B). 
Figure 1 | Metformin treatment does not affect body weight, but reduces food intake and 
urinary glucose excretion in db/db mice
Db/m and db/db mice were treated with metformin for four weeks. (A) Body weight of the animals, 
measured twice weekly and on the days of the metabolic cage experiments. Triangles, db/m 
mice; circles, db/db mice; open symbols, placebo-treated mice; closed symbols, metformin- 
treated mice. (B) Body weight at the end of the experiment, after four weeks of treatment. (C) 
Food intake, (D) total feces weight, (E) water intake and (F) urinary volume determined over 
a period of 24 hours, using metabolic cages, after four weeks of treatment. (G) Non-fasted 
serum glucose concentration and (H) 24-hour urinary glucose excretion after four weeks of 
treatment. Open bars, placebo-treated mice; closed bars, metformin-treated mice. Data are 
mean ± SEM. * indicates a p≤0.05.
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Metformin treatment reduced the food intake only in the db/db mice (Fig. 1C). The 
lower food intake was accompanied by a decreased feces weight, water intake and 
urinary volume in the metformin-treated db/db mice (Fig. 1D-F). Metformin did not 
influence non-fasting serum glucose levels in both genotypes (Fig. 1G). However, the 
glycosuria of the db/db mice was attenuated by metformin treatment (Fig. 1H). 
Db/db mice have reduced serum magnesium concentrations 
Serum Mg2+ concentrations were lower in db/db than db/m mice at two weeks (Fig. 2A, 
1.17 ± 0.04 vs. 0.88 ± 0.04 mmol/L in db/m vs. db/db placebo-treated mice, 
respectively, Holm-Sidak’s multiple comparison p≤0.05) and four weeks (Fig. 2B, 
1.10 ± 0.05 vs. 0.95 ± 0.04 mmol/L in db/m vs. db/db placebo-treated mice, 
respectively, Holm-Sidak’s multiple comparison p≤0.05). At two weeks, there was a 
significant genotype effect on urinary Mg2+ excretion, demonstrating an increased 
urinary Mg2+ loss in db/db mice (Fig. 2C, 6.8 ± 0.6 vs. 8.6 ± 0.6 μmol/24h in db/m 
vs. db/db mice, respectively, two-way ANOVA p≤0.05), whereas no significant 
difference was observed at four weeks (Fig. 2D). At four weeks, the serum Ca2+ 
concentration was higher in db/db compared to db/m mice, indicated by a significant 
genotype effect (Fig. 2E, 1.28 ± 0.05 vs. 1.46 ± 0.06 mmol/L Ca2+ in db/m vs. db/db 
mice, respectively, two-way ANOVA p≤0.05). There were no significant differences on 
urinary Ca2+ excretion (Fig. 2F). Despite the higher food intake of db/db animals, a 
significant genotype effect demonstrated lower serum Na+ levels in db/db compared 
to db/m mice (Fig. 2G, 167 ± 2 vs. 159 ± 3 mmol/L Na+ in db/m vs. db/db mice, 
respectively, two-way ANOVA p≤0.05). Urinary excretion of Na+ and K+ was higher in 
db/db than db/m mice, and metformin treatment reduced Na+ and K+ excretion only 
in db/db mice (Fig. 2H,J). Serum K+ concentrations were not different between all 
experimental groups (Fig. 2I).
Db/db mice have an enhanced colonic expression of Trpm6 
When serum Mg2+ levels decrease, intestinal uptake of Mg2+ is enhanced (11). 
Colonic mRNA expression of Trpm6, the major channel for regulated Mg2+ absorption, 
was elevated in db/db compared to db/m mice (Fig. 3A). There was no difference in 
mRNA expression of the ubiquitous Mg2+ channel Trpm7 and of the Mg2+ transport 
regulator Cyclin m4 (Cnnm4) (Fig. 3B, C). The colonic gene expression of the 
basolateral Mg2+ transporter solute carrier family 41 (Slc41a1) was lower in both db/
db groups (Fig. 3D).  
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Figure 2 | Db/db mice have a lower serum Mg2+ concentration which is not modulated by 
metformin treatment
(A) Serum Mg2+ concentration after two weeks of treatment and (B) after four weeks of 
treatment. (C) 24-Hour urinary Mg2+ excretion after two weeks of treatment (6.8 ± 0.6 vs. 8.6 
± 0.6 μmol/24h in db/m vs. db/db mice, respectively, two-way ANOVA p≤0.05) and (D) after 
four weeks of treatment. (E) Serum Ca2+ concentration (1.28 ± 0.05 vs. 1.46 ± 0.06 mmol/L 
Ca2+ in db/m vs. db/db mice, respectively, two-way ANOVA p≤0.05) and (F) 24-hour urinary 
Ca2+ excretion, after four weeks of treatment. (G) Serum Na+ concentration (167 ± 2 vs. 159 ± 
3 mmol/L Na+ in db/m vs. db/db mice, respectively, two-way ANOVA p≤0.05) and (H) 24-hour 
urinary Na+ excretion, after four weeks of treatment. (I) Serum K+ concentration and (J) 24-hour 
urinary K+ excretion, after four weeks of treatment. Open bars, placebo-treated mice; closed 
bars, metformin-treated mice. Data are mean ± SEM. * indicates a p≤0.05.
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Db/db mice have an elevated renal expression of genes involved  
in magnesium handling
Db/db mice had an enhanced gene expression of the DCT-specific apical Mg2+ 
channel Trpm6, and the basolateral Mg2+ extruder Slc41a3 (Fig. 4A,B). While both 
db/db groups showed a higher expression of Slc12a3, encoding for NCC, metformin 
further enhanced the expression of this gene in db/db mice (Fig. 4C). The driving 
force for paracellular Mg2+ uptake in the TAL is generated by NKCC2, encoded by 
Slc12a1, which is expressed higher in db/db mice (Fig. 4D). 
A significant genotype effect indicated a decreased expression of Claudin 10b 
(Cldn10b) in db/db mice (Fig. 4E, 1.00 ± 0.05 vs. 0.83 ± 0.02 relative gene expression 
in db/m vs. db/db mice, two-way ANOVA p≤0.05). In contrast, the mRNA expression 
of Cldn14, Cldn16 and Cldn19 was enhanced in db/db mice (Fig. 4F-H). The gene 
expression of the ubiquitous Mg2+ channel Trpm7 was elevated in the placebo-treat-
ed db/db mice and the expression of Fxyd2, encoding for the gamma subunit of the 
Na+-K+-ATPase, was enhanced in both db/db groups (Fig. 4I,J). 
Figure 3 | Upregulation of Trpm6 mRNA expression in the colon of db/db mice
Colonic mRNA expression of (A) Trpm6, (B) Trpm7, (C) Cnnm4 and (D) Slc41a1. Open bars, 
placebo-treated mice; closed bars, metformin-treated mice. Data are mean ± SEM. * indicates 
a p≤0.05.
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Figure 4 | Higher gene expression of essential magnesiotropic in db/db mice mRNA expression 
of genes involved in renal electrolyte handling
(A) Trpm6, (B) Slc41a3, (C) Slc12a3, (D) Slc12a1, (E) Cldn10b (1.00 ± 0.05 vs. 0.83 ± 0.02 
relative gene expression in db/m vs. db/db mice, two-way ANOVA p≤0.05), (F) Cldn14, (G) 
Cldn16, (H) Cldn19, (I) Trpm7 and (J) Fxyd2. Open bars, placebo-treated mice; closed bars, 
metformin-treated mice. Data are mean ± SEM. * indicates a p≤0.05.
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Discussion
Hypomagnesemia is a common clinical feature in T2D patients (1, 3). Metformin use 
is associated with a lower blood Mg2+ concentration in these patients (1, 23). In this 
study, db/db mice developed hypomagnesemia with compensatory upregulation of 
key renal and colonic magnesiotropic genes. Metformin treatment had no effect on 
Mg2+ homeostasis in either control or diabetic mice. Our data demonstrate that 
hypomagnesemia is a consequence of T2D and is not modulated by metformin 
treatment in mice.  
  Metformin is the first-line therapy for T2D (24). In large-scale observational cohort 
studies metformin-use is associated with lower serum Mg2+ levels and reduced renal 
Mg2+ wasting in T2D patients (1, 23, 25-27). In a small intervention study in T2D 
patients, metformin treatment resulted in a minor reduction in the serum Mg2+ 
concentration (from 0.72 to 0.70 mmol/L), despite major improvements in the blood 
glucose concentration (26). In our study, metformin treatment did not affect the serum 
Mg2+ concentration and urinary Mg2+ excretion in db/db and db/m mice. In addition, 
metformin did not alter gene expression of colonic and renal Mg2+ transporters. 
This is in line with a study that observed no effect of a two-week metformin treatment 
on serum Mg2+ levels in streptozotocin-induced diabetic rats (28). Possibly, a two- 
to four-week treatment duration is too short to detect effects on Mg2+ homeostasis. 
The association between metformin and lower serum Mg2+ levels in T2D patients 
could also be caused by other factors that were not included in the analyses. For 
instance, a well-known side effect of metformin-treatment is chronic diarrhea, leading 
to intestinal malabsorption and hypomagnesemia (25).  
  Hypomagnesemia is prevalent in over 30% of T2D patients (29-32). A remaining 
question is whether hypomagnesemia is the cause or the consequence of T2D (5). In 
the present study, db/db mice developed hypomagnesemia, indicating that 
hypomagnesemia is a consequence of T2D. At the fourth week of the experiment, db/
db mice developed massive glycosuria but no renal Mg2+ wasting. This finding is 
against the leading hypothesis that renal Mg2+ wasting in T2D patients is a result of 
glycosuria (2, 3, 33). Indeed, metformin treatment noticeably decreased glycosuria in 
db/db mice but did not modify the urinary Mg2+ excretion. This is in line with recent 
observations that glycosuria-causing SGLT2 inhibitors, lead to a mild increase in 
serum Mg2+ levels (34, 35). Therefore, it is unlikely that glycosuria underlies hyperma-
gnesuria-induced hypomagnesemia in T2D.  
  The kidneys are essential in maintaining the serum Mg2+ concentration within 
the physiological range (11). The DCT is the final segment where Mg2+ can be 
reabsorbed (6). In the DCT, regulated Mg2+ reabsorption takes place transcellularly 
via TRPM6 (14). Mg2+ uptake by TRPM6 is dependent on NCC, although the 
underlying mechanism remains largely unknown (36, 37). Gene expression levels of 
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Trpm6 and Slc12a3, encoding for NCC, were enhanced in db/db mice, indicative of 
compensation in the DCT. As only a minor hypermagnesuria is observed at 
two-weeks, and no hypermagnesuria at four-weeks, there appears to be proper renal 
compensation in the db/db mice. 
  The TAL is responsible for the bulk of renal Mg2+ reabsorption (6). In the TAL, 
paracellular Mg2+ and Ca2+ reabsorption is regulated by the Cldn14/16/19 complex 
(38, 39). Cldn14 mRNA expression is strongly regulated by dietary Ca2+ intake (40, 
41). The high food intake, and therefore high Ca2+ intake, of db/db mice is likely the 
underlying cause of the extensive upregulation of Cldn14 expression. The high 
expression of Cldn14 will have a negative effect on Mg2+ reabsorption in the TAL, 
leading to a compensatory increase in Cldn16/19 expression (42). In contrast, gene 
expression of Cldn10b was decreased. Cldn10b enhances the Na+-permeability of 
the TAL, and thereby indirectly increases uptake of Mg2+ and Ca2+ in the TAL. 
Therefore, Cldn10b-deficient mice develop hypermagnesemia and hypomagnesuria. 
Likely, the observed reduction in Cldn10b expression in the db/db mice is a response 
to the high osmolality of the pro-urine.  
  The strength of this study is that using oral metformin treatment in diabetic mice 
closely resembles the human situation. Db/db mice developed hypomagnesemia 
making them an excellent model to study the mechanisms of hypomagnesemia in 
T2D. Moreover, this study extensively investigated differences in expression of all 
known genes involved in Mg2+ transport, in both kidney and colon. Some limitations 
have to be considered. The fact that metformin treatment did not affect Mg2+ 
homeostasis raises the question whether the dose and duration of metformin 
treatment were sufficient. The expression of genes such as Cldn10b/14, Slc12a1 and 
Slc12a3 are regulated by both dietary intake and serum levels of K+, Na+ and Ca2+ 
(37, 38, 43). As db/db mice have hyperphagia, their dietary intake of ions is also 
increased. Despite the higher food intake, db/db mice still develop hypomagnesemia. 
However, for other differences between db/m and db/db mice it is difficult to 
differentiate whether they are caused by T2D-related factors or by a higher food 
intake. 
 In conclusion, hypomagnesemia is a consequence of T2D, which is not affected 
by metformin treatment. The reason that metformin-users have lower serum Mg2+ 
concentrations is likely mediated by other factors, and not by a direct effect of 
metformin on Mg2+ (re)absorption. 
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Materials and methods 
Animal study
The animal study was approved by the animal ethics board of the Radboud University 
Nijmegen (RU DEC 2015-0073) and by the Dutch Central Commission for Animal 
Experiments (CCD, AVD103002015239). Twenty diabetic (db/db) and twenty control 
(db/m) male mice (Charles River, Germany), aged 8-10 weeks, were acclimatized for 
two weeks in a temperature- and light-controlled room two mice per cage 
(Eurostandard Type IIL), with ad libitum access to tap water and standard pellet chow. 
At day 0, diets were changed to a diet containing 0.05% (w/w) MgO (#S9074-E1107, 
Ssniff Spezialdiäten, GmbH, Germany) and drinking water to demineralized water. At 
days -2, 12 and 26 mice were housed individually in metabolic cages for 48 hours (24 
hours adaptation, 24 hours collection) to measure food and water intake and to 
collect urine and feces. Mice were weighed twice weekly and blood was collected via 
the submandibular vein at days -2 and 15. Mice were randomly divided into four 
experimental groups of ten mice per group, of which half received metformin 
hydrochloride (0.5 mg/ml, Sigma Aldrich, MI, USA), dispersed in the drinking water. 
Researchers and animal caretakers were blinded for the metformin treatment. After 
28 days of treatment, mice were anaesthetized by 4% (v/v) isoflurane and 
exsanguinated by orbital sinus bleeding, and death was confirmed by cervical 
dislocation. Colon and kidney tissues were cleaned with ice-cold PBS and snap-frozen 
in liquid nitrogen. 
RT-qPCR
TRIzol reagent (Invitrogen, Bleiswijk, the Netherlands) was used to extract total RNA 
from kidney and distal colon according to the manufacturer’s protocol. RNA was 
subjected to DNase (Promega, the Netherlands) treatment at 37°C for 30 min and 
then to DNase stop buffer at 65°C for 10 min. The RNA concentration was measured 
using the Nanodrop 2000c (Thermoscientific, Wilmington, DE). To synthetize cDNA, 
1.5 μg of total RNA was reverse transcribed for 1 hour at 37°C using Moloney-Murine 
Leukemia Virus (M-MLV) reverse transcriptase (Invitrogen, Bleiswijk, the Netherlands). 
SYBR Green Supermix (BioRad, Veenendaal, the Netherlands) was used to analyze 
the gene expression levels on a BioRad (Hercules, CA, USA) analyzer. After 
normalizing to housekeeping gene expression (Hprt), the relative gene expression 
was calculated by the Livak method (2-∆∆ct). Primers sequences are provided in Table 1. 
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Analytical measurements 
Serum and urinary Mg2+ concentrations were determined using a spectrophotomet-
ric assay (Roche/Hitachi, Tokyo, Japan), according to manufacturer’s protocol. Ca2+ 
concentrations were determined by the o-cresophthalein complexone method. 
Absorbance for the Mg2+ and Ca2+ assays was measured at 600 nm and 570 nm, 
respectively, on a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad 
Laboratories, CA, USA). Serum and urinary Na+ and K+ concentrations were 
measured at the clinical chemistry department applying standardized methods (1). 
Serum and urinary glucose concentrations were determined by a spectrophotometric 
assay according to the manufacturer’s protocol (Instruchemie, Delfzijl, the 
Netherlands).  
Statistical analyses 
Interaction between the two main variables (genotype and treatment) was investigated 
using a two-way ANOVA test. If there was a significant interaction effect, an unpaired 
multiple t test, with the Holm–Sidak method for multiple comparisons, was used. In 
the absence of a significant interaction effect, a two-way ANOVA approach with a 
Tukey’s multiple comparisons test was used. Statistical significance was assessed 
using Graphpad Prism v7 (La Jolla, CA, USA, RRID: SCR_002798. A p-value of ≤0.05 
was considered statistically significant. Results are presented as mean ± SEM. 
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Abstract
The blood triglyceride level is one of the main determinants of the blood magnesium 
(Mg2+) concentration in patients with type 2 diabetes (T2D). Hypomagnesemia 
(blood Mg2+ concentration <0.7 mmol/L) has serious consequences as it increases 
the risk of developing T2D from a pre-diabetic state and accelerates the disease 
progression. This study aimed to determine by which mechanism triglyceride levels 
affect blood Mg2+ concentrations.  
  In a cohort of overweight subjects, serum Mg2+ levels inversely correlated with 
triglycerides incorporated in large very low-density lipoprotein particles. After lipid 
loading, we observed a post-prandial increase in plasma triglyceride and free fatty 
acid (FFA) levels and a reciprocal reduction in the blood Mg2+ concentration, both in 
mice and in healthy subjects. Further in vitro experiments revealed that the decrease 
of plasma Mg2+ is explained by direct binding of Mg2+ to FFAs. Moreover, the binding 
of Mg2+ to albumin is dependent on FFA, as Mg2+ did not bind to fatty-acid-free 
albumin. FFA-dependent reduction of the free Mg2+ concentration was not affected 
by the presence of physiological concentrations of other cations. 
  This study shows that elevated FFA and triglyceride levels directly reduce blood 
Mg2+ levels, in part explaining the high prevalence of hypomagnesemia in metabolic 
disorders. Our data challenge how the fractional excretion of magnesium is calculated 
and interpreted in the clinic.
Keywords: Albumin; free fatty acid; hypomagnesemia; hypertriglyceridemia; magnesium; 
magnesium deficiency; obesity; triglycerides.
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Introduction
Hypomagnesemia (blood magnesium (Mg2+) concentration <0.7 mmol/L) is commonly 
observed in patients with type 2 diabetes (T2D) or the metabolic syndrome (1-3) and can 
result in general complaints such as fatigue, headache and weakness (4, 5). Low oral Mg2+ 
intake and low blood Mg2+ levels increase the risk of developing T2D, but also accelerate 
the disease progression (6-8). A reduced blood Mg2+ is also associated with more 
diabetes- related complications such as cardiovascular disease and renal failure (9-12).
  Blood Mg2+ levels are carefully maintained between 0.7 and 1.1 mmol/L by the 
interplay of the intestine, bone and kidney (13). In blood, approximately 27% of Mg2+ 
is bound to albumin, 8% is complexed to anions such as phosphate, bicarbonate and 
citrate, leaving 65% as the free fraction, which is the biologically active form (14). 
Although albumin-binding has been known for decades, the buffering effect of 
albumin on the regulation of Mg2+ homeostasis has been largely neglected (15). 
  Blood fatty acid (FA) and triglyceride levels are largely regulated by four organs: 
the intestine, liver, muscle and adipose tissue. In the postprandial state, the intestine 
absorbs dietary lipids as FAs, which are re-esterified into triglycerides and incorporated 
into chylomicrons that reach metabolically active tissues via the circulation (16). The liver 
can also incorporate FAs into triglyceride and secrete these as very low-density 
lipoprotein (VLDL) particles, which is especially important during fasting (17). Skeletal 
muscle stores FAs in the form of triglycerides, but also consumes large amounts of 
FAs during exercise (18).  White adipose tissue also stores FAs as triglycerides, which 
can be released by lipolysis as free fatty acids (FFA) during a state of energy 
deprivation (19, 20). In blood, these negatively charged FFAs are bound to carrier 
proteins, predominantly albumin, with a non-polar interaction (21). In physiological 
conditions, approximately two FFA molecules are bound to a single albumin molecule 
(22). However, in a state of hypertriglyceridemia up to seven FFA molecules are able 
to bind, but with sequentially lower binding constants (21, 22). 
  In metabolic diseases, high blood triglycerides are associated with a lower blood 
Mg2+ concentration, but the directionality of this correlation remains unclear (1, 23, 24). 
Severe hypomagnesemia in animals leads to increased blood triglyceride levels, 
possibly by disrupting the function of the enzyme lecithin-cholesterol acyltransferase 
or by activating lipolysis in adipose tissue (25, 26).  However, whether triglycerides 
can affect Mg2+ homeostasis has not been investigated. 
  In this study, we measured serum Mg2+ concentrations and the plasma lipoprotein 
concentration and composition by use of a metabolomics platform in a cohort of 
overweight individuals (27). To further unravel the exact relationship between hyper-
triglyceridemia and Mg2+ levels, we combined the population-based cross-sectional 
study with in vivo oral lipids loads both in men and in mice and with subsequent 
in vitro experiments. 
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Results
Serum magnesium levels inversely correlate with plasma 
triglyceride levels in overweight individuals 
Factors affecting blood Mg2+ levels were evaluated in 285 overweight human 
individuals from the 300-Obesity cohort, with a BMI >27 kg/m2 (Table 1). The average 
serum Mg2+ concentration in this cohort was 0.89 ± 0.09 (SD) mmol/L with only 2% 
of the individuals having hypomagnesemia (serum Mg2+ <0.7 mmol/L, see Fig. 1 
and Table 1). Despite the fairly normal serum Mg2+ levels in these subjects, serum 
Mg2+ and triglyceride levels, predominantly those in VLDL particles, were inversely 
correlated (Table 1). The serum Mg2+ concentration was also inversely correlated 
with the HOMA-IR. As the HOMA-IR is strongly correlated with the plasma triglyceride 
concentration (Supplementary tables 1-2), we questioned whether insulin resistance 
modulated the inverse correlation between Mg2+ and triglyceride, and triglycerides in 
VLDL particles. However, the HOMA-IR did not influence these correlations in 
multivariable regression analyses (Supplementary tables 3-4).
  To further investigate the relationship between lipoproteins and the serum Mg2+ 
level, the composition of the lipoprotein particles was investigated and also correlated 
to the serum Mg2+ concentration (Table 1). The concentration of the larger VLDL particles 
showed the strongest inverse correlations to the serum Mg2+ levels (Table 1). Interestingly, 
the concentration of smaller HDL particles positively correlated to serum Mg2+.
  There was no correlation between the serum Mg2+ and any of the intermediate and 
low-density lipoprotein (IDL and LDL) particle concentrations (Table 1). No significant 
correlation was observed between serum Mg2+ and the diameter of the VLDL, LDL 
or HDL particles (Table 1).
Increased triglyceride levels directly reduce plasma magnesium 
concentrations in mice
To unravel the underlying mechanism that explains how blood triglycerides are 
associated with blood Mg2+ concentrations, mice were subjected to an oral gavage 
of olive oil following an overnight fast. Plasma triglycerides and FFA levels both 
peaked at four hours post-gavage (Fig. 2A,B). 
 Interestingly, the plasma Mg2+ concentration showed a reciprocal decrease and 
reached a nadir also at four hours post-gavage (Fig. 2A,B). At basal levels (t=0 hours) 
no significant correlation was observed between plasma Mg2+ levels and FFA 
concentrations (Fig. 2C, p=0.27). However, when plasma FFA levels increased 
(t=4 and 6 hours), there was a clear inverse correlation between Mg2+ and FFA 
concentrations (Fig. 2D,E, p≤0.05). When plasma FFA levels decreased and reached 
a concentration comparable to baseline (t=8 hours), there was no longer a significant 
correlation between plasma FFA and Mg2+ concentrations (Fig. 2F, p=0.54). 
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Table 1 | Mg2+ and triglycerides inversely correlate in overweight individuals 
Univariate analyses for the correlation of demographics, laboratory analyses and lipoprotein 
particle concentration of overweight individuals (300-Obesity cohort) with the serum Mg2+ 
concentration.
Variable Correlation
Coefficient
p-value n
Demographics
Gender (m=0, f=1) 
BMI (kg/m2)
Age (years)
Waist circumference (cm)
SBP (mmHg)
DBP (mmHg)
Heart rate (beats/min)
-0.051
-0.063
-0.099
-0.071
-0.016
0.079
-0.083
0.391
0.291
0.096
0.231
0.791
0.186
0.164
285
285
285
285
285
285
282
Laboratory analyses
Triglycerides (mmol/L)
Glucose (mmol/L)
HbA1c (mmol/mol)
HOMA-IR
Total cholesterol (mmol/L)
Triglycerides in VLDL (mmol/L)
Triglycerides in LDL (mmol/L)
Triglycerides in HDL (mmol/L)
Cholesterol in VLDL (mmol/L)
Cholesterol in LDL (mmol/L)
Cholesterol in HDL (mmol/L)
ApoA1 (g/L)
ApoB (g/L)
Mean diameter VLDL (nm)
Mean diameter LDL (nm)
Mean diameter HDL (nm)
-0.159
-0.062
-0.032
-0.123
0.041
-0.158
-0.026
-0.052
-0.093
0.075
0.116
0.071
-0.037
-0.095
-0.030
0.026
0.007
0.299
0.595
0.038
0.495
0.008
0.667
0.380
0.118
0.205
0.050
0.235
0.539
0.111
0.612
0.320
284
284
284
283
284
284
284
284
284
284
284
283
283
284
284
284
Lipoprotein particle concentration
Concentration of Chylomicrons & EL-VLDL
Concentration of VL-VLDL
Concentration of L-VLDL
Concentration of M-VLDL
Concentration of S-VLDL
Concentration of VS-VLDL
Concentration of IDL
Concentration of L-LDL
Concentration of M-LDL
Concentration of S-LDL
-0.170
-0.174
-0.163
-0.149
-0.108
-0.004
0.058
0.060
0.059
0.053
0.004
0.003
0.006
0.012
0.068
0.942
0.333
0.313
0.319
0.377
284
284
284
284
284
284
284
284
284
284
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Table 1 | Continued.
Variable Correlation
Coefficient
p-value n
Lipoprotein particle concentration
Concentration of VL-HDL
Concentration of L-HDL
Concentration of M-HDL
Concentration of S-HDL
0.020
0.089
0.163
0.179
0.739
0.137
0.006
0.002
284
284
284
284
m, male; f, female; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; 
HOMA-IR, homeostatic model assessment of insulin resistance; VLDL, very-low-density lipoprotein; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; 
EL-VLDL, extra large VLDL; VL-VLDL, very large VLDL; L-VLDL, large VLDL; M-VLDL, medium VLDL; S-VLDL, small 
VLDL; VS-VLDL, very small VLDL; IDL, intermediate-density lipoprotein; L-LDL, large LDL; M-LDL, medium LDL; 
S-LDL, small LDL; VL-HDL, very large HDL; L-HDL, large HDL; M-HDL, medium HDL; S-HDL, small HDL.
Figure 1 | The prevalence of hypomagnesemia is low in overweight subjects of the 300-Obesity 
cohort
Distribution of the serum Mg2+ concentration of overweight subjects of the 300-Obesity cohort. 
The dotted vertical line indicates the threshold for hypomagnesemia.
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Similar correlations were observed between plasma Mg2+ and triglyceride levels 
(Supplementary Fig. 1A-D).
  Increased blood lipids can enhance glucose-induced insulin secretion (28). 
Insulin is known to result in a compartmental shift of Mg2+, decreasing blood 
concentration and increasing intracellular levels (29). To rule out insulin-dependent 
effects, the same oral gavage experiment was performed in inducible Kir6.2-p.
Val59Met mice, which develop hypoinsulinemia and hyperglycemia (30). A similar 
reduction in plasma Mg2+ was observed in response to the oral gavage of olive oil. 
While this reduction was numerically similar, it did not reach statistical significance 
due to a high variation between the animals, which was substantially larger than in the 
initial experiment (Fig. 2G). However, a significant inverse correlation between plasma 
Mg2+ and triglycerides was still observed in these hypoinsulinemic animals (Fig. 2H, 
p≤0.05). 
Binding of magnesium to albumin is dependent on free fatty acids
As ~30% of Mg2+ is bound to albumin, the predominant carrier of FFAs, we 
investigated whether the binding of Mg2+ to albumin is dependent on FFAs (14). The 
Mg2+ concentration declined over increasing levels of bovine serum albumin (BSA) 
dissolved in a MgCl2 solution (Fig. 3A). At a near-physiological concentration of BSA 
(0.5 mmol/L or 33.25 g/L) Mg2+ concentrations decreased from 0.85 ± 0.02 to 0.64 
± 0.01 mmol/L (25% reduction, Fig. 3A). Interestingly, dissolving fatty-acid-free-BSA 
(FF-BSA) in a MgCl2 solution abrogated this effect, in line with binding of Mg2+ to 
albumin being FFA-dependent (Fig. 3B). Linear regression analyses showed a 
significant inverse correlation between Mg2+ and BSA, of which the regression 
constant was approximately four times stronger for BSA than for FF-BSA (Fig. 3C). To 
exclude that other cations present in blood compete with the binding of Mg2+ to BSA, 
BSA was dissolved in a physiological buffer, which mimicked the concentration of 
other abundant blood electrolytes. This approach resulted in a similar decrease in the 
Mg2+ concentration (Fig. 3D). Again, the FF-BSA had no significant effect on Mg2+ 
levels (Fig. 3E). In the physiological buffer, BSA and FF-BSA displayed similar 
correlations compared to the MgCl2 buffer (Fig. 3F).
Free fatty acids directly decrease magnesium concentrations
We then set out to modify the binding of Mg2+ to albumin by increasing the 
concentration of FFA. Elevating the concentration of FFA in a BSA solution directly 
reduced the Mg2+ concentration (linear regression: y=-0.12x + 0.83, p≤0.05, Fig. 4A). 
To resemble the in vivo setting, the experiment was repeated using fetal bovine serum 
(FBS) instead of BSA. Increasing the FFA levels in FBS reduced Mg2+ concentrations 
to a similar extent (linear regression: y=-0.10x + 1.36, p≤0.05, Fig. 4B). Interestingly, 
the reduction in the Mg2+ concentration is protein-independent, as increasing the 
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Figure 2 | Increased plasma FFA and triglyceride levels directly reduce the plasma Mg2+ 
concentration in mice
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FFA levels in a MgCl2 solution also lowers the Mg2+ concentration (linear regression: 
y=-0.08x + 1.00, p≤0.05, Fig. 4C). 
Elevating triglyceride levels reduces the serum Mg2+ concentration 
in healthy subjects
To demonstrate that triglycerides and FFAs also affect the blood Mg2+ concentration 
in humans, samples obtained from 24 healthy female subjects, with a BMI >25 kg/
m2, who received an oral fat load, were investigated (31). Serum FFA and Mg2+ levels 
and plasma triglyceride concentrations were measured over a period of eight hours. 
Plasma triglyceride levels significantly increased from 1.18 ± 0.10 (t=0 hours) to 2.13 
± 0.18 (peak at t=4 hours) mmol/L (Fig. 5A). Serum FFA concentrations were 
significantly elevated from 0.38 ± 0.03 (t=0 hours) to 0.76 ± 0.04 (peak at t=6 hours) 
mmol/L (Fig. 5B). In accordance with our previous findings, serum Mg2+ levels 
dropped from 0.82 ± 0.01 (t=0 hours) to 0.75 ± 0.02 (nadir at t=6 hours) mmol/L 
(Fig. 5A,B). We then measured total serum Mg2+ levels using inductively coupled 
plasma mass spectrometry (ICP-MS) and found that the total serum Mg2+ 
concentration was not affected by the cream intake; hence only the free Mg2+ levels 
are affected (Fig. 5C).   
Figure 2 | Continued.
(A) Plasma Mg2+ (circles, left y-axis) and triglyceride (squares, right y-axis) concentrations 
before (t=0) and at 1, 2, 4, 6 and 8 hours after an oral gavage of 200 μL olive oil in wild-type 
mice (n=12). (B) Plasma Mg2+ (circles, left y-axis) and FFA (squares, right y-axis) concentrations 
before (t=0) and at 1, 2, 4, 6 and 8 hours post-gavage. (C-F) Linear regression analyses 
between plasma Mg2+ and FFA concentrations at t= (C) 0, (D) 4, (E) 6 and (F) 8 hours 
post-gavage, data from the experiment in graph A-B. Each dot represents an individual mouse. 
Several data points are missing due to insufficient sample availability. (G) Plasma Mg2+ (circles, 
left y-axis) and triglyceride (squares, right y-axis) concentrations before (t=0) and at 1, 2, 4, 6 
and 8 hours after an oral gavage of 200 μL olive oil in hypoinsulinemic Kir6.2-p.Val59Met mice 
(n=7). Linear regression analysis between the plasma Mg2+ and triglyceride concentration at 
t=4 hours post-gavage, data from the experiment in graph G. Each dot represents an individual 
mouse. Two mice were excluded due to insufficient sample availability. Data are mean ± SEM. 
* Indicates a p≤0.05 of Mg2+ concentrations compared to t=0 hours. † Indicates a p≤0.05 of 
triglyceride or FFA concentrations compared to t=0 hours.
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Figure 3 | Binding of Mg2+ to albumin is FFA-dependent
(A-B) The Mg2+ concentration in an increasing level of (A) BSA or (B) FF-BSA dissolved in a 1 
mmol/L MgCl2 solution. (C) Linear regression analyses of the Mg2+ concentration in increasing 
levels of BSA (circles, y=-0.21x + 0.78, r2=0.96, p≤0.05) or FF-BSA (triangles, y=-0.05x + 0.83, 
r2=0.90, p≤0.05), data from graph A-B. (D-E) The Mg2+ concentration in an increasing level 
of (D) BSA or (E) FF-BSA dissolved in a physiological buffer. (F) Linear regression analyses of 
the Mg2+ concentration in increasing levels of BSA (circles, y=-0.21x + 0.78, r2=0.96, p≤0.05) 
or FF-BSA (triangles, y=-0.05x + 0.83, r2=0.90, p≤0.05), data from graph D-E. The striped 
bars indicate a BSA/FF-BSA concentration (0.5 mmol/L) that is near the physiological range. 
Data are mean ± SEM of three replicate experiments. * Indicates a p≤0.05. FF-BSA: free-fatty-
acid-free BSA.
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Figure 4 | FFAs directly reduce Mg2+ concentrations
(A-C) Linear regression analyses of the Mg2+ versus the FFA concentration in (A) BSA in 
1 mmol/L MgCl2 (y=-0.12x + 0.83, r2=0.97, p≤0.05), (B) FBS (y=-0.10x + 1.36, r2=0.90, 
p≤0.05) and (C) a 1 mmol/L MgCl2 solution (y=-0.08x + 1.00, r2=0.99, p≤0.05). Results of one 
representative experiment are shown. The experiment was repeated three additional times with 
similar results.
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Discussion
Hypomagnesemia is a common phenomenon in T2D. In the current study, we show 
that high blood FFA and triglyceride concentrations directly reduce blood Mg2+ 
levels. High FFA levels bind Mg2+ resulting in decreased circulating free Mg2+ levels. 
  This conclusion is based on complementary results from our in vitro, animal and 
human in vivo studies. First, in a large cohort of overweight individuals, the 
concentration of triglycerides in large VLDL particles was inversely correlated with the 
blood Mg2+ concentration. Second, a dietary lipid load directly reduced the blood 
Mg2+ concentration in both mice and man, independent of insulin action. Third, we 
Figure 5 | Increased serum FFA and plasma triglyceride levels directly reduce the serum Mg2+ 
concentration in healthy overweight or obese female individuals
(A) Serum Mg2+ (circles, left y-axis) and plasma triglyceride (squares, right y-axis) 
concentrations before (t=0) and at 1, 2, 4, 6 and 8 hours after an oral lipid load in healthy 
overweight females (n=22). (B) Serum Mg2+ (circles, left y-axis) and FFA (squares, right y-axis) 
concentrations before (t=0) and at 1, 2, 4, 6 and 8 hours after an oral lipid load in healthy 
overweight females (n=22). (C) Total serum Mg2+ levels measured by inductively coupled 
plasma mass spectrometry (ICP-MS) at t=0, 4 and 8 hours after oral lipid intake. Data are 
mean ± SEM. * Indicates a p≤0.05 of Mg2+ concentrations compared to t=0 hours. † Indicates 
a p≤0.05 of triglyceride or FFA concentrations compared to t=0 hours.
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demonstrated that this phenomenon occurs due to direct binding of FFA molecules 
to Mg2+. These findings demonstrate that triglycerides reduce free blood Mg2+ 
concentrations and consequently place hypertriglyceridemic patients at risk for Mg2+ 
deficiencies.
  Here, we demonstrated that increased triglyceride and FFA levels reduce free 
Mg2+ concentrations, the biologically active form of Mg2+, by a direct interaction 
between negatively charged FFA molecules and Mg2+ ions. This binding is highly 
specific for Mg2+, as the presence of physiological concentrations of other cations 
did not affect the interaction between Mg2+ and FFAs. The phenomenon of reduced 
Mg2+ levels as a result of elevated FFA levels has been observed in dogs, however 
no underlying mechanism was suggested (32). Moreover, previous studies showed 
that Ca2+ can bind to FFAs, and that elevating FFA levels in patients reduces blood 
Ca2+ concentrations (33). However, in our in vitro experiments the addition of 
physiological concentrations of Ca2+ did not affect the Mg-FFA interaction, indicating 
a higher affinity of Mg2+ compared to Ca2+ for binding FFAs. This is likely due to the 
fact that a Mg2+ ion has a significantly higher charge density than a Ca2+ ion (34).
  Our findings may explain why certain factors that affect circulating FFAs are 
associated with changes in blood Mg2+ concentrations. Molecules that activate 
lipolysis, resulting in increased blood FFA levels, such as β-adrenergic agonists, 
ethanol and epinephrine, are associated with reduced blood Mg2+ levels (1, 35-37). 
Indeed, an intravenous infusion of the β-adrenergic agonist terbutaline causes a 
reduction in the serum Mg2+ concentration, which is correlated to the elevated 
concentration of plasma FFAs, but not glucose (38). This does not exclude the 
possibility of additional potential mechanisms. Prolonged fasting, which induces 
lipolysis and increases circulating FFAs, also results in hypomagnesemia (39). 
  Approximately 30% of blood Mg2+ is bound to albumin (14). However, our data 
indicate that the binding of Mg2+ to albumin depends on the availability of FFAs. 
Direct binding of Mg2+ to albumin is minimal, because albumin depleted of FFAs 
showed little binding to Mg2+. To correct for albumin binding, the factor of 0.7 is used 
when calculating the fractional excretion of Mg2+ (FEMg, [(uMg × sCr)/
(sMg × uCr × 0.7)] × 100) (40). As the large majority of FFAs in blood is bound to 
albumin, alterations in the FFA concentration may be the determining factor in the 
binding of Mg2+ to albumin (22). This paradigm change questions the current protocol 
to calculate the FEMg. The use of the factor of ‘0.7’ is accurate in physiological 
conditions, but will lead to inaccurate calculations in pathological conditions, such as 
hypertriglyceridemia. 
  Several limitations need to be considered. Hypertriglyceridemia in mice was 
achieved using olive oil, while in human subjects this was done by an oral load of 
cream. Olive oil contains no Mg2+, while the cream used in the human study contains 
3.3 mmol/L Mg2+, leading to a potential underestimation of the reduction in serum 
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Mg2+ in the healthy volunteers. Moreover, in the in vitro experiments, FFAs extracted 
from BSA were used to increase FFA levels in several solutions. However, the yield of 
this extraction procedure was not equal in each performed experiment, making it 
difficult to combine the data of all experiments. Despite these differences in FFA-yield, 
the results were similar in all four replicate experiments. Lastly, in overweight 
individuals and T2D patients, Mg2+ inversely correlates with triglycerides (1, 23, 24). 
Our in vitro data show direct binding of Mg2+ to FFA molecules, which, in contrast to 
triglyceride molecules, contain a negative charge. It is unlikely that Mg2+ binds to 
uncharged triglyceride molecules. However, in humans the blood triglycerides and 
FFA levels strongly correlate, meaning that most patients with hypertriglyceridemia 
also have elevated FFA levels, which would underlie the inverse correlation between 
Mg2+ and triglycerides (41-44).   
  This study has several strengths. Our data extend from molecule to population 
and have clinical implications. Moreover, we demonstrated the directionality of the 
inverse association between triglycerides and Mg2+, which could explain why 
hypomagnesemia is so prominent in diseases such as T2D. Our data do not rule out 
that changes in Mg2+ concentrations could also influence lipid levels.
  In conclusion, we show that elevated blood FFA and triglyceride levels directly 
reduce the blood Mg2+ concentration by binding of Mg2+ ions to FFA molecules. Our 
data explain the high prevalence of hypomagnesemia in several metabolic diseases 
characterized by elevated triglyceride levels (1-3). In these patient groups, hypertri-
glyceridemic patients are at particular risk for hypomagnesemia, and therefore, blood 
Mg2+ levels should be routinely measured and monitored in these patients.
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Materials and methods
300-Obesity cohort
302 Individuals aged 55 to 80 were enrolled in the 300-Obesity cohort study at the 
Radboud university medical center in the period between 2014 and 2016 (45). All 
subjects had a BMI above 27 kg/m2. Subjects with a recent cardiovascular event (MI, 
transient ischemic attack, stroke <6 months), a history of bariatric surgery or bowel 
resection, inflammatory bowel disease, renal dysfunction, increased bleeding 
tendency, use of oral subcutaneous anti-coagulant therapy, use of thrombocyte 
aggregation inhibitors other than acetylsalicylic acid and carbasalate calcium were 
excluded. Blood samples were taken in the morning following an overnight fast. 
Blood glucose, triglycerides, total cholesterol and high density lipoprotein cholesterol 
were measured using standard laboratory procedures. HOMA-IR was calculated by 
the formula: (fasting plasma glucose × fasting plasma insulin)/22.5. High-throughput 
nuclear magnetic resonance (NMR) metabolomics platform (Nightingale’s Biomarker 
Analysis Platform) (27) was used for the quantification of 231 lipid and metabolite 
measures. The metabolites were measured in a single experiment setup for the 
quantification of different metabolite groups. In this paper we focus on the lipoproteins: 
total lipid concentrations of 14 lipoprotein subclasses, lipoprotein particles sizes, 
apolipoproteins and cholesterol. The NMR metabolomics platform has previously 
been used in various epidemiological studies (46, 47). Details of the experimentation 
have been described previously (27).
Oral gavage of olive oil in mice
This study was approved by the animal ethics board of the Radboud University 
Nijmegen (RU DEC 2015-0073) and by the Dutch Central Commission for Animal 
Experiments (CCD, AVD103002015239). 12 Male C57BL6/J mice (Charles River, 
Germany) were obtained at an age of 9-10 weeks, and were acclimatized for two 
weeks in a temperature- and light-controlled room, with six mice per cage 
(Eurostandard Type III) and were allowed ad libitum access to acidified tap water and 
standard pellet chow (Ssniff Spezialdiäten, GmbH, Germany). After the acclimatiza-
tion period, mice received experimental chow containing 18.3% protein (wt/wt), 4.1% 
crude fat (wt/wt), 25.1% starch (wt/wt) and 33.6% sugar (wt/wt) (Ssniff Spezialdiäten, 
E15000-04). After 2 weeks on the synthetic diet, mice were fasted overnight, from 
9:00 PM to 9:00 AM. Mice received 200 μL intragastric olive oil (extra virgin, Carbonell, 
Cordoba, Spain) via oral gavage. Blood was drawn via tail-bleed, using chilled 
Na-heparin capillaries (Praxisdienst, Longuich, Germany) coated with paraoxon 
(Sigma, St. Louis, MO, USA), before the gavage (t=0 hours) and at 1, 2, 4, 6 and 8 
hours post-gavage. The capillaries were spun down at 3000 g and plasma was 
separated. 
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Oral gavage of olive oil in mice with diabetes
All experimental procedures were conducted in compliance with the UK Animals 
Scientific Procedures Act (1986) and University of Oxford ethical guidelines. In four 
male and four female C57BL6 mice expression of a Kir6.2-p.Val59Met transgene was 
induced using a 400 μL tamoxifen (0.02 g/mL corn oil) subcutaneous injection. This 
inducible mouse model recapitulates the phenotype of neonatal diabetes and 
develops diabetes by impaired insulin secretion (48). Three days after induction, mice 
were fasted overnight from 5:00 PM to 9:00 AM. Successful induction was validated 
by measuring fasted glucose levels. One female mouse did not have elevated fasting 
glucose levels and was excluded from subsequent analyses. The subsequent 
experimental setup of the oral gavage and blood drawing was identical to the 
above-described experiment in C57BL6/J wild-type mice.    
Bovine serum albumin (BSA) and fatty-acid-free-BSA (FF-BSA) 
dissolved in a MgCl2 solution or a physiological buffer
  BSA (Sigma Aldrich) and FF-BSA (Sigma Aldrich) were separately dissolved at 
several concentrations in a 1 mmol/L MgCl2 (Merck Millipore, Darmstadt, Germany) 
solution or a physiological buffer, both set at pH 7.5 by adding NaOH. The physiological 
buffer contained 27 mmol/L NaHCO3 (Merck Millipore), 112 mmol/L NaCl (Merck Millipore), 
5 mmol/L KCl (Merck Millipore), 1 mmol/L MgCl2, 1 mmol/L Na2HPO4 (VWR International, 
USA), and 2.5 mmol/L CaCl2 (Merck Millipore) dissolved in Milli-Q.   
Increasing FFA levels in BSA, fetal bovine serum (FBS) and  
MgCl2 solutions
To extract endogenous FFAs, BSA (0.2 g/mL) dissolved in Milli-Q was mixed (1:2 
(vol./vol.)) with ice-cold ethanol:diethyl ether (3:1 (vol./vol.)). The lipid phase was 
evaporated overnight at room temperature. In order to remove trace amounts of BSA 
from the solution, it was centrifuged three times with an Amicon® 50 kDa filter for 15 
minutes at 2500 g to clog the protein in the filter. Extracted FFAs were added to 250 
μl of FBS (Biowest, South America), 1 mmol/L MgCl2, or 0.5 mmol/L BSA in the 
amounts of 0, 25, 50, 100, 200, 350, 500, and 700 μL. Dilution factors were accounted 
for when measuring the concentrations of Mg2+ and FFA.
Analytical measurements
Protein (Pierce, Thermo Scientific, Massachusetts, USA), FFA (WAKO Diagnostics, 
Delfzijl, The Netherlands), triglycerides (Roche Molecular Biochemicals, Indianapolis, 
USA) and Mg2+ (Roche/Hitachi, Tokyo, Japan) concentrations were measured using 
a spectrophotometric assay according to the manufacturer’s protocols. The Mg2+ 
calorimetric assay is based on a Xylidyl Blue-I method and was measured at 600 nm. 
FFAs were measured at 546 nm, triglycerides at 500 nm, and protein at 562 nm on a 
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Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad laboratories, 
California, USA). For the inductively coupled plasma mass spectrometry (ICP-MS) 
measurements, serum samples were dissolved in HNO3 (>65%, Sigma), diluted, and 
subjected to ICP-MS. 
Oral lipid load in human subjects
A total of 24 female volunteers underwent an oral fat loading test. The study was 
approved by the Institutional Review Board of the Franciscus Gasthuis & Vlietland 
Rotterdam and the regional independent medical ethics committee of the Maasstad 
Hospital Rotterdam (31). The study was registered at ClinicalTrials.gov under clinical 
trial number NCT01967459, which aimed to study the effect of vitamin D supplemen-
tation on postprandial leukocyte activation. Samples from the baseline oral cream 
load (before the vitamin D treatment) were used in this study to measure serum Mg2+ 
and FFA concentrations.
  Inclusion criteria were an age above 18 years, a premenopausal status, a body 
mass index (BMI) of 25 kg/m2 or above and vitamin D deficiency. Exclusion criteria 
were the use of any kind of medication, except for oral contraceptives, smoking, 
pregnancy, participation in a clinical study less than 6 months before inclusion, and 
the use of vitamin supplements. All subjects visited the hospital after a 10 hours 
overnight fast. A fasting venous blood sample was obtained. Subject received an oral 
fat load using fresh cream (Albert Heijn, Zaandam, the Netherlands) in a dose of 50 
grams of fat per square meter body surface calculated by the Mosteller formula. 
During the oral fat loading test participants were not allowed to eat or to drink except 
water and they were asked to refrain from physical activity. Venous blood sampling 
was repeated at a two-hour interval until eight hours and serum Mg2+ and FFA levels 
and plasma triglyceride levels were measured. Two patients were excluded due to 
insufficient sample availability. 
Statistical analyses
Results are presented as mean ± standard error of the mean (SEM), unless stated 
otherwise. Variables of overweight individuals were correlated univariately to serum 
Mg2+ levels using Pearson’s correlation analyses using SPSS for Windows (V22.0.0.1 
IBM). Based on the initial animal experiment in wild-type mice, the sample size for the 
experiment in Kir6.2-p.Val59Met mice was calculated using a one-way ANOVA 
statistic (with Dunnett’s correction for multiple comparison), to detect an effect size of 
0.3 (SD 0.13) with a power of 80% and alpha level of 5%, a total of 6 animals are 
required per group. The sample size of the oral cream load study in healthy individuals 
was assessed using a one-way ANOVA (with Dunnett’s correction for multiple 
comparison), to detect an effect size of 0.1 (SD 0.1) with a power of 80% and an alpha 
of 5%, a total of 23 individuals are required. Significance of Mg2+, triglyceride and 
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FFA concentrations compared to t=0 hours were evaluated using a one-way ANOVA 
with Dunnett’s correction for multiple comparisons. Direct correlations between Mg2+ 
and triglyceride or FFA concentrations were assessed using linear regression 
analyses. A p-value of ≤0.05 was considered statistically significant. All statistical 
analyses were performed using Graphpad Prism v7.
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Supplementary data
Supplementary figure 1 | Plasma Mg2+ and triglyceride concentrations inversely correlate in 
hypertriglyceridemic states
(A-D) Linear regression analyses between serum Mg2+ and triglyceride concentrations at 
t = (A) 0, (B) 4, (C) 6 and (D) 8 hours post-gavage from the experiment in Figure 2A-B. Each 
dot represents an individual mouse. Several mice were excluded due to insufficient sample 
availability.
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Supplementary table 1 | Characteristics of the Overweight Individuals from the 300-Obesity 
Cohort.
Variable 300-Obesity cohort mean ± SD
Demographics
Gender (m:f, %)
BMI (Kg/m2)
Age (years)
Waist circumference (cm)
SBP (mmHg)
DBP (mmHg)
Heart rate (beats/min)
45:55 (m:f)
30.7 ± 3.4
67 ± 5
107 ± 10
130 ± 14
80 ± 9
63 ± 10
Laboratory analyses
Magnesium (mmol/L)
Triglycerides (mmol/L)
Glucose (mmol/L)
HOMA-IR
HbA1c (mmol/mol)
Total cholesterol (mmol/L)
Triglycerides in VLDL (mmol/L)
Triglycerides in LDL (mmol/L)
Triglycerides in HDL (mmol/L)
Cholesterol in VLDL (mmol/L)
Cholesterol in LDL (mmol/L)
Cholesterol in HDL (mmol/L)
ApoA1 (g/L)
ApoB (g/L)
Mean diameter VLDL particle (nm) 
Mean diameter LDL particle (nm)
Mean diameter HDL particle (nm)
0.89 ± 0.09
1.8 ± 1.0
5.7 ± 1.3
13.7 ± 19.1
41.8 ± 8.0
6.3 ± 1.1
1.23 ± 0.72
0.23 ± 0.07
0.15 ± 0.04
1.14 ± 0.37
2.25 ± 0.64
1.31 ± 0.29
1.59 ± 0.01
1.19 ± 0.02
36.6 ± 1.2
23.5  ± 0.1
9.8  ± 0.2
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; DBP, diastolic blood pressure; f, female; HbA1c, glycated 
hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; 
LDL, low-density lipoprotein; m, male; SBP, systolic blood pressure; VLDL, very-low-density lipoprotein.
Supplementary table 2 | Univariate regression analysis of HOMA-IR, as dependent variable, 
and triglycerides 
Variable Correlation
coefficient
p-value n
Triglycerides (mmol/L) 0.245 0.000 284
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Supplementary table 3 | Univariate regression analysis of HOMA-IR, as dependent variable, 
and triglycerides in VLDL
Variable Correlation
coefficient
p-value n
Triglycerides in VLDL 0.236 0.000 284
Supplementary table 4 | Multivariate regression analysis of HOMA-IR and triglycerides with 
the serum Mg2+ concentration as dependent variable
Variable Correlation
coefficient
p-value n
HOMA-IR  
Triglycerides (mmol/L)
-0.089 
-0.137
0.143 
0.024
283 
284
HOMA-IR, homeostatic model assessment of insulin resistance
Supplementary table 5 | Multivariate regression analysis of HOMA-IR and triglycerides in 
VLDL particles with the serum Mg2+ concentration as dependent variable
Variable Correlation
coefficient
p-value n
HOMA-IR  
Triglycerides in VLDL 
-0.092 
-0.137
0.128 
0.024
283 
284
HOMA-IR, homeostatic model assessment of insulin resistance
“Without the element of enjoyment, 
it is not worth trying to excel at anything”
– Magnus Carlsen
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Summary
Hypomagnesemia in type 2 diabetes, cause or consequence?
Magnesium (Mg2+) is an essential ion in the functioning of over 600 enzymes and has 
a wide variety of functions throughout the body. Hypomagnesemia (blood Mg2+ 
concentration <0.7 mmol/L) can result in clinical symptoms including, but not limited to, 
muscle spasms, arrhythmias, migraines, depression, tiredness and generalized weakness. 
Therefore, the body maintains the blood Mg2+ concentration in the physiological range, 
between 0.70-1.05 mmol/L, by the complex interplay of the kidneys, intestine and bone. 
Hypomagnesemia is a common clinical finding in patients with type 2 diabetes (T2D). 
The causal relationship and main mechanisms underlying the hypomagnesemia in 
these patients is still unknown despite numerous hypotheses described in the literature. 
Recently, lower Mg2+ levels have been associated with an increased risk of developing 
T2D in the general population. In T2D patients, lower blood Mg2+ levels result in a more 
rapid disease progression and more severe T2D-related complications, including a 
quicker renal function decline. How reduced Mg2+ levels affect energy and lipid 
metabolism, leading to this increased risk and disease progression, has not been 
investigated in detail. Therefore, this thesis aimed to establish the causal relationship 
and the molecular mechanism(s) underlying hypomagnesemia in T2D.
Which factors contribute to the hypomagnesemia in type 2  
diabetes patients?
Identifying which T2D-related factors contribute to reductions in the blood Mg2+ 
concentration of T2D patients will facilitate more focused future research. As T2D is a 
complex disease with a wide array of different comorbidities, polypharmacy is 
unavoidable when treating T2D. Several of these medications are known to influence 
the Mg2+ balance and could, therefore, explain the Mg2+ deficiency of T2D patients.   
 To determine which factors affect the Mg2+ balance, the plasma Mg2+ concentration 
of 395 T2D patients of the PARELSNOER cohort was measured. As described in 
Chapter 2, in total 31% of these patients had hypomagnesemia. To investigate which 
factors contributed to this hypomagnesemia, changes in the plasma Mg2+ concentration 
were correlated to patient characteristics, laboratory results and medication use. 
Plasma glucose and triglyceride levels showed the strongest inverse correlations 
with the plasma Mg2+ concentration, whereas the use of medication was not 
responsible for major changes. However, treatment with metformin was associated 
with a lower plasma Mg2+ level, independent of the fasting glucose concentration. 
The findings presented in this chapter indicate that hypomagnesemia is associated 
with factors that are intrinsic to T2D. This study has established the prevalence of 
hypomagnesemia in a large cohort of T2D patients and has identified which of the 
factors are most strongly associated with changes in plasma Mg2+ levels.
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Metabolic consequences of hypomagnesemia 
From this cohort study, the causal relationship between T2D and hypomagnesemia 
cannot be established. Recently, in collaboration with the group of Prof. Hoorn of the 
Erasmus MC in Rotterdam, it was found that lower Mg2+ levels were associated with 
an increased risk of developing T2D in the general population.   
  To identify how a Mg2+ deficiency affects energy and lipid metabolism in T2D, 
mice were fed a low or high fat diet (LFD, HFD), combined with a low or normal Mg2+ 
food content. A low dietary Mg2+ intake resulted in less HFD-induced weight gain, 
described in Chapter 3. The reduced body weight of the Mg2+ deficient animals was 
associated with improved insulin sensitivity, absent liver steatosis, and lower fasting 
glucose concentrations. In contrast, these animals had elevated serum triglyceride 
and free fatty acid (FFA) levels, caused by increased lipolysis in white adipose tissue, 
resulting in a lower fat mass. Lipolysis is a process that is regulated by the 
β3-adrenergic receptor, which was increased in expression in the white adipose 
tissue of the Mg2+ deficient HFD-fed mice. Brown adipose tissue is an important 
organ in metabolism as it consumes energy to produce heat. The activity of brown 
adipose tissue, which is also regulated by the β3-adrenergic receptor, was enhanced 
in the Mg2+-deficient HFD-fed mice, resulting in a higher body temperature. However, 
no difference was observed in total energy expenditure between the two HFD-fed 
groups. Taken together, our data show that Mg2+ deficiency results in disturbances 
in lipid and energy homeostasis, indicative of a catabolic phenotype, which is 
possibly a result of activation of the β-adrenergic system. This highlights the essential 
role of Mg2+ in lipid metabolism and, therefore, Mg2+ deficient T2D patients could be 
at additional risk for dyslipidemia.
  In Mg2+ deficient mice on a HFD, lipid metabolism was also disturbed in the 
kidney, which is reported in Chapter 4. The mice had massive lysosomal accumulations 
of charged lipids, such as phospholipids or sphingolipids, in the cells of the proximal 
tubule. The exact lipid composition and underlying mechanism was not identified. 
However, the extent of the damage proposes a novel mechanism to explain the 
association between reduced Mg2+ levels and renal function decline.  
Mice with type 2 diabetes develop hypomagnesemia
To address the other side of the coin, namely whether hypomagnesemia can be a 
consequence of T2D, two different T2D animal models were analyzed in this thesis, a 
HFD model and a genetic diabetes model (db/db). The results of these studies are 
described in Chapter 4 and 5. Mice on a HFD had reduced serum Mg2+ levels already 
after 4 weeks on the diet; predominantly in the mice receiving a diet low in Mg2+. 
The intestines and kidneys are the major organs regulating blood Mg2+ levels. Despite 
the hypomagnesemia in the HFD-fed mice, there was a reduced intestinal expression 
of an epithelial Mg2+ channel, Trpm6. However, no fecal Mg2+ loss was observed. Also 
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in the kidney, the expected upregulation of Trpm6 was not present in the hypomagnesemic 
HFD-fed mice. There was no urinary Mg2+ loss, indicative of intact renal compensation 
despite the lower Trpm6 expression. Db/db mice, a genetic model for T2D, also developed 
hypomagnesemia. As described in Chapter 5, in db/db mice the compensatory 
upregulation in Trpm6 is present both in kidney and intestine. This is in contrast to the 
HFD-fed mice, which had reduced gene expression of Trpm6 in colon and kidney 
(Chapter 4). However, as in the HFD-fed mice, no renal Mg2+ wasting occurred in the 
db/db mice, despite massive glucosuria. Treating the db/db mice with metformin, 
which was associated with a lower plasma Mg2+ concentration in the PARELSNOER 
cohort, did not affect the Mg2+ homeostasis. This indicates that the lower plasma Mg2+ 
level in metformin users is likely mediated by indirect factors. 
  Together, these data clearly show that hypomagnesemia is a consequence of 
T2D, which is not mediated by metformin use. As no renal or intestinal Mg2+ loss was 
observed, it remains unclear what the exact underlying cause of the hypomagnesemia 
in these mice is. 
Free fatty acids reduce blood magnesium levels 
As no renal or intestinal loss of Mg2+ was observed in the animal models, despite the 
development of hypomagnesemia, we hypothesized other causes for reduced Mg2+ 
levels. Plasma triglycerides are one of the major determinants of changes in the blood 
Mg2+ concentration both in T2D patients (Chapter 2) and overweight individuals 
(Chapter 6). 
 To investigate whether triglycerides could affect the blood Mg2+ concentration, 
hypertriglyceridemia was induced in mice using an oral gavage of olive oil (Chapter 6). 
Indeed, increasing concentrations of plasma triglycerides caused a severe and 
immediate reduction in the plasma Mg2+ concentration. Interestingly, when plasma 
triglyceride and FFA levels returned to baseline, plasma Mg2+ levels also returned to 
normal. Performing a lipid load of cream in healthy volunteers yielded similar results, 
indicating that the changes observed in mice also occur in humans. As the plasma 
Mg2+ concentration was almost perfectly inversely correlated with plasma triglyceride 
and FFA levels in hypertriglyceridemic mice, we suspected direct binding of Mg2+ to 
negatively charged FFA molecules. Adding increasing amounts of FFAs to Mg2+ 
containing solutions in vitro, reduced ionized Mg2+ concentrations in a dose-dependent 
manner. These findings add FFAs as an important contributor in Mg2+ homeostasis 
and explain the molecular mechanism underlying the inverse correlation between 
blood triglycerides and Mg2+ concentrations in metabolic disorders. 
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Perspectives
The studies performed in this thesis expand our knowledge on the etiology and 
metabolic consequences of hypomagnesemia in T2D. The data open up new 
research directions on the role of Mg2+ in both physiology and pathophysiology.
 In the PARELSNOER cohort of T2D patients we have shown that hypomagnesemia 
is correlated to factors intrinsic to the disease, namely plasma glucose and 
triglycerides concentrations. Some factors that were not included in this study could 
also impact the Mg2+ status of T2D patients, such as dietary intake, genetic differences 
and the presence of comorbidities. Also, it would be interesting to collect data of 
these patients after several years, to be able to draw conclusions regarding causality. 
Do lower Mg2+ levels lead to a worse disease progression and mortality? Including 
these analyses in future research would provide essential information regarding the 
causes of hypomagnesemia, and its metabolic consequences, in T2D patients. 
  In this cohort of T2D patients there was a strong inverse correlation between 
plasma triglyceride and Mg2+ concentrations. From the animal data it became 
apparent that Mg2+ deficiency results in high blood triglyceride levels. On the other 
hand, inducing hypertriglyceridemia in mice using an oral gavage resulted in a rapid 
decrease in the blood Mg2+ concentration. This indicates that severely hyper-
triglyceridemic T2D patients are at extra risk of developing hypomagnesemia. 
An interesting approach is to measure Mg2+ levels in patients with primary hyper-
triglyceridemia, who do not have T2D. This could differentiate the effects of 
triglycerides and insulin resistance on Mg2+ homeostasis. 
  In this thesis, we unraveled that the effect of triglycerides on Mg2+ is due to direct 
binding of Mg2+ to FFA molecules. Interestingly, several factors that induce increases 
in blood FFA levels are also associated with hypomagnesemia, such as β-adrenergic 
agonists, fasting, acute stress and ethanol use. These findings will open new research 
opportunities for understanding the etiology of hypomagnesemia in conditions such 
as asthma, admittance to intensive care, metabolic syndromes and alcohol 
dependence or withdrawal. In this thesis only the short-term effects of hypertriglycer-
idemia on Mg2+ homeostasis have been investigated. Does the binding of Mg2+ to 
FFA also induce a chronic hypomagnesemia? Potentially, reducing blood triglyceride 
and FFA levels is a new way to normalize blood Mg2+ levels.
  Mice on Mg2+ deficient high fat diet had increased expression of the β3-adrenergic 
receptor, which was associated with a higher lipid breakdown and heat production. 
This thesis has only focussed on the effects on the β3-adrenergic receptor, but it was 
not investigated whether the Mg2+ deficiency also caused other downstream effects 
of the β-adrenergic system (via the β1 or β2 receptors). In literature Mg2+ has been 
described to suppress the effects of adrenaline on heart rate. Studying how Mg2+ 
can inhibit the β-adrenergic system will be relevant for both physiology and for 
stress-related conditions.
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In clinical practice, blood Mg2+ levels are not routinely measured in T2D patients, 
despite the high prevalence of hypomagnesemia, occurring in almost one in three 
patients with T2D. Several new mechanisms and factors that contribute to the 
hypomagnesemia in T2D patients have been identified in this thesis. Now that we 
better understand why T2D patients develop hypomagnesemia, which factors are 
involved in this process and what metabolic consequences this has, it is important 
that Mg2+ will receive more attention both in the clinic and in the general population. 
“It’s the job that’s never started as takes longest to finish”
– J.R.R. Tolkien | The Lord of the Rings
Discussion and clinical implications
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Discussion and clinical implications
Magnesium (Mg2+) plays an important role in human physiology in general and 
energy metabolism in particular. Hypomagnesemia (blood Mg2+ concentration <0.7 
mmol/L) is a common clinical finding in T2D patients (1). However, little is known 
regarding the metabolic consequences of hypomagnesemia (2). It is still unclear 
whether hypomagnesemia in T2D patients contributes towards the development of 
the disease, or that hypomagnesemia is merely a consequence of T2D (3). This 
thesis contains a number of studies that further unravel the metabolic consequences 
and the underlying cause of hypomagnesemia in T2D.
Hypomagnesemia in type 2 diabetes patients
We determined the prevalence of hypomagnesemia and the extent of urinary Mg2+ 
loss in a cohort of patients with advanced T2D (PARELSNOER), and investigated 
clinical and laboratory factors associated with low plasma Mg2+ levels. The 
prevalence of hypomagnesemia in the PARELSNOER cohort of 395 T2D patients 
was 31% (Chapter 2), which matches the prevalence numbers of previous studies 
(Table 1 in Chapter 1). 
 Knowing which T2D-related parameters are associated with hypomagnesemia 
will aid in identifying the key risk factors, will provide insight into the underlying 
mechanisms and will contribute to the awareness of hypomagnesemia in T2D patients 
in the clinics. The major factors that correlated with reduced plasma Mg2+ levels in 
the PARELSNOER cohort of T2D patients were elevated plasma concentrations of 
glucose and triglycerides (Chapter 2). Multiplying plasma glucose by triglycerides 
levels is known as the ‘triglyceride glucose index’ (TyG index), which is a marker of 
insulin resistance (4, 5). Hypomagnesemia was not a prominent feature of overweight 
individuals from the 300-Obesity cohort (hypomagnesemia in 5 out of 285 individuals, 2%, 
Chapter 6), who do not have severe insulin resistance, suggesting that insulin 
resistance is key in the development of hypomagnesemia in metabolic disorders. 
This is substantiated by observational cohort studies that identified an inverse 
correlation between the serum Mg2+ concentration and the ‘homeostatic model 
assessment of insulin resistance’ (HOMA-IR) score, the clinical measure of insulin 
resistance (6, 7). 
 These data suggest that patients with the most severe T2D are at the highest risk 
to develop hypomagnesemia. It cannot be concluded whether this is a direct effect 
of insulin resistance on Mg2+ homeostasis, or whether this is mediated by factors that 
are secondary to the insulin resistance, including hyperglycemia and hypertrigly-
ceridemia, or a combination of these factors (8). By using animal studies, such as 
dietary interventions or genetically modified mice, the effect of these factors on the 
Mg2+ balance can be individually investigated. 
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Potential causes of hypomagnesemia in type 2 diabetes
Many T2D-related factors have been proposed to contribute to the development of 
hypomagnesemia, including, but not limited to, medication use, urinary Mg2+ wasting, 
reduced dietary intake and intestinal malabsorption (9). 
The effect of medication use on magnesium homeostasis
Due to the complexity of T2D, its wide range of complications and associated multi-
morbidity, polypharmacy is common when treating T2D patients (10, 11). Some of the 
medication extensively used among T2D patients, such as proton pump inhibitors (PPIs) 
and thiazide diuretics, are known to induce hypomagnesemia (12-14). Therefore, 
medication use was expected to be a major contributor to the etiology of hypo-
magnesemia in T2D patients. However, the contribution of PPIs and thiazides towards 
a reduction in plasma Mg2+ was minimal, substantiating the notion that hypo-
magnesemia is intrinsic to T2D, and not merely a consequence of medication use 
(Chapter 2).   
  Metformin use correlated with a reduced plasma Mg2+ level (Chapter 2), which 
was also reported in other observational cohort studies (15, 16). In a small short-term 
intervention study in fourteen T2D patients metformin treatment resulted in a mild 
reduction in plasma Mg2+ levels after 2-4 weeks (from 0.72 to 0.70 mmol/L, p<0.05), 
despite substantially improving blood glucose levels (17). Possibly, the effect of 
metformin on Mg2+ homeostasis is indirect, as metformin treatment can result in chronic 
diarrhea, leading to intestinal malabsorption (18). An indirect effect of metformin is in 
line with our animal data, in which metformin treatment did not affect Mg2+ homeostasis 
in either db/db or db/m mice (Chapter 5). These findings are in accordance with a 
study that observed equal serum Mg2+ levels when treating type 1 diabetic and control 
rats with metformin (19). It is, therefore, likely that the association between metformin 
use and lower serum Mg2+ levels in T2D patients is caused by factors that were not 
included in the analyses of these cohort studies. It would be interesting to measure 
Mg2+ levels in blood samples of T2D patients receiving metformin versus placebo to 
conclude whether metformin directly affects Mg2+ homeostasis in T2D patients.
Triglycerides and free fatty acids
Elevated blood triglyceride concentrations are associated with reduced blood Mg2+ 
levels in T2D patients and overweight individuals (Chapter 2 and 6). Inducing hyper-
triglyceridemia via an oral lipid load in mice and healthy individuals resulted in a rapid 
reduction in blood Mg2+ levels, showing that a high fat intake diminishes blood Mg2+ 
levels (Chapter 6). As triglycerides consist of three free fatty acid (FFA) molecules, 
plasma triglycerides concentrations strongly correlate with plasma FFA levels 
(Chapter 6) (20-22). These negatively charged FFA molecules bind to Mg2+, reducing 
the free Mg2+ concentration in the blood (Chapter 6).   
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The major organs regulating the blood Mg2+ level are the intestine, bone and kidney 
(23). The data of our studies postulate that FFAs should be considered as a novel 
player in the blood Mg2+ axis. The finding that FFAs directly influence blood ionized 
Mg2+ concentrations provides new directions for the field of Mg2+ research and 
proposes novel potential mechanisms for hypomagnesemia observed in conditions 
such as asthma, critical illness and alcohol addiction (24-28). Activation of lipolysis in 
white adipose tissue (WAT) is regulated primarily by the β3-adrenergic receptor (29). 
Several factors that affect FFA levels also influence blood Mg2+ concentrations (Table 1). 
For instance, β-adrenergic agonists are associated with reduced blood Mg2+ 
concentrations (24, 30-32) (Chapter 2). Certain β-adrenergic agonists, such as 
isoproterenol and salbutamol, are commonly subscribed to asthma patients, and 
interestingly, hypomagnesemia is frequently observed in asthma patients (24, 45-47). 
One of the factors contributing to the reduction in serum Mg2+ levels in asthma 
patients is the use of β-adrenergic agonists (48). Moreover, in a small intervention 
study the administration of the β-adrenergic agonist terbutaline lowered blood Mg2+ 
levels, which significantly correlated with increased blood FFA levels, underlining the 
role of FFAs in β-adrenergic-agonist-induced hypomagnesemia (49). The use of 
β-adrenergic agonists may be the underlying cause of hypomagnesemia in asthma 
patients, by increasing blood FFA levels and thereby reducing the ionized Mg2+ 
concentration. The novel notion that FFAs affect Mg2+ homeostasis could contribute 
Table 1 | Interventions that cause changes in the blood FFA level induce opposite changes in 
the blood Mg2+ concentration.
Intervention Context Change 
in blood 
FFA
Change 
in blood 
Mg2+
Reference
Isoproterenol Treatment for bradycardia,  
heart block or asthma
(33)
Salbutamol Treatment for asthma or COPD (34)
Epinephrine Stress/critical illness (34-36)
Lipid load High fat meal Chapter 6
Fasting Generally performed before blood  
drawing in human studies
(37)
Ethanol Alcohol addiction or withdrawal (38-40)
Cold exposure (41-44)
Nicotinic acid 
(vitamin B3)
Blocks lipolysis and lowers  
triglyceride levels
(38)
COPD: chronic obstructive pulmonary disease
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to the etiology of hypomagnesemia in metabolic disorders, alcohol addiction, 
stress-related disorders and asthma. From these data it remains unclear if the 
FFA-Mg binding, leading to a reduced blood Mg2+ concentration, should be 
considered as a ‘pseudo-hypomagnesemia’. Is the binding merely affecting the 
spectrophotometric assay, or do the reduced ionized Mg2+ levels also have clinical 
effects and implications that are similar to a Mg2+ depletion?
 
Urinary magnesium wasting
In T2D patients of the PARELSNOER cohort over 40% of the patients displayed hyper-
magnesuria (Chapter 2), defined as a fractional excretion of Mg2+ (FEMg) >4% (50). 
Interestingly, FEMg did not differ between hypomagnesemic and normomagnesemic 
patients. Possibly, some hypermagnesuric patients were able to compensate for the 
urinary Mg2+ loss by increasing intestinal uptake or by releasing Mg2+ from storage 
compartments, such as the bone, and thereby maintaining normal plasma Mg2+ levels.
 Which mechanism can be responsible for the high FEMg in T2D patients? 
An important hypothesis for hypermagnesuria in T2D patients is glucosuria. Because 
of its osmotic effect glucose may reduce tubular Mg2+ reabsorption by preventing 
the pre-urine from being concentrated and, thereby, lowering its Mg2+ concentration 
(9, 51-53). However, when feeding mice a high fat diet (HFD) severe hypomagnesemia 
developed in the absence of glucosuria (Chapter 4). Moreover, sodium-glucose 
transporter 2 (SGLT2) inhibitors induce massive glucosuria, but lead to a moderate 
increase in serum Mg2+ levels, making it unlikely that glucosuria underlies the hyper-
magnesuria and hypomagnesemia observed in T2D patients (54, 55).
 Another potential mechanism is that insulin stimulates the Mg2+ channel, TRPM6, 
essential for Mg2+ reabsorption in the DCT (56). Therefore, insulin resistance could 
reduce Mg2+ reabsorption by TRPM6 and lead to hypermagnesuria. Colonic and 
renal mRNA expression of Trpm6 was decreased in hypomagnesemic HFD-fed mice, 
but no fecal or urinary Mg2+ wasting was observed (Chapter 4).   
  Kidney damage with associated proteinuria is present in 20-40% of T2D patients 
(57, 58). As ~30% of blood Mg2+ is bound to albumin, proteinuria is associated with 
hypomagnesemia (59). In contrast to the current paradigm, Mg2+ does not bind 
albumin directly, but via an interaction with FFAs attached to the albumin molecule 
(Chapter 6 and Figure 1). Therefore, when more FFAs are attached to an albumin 
molecule it will increase the number of bound Mg2+ ions (Figure 1). Possibly, hyper-
triglyceridemia can exacerbate the albuminuria-induced urinary Mg2+ wasting.
  The urinary Mg2+ loss is determined by calculating the fractional excretion of 
Mg2+ (FEMg) according to the formula (60):
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The factor of 0.7 is used in this formula to correct for the 30% bound Mg2+ fraction in 
physiological conditions. As the amount of Mg2+ bound to an albumin molecule is 
dependent on the number of FFAs bound to the albumin, the aforementioned 30% 
of bound Mg2+ would not be a fixed percentage, but would fluctuate depending on 
the lipid status of the individual. Moreover, an increased bound fraction of Mg2+ in 
the blood will reduce the filterable fraction, reducing the FEMg. On the other hand, 
in hypertriglyceridemic states the measured serum Mg2+ concentration will also be 
lower, resulting in a higher FEMg. The fact that triglyceride and FFA levels have a 
strong influence on the calculated FEMg could explain the equal distribution of urinary 
Mg2+ wasting between normomagnesemic and hypomagnesemic patients (61).   
The metabolic consequences of hypomagnesemia 
As ATP requires Mg2+ for its phosphoryl transfer reactions, Mg2+ is required for the 
proper functioning of over 600 enzymes (2, 23). Mg2+ deficiency has been linked to 
defects in several metabolic pathways, including glucose handling, mitochondrial 
Figure 1 | Mg2+ binds to albumin via FFAs
In the old paradigm, Mg2+ was thought to bind directly to albumin. The results from this thesis 
have elucidated that Mg2+ is bound to albumin by an interaction with FFAs. In hypertriglyceridemic 
states this will lead to a larger fraction of the blood Mg2+ to be bound to FFAs attached to the 
albumin molecules. 
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function and lipid metabolism (62-66). However, it remains unclear how reduced 
blood Mg2+ levels could contribute to the development of T2D and its associated 
complications.
Magnesium on body weight
Obesity is one of the major risk factors for the development of T2D (67). Several 
patient studies have identified a univariate inverse correlation between the blood 
Mg2+ concentration and BMI (Chapter 2) (68, 69). However, multivariate regression 
analyses revealed that this correlation is confounded by other variables, such as 
plasma triglyceride levels (Chapter 2) (70). In T2D patients, a higher dietary intake of 
Mg2+ does not affect body weight (71). In several animal studies hypomagnesemia 
resulted in a reduced body weight gain, without differences in energy expenditure or 
food intake (Chapter 3 and Table 2). However, in these animals, the hypomagnesemia 
was more severe than the mild hypomagnesemia commonly observed in T2D 
patients (Chapter 2).
The effect of magnesium on insulin sensitivity   
Insulin resistance is one of the hallmarks of T2D and strongly correlates with obesity 
(72-74). There is a discrepancy between animal and patient data regarding the role of 
Mg2+ on insulin sensitivity.   
  In humans a lower Mg2+ intake and reduced serum Mg2+ levels are correlated 
with a decreased insulin sensitivity (6, 75, 76). In a population study, lower serum 
Mg2+ levels increased the risk of developing T2D, which was mediated for 29% 
through insulin resistance (76). However, the effect of oral Mg2+ supplementation on 
insulin sensitivity in subjects with the metabolic syndrome or T2D has provided 
conflicting results (Table 2 in Chapter 1). 
 Animal and in vitro studies have unraveled that Mg2+ is essential for the tyro-
sine-kinase activity of the insulin receptor (79, 85-87). Mg2+ is thus required for insu-
lin-stimulated glucose uptake, whereas it does not affect basal glycolysis (88). In 
contrast, different animal models of Mg2+ deficiency have shown improvements on 
whole-body insulin sensitivity (Table 2). As Mg2+ also affected the body weight of 
these animals, it is difficult to determine whether the effects of Mg2+ on insulin 
sensitivity are a direct effect, or merely mediated by differences in body weight. This 
finding makes these animal models less ideal to investigate the direct effects of Mg2+ 
deficiency on insulin sensitivity. 
Hypomagnesemia enhances β-adrenergic signaling
Depending on the tissue type, activation of β-adrenergic receptors leads to different 
downstream effects (Figure 2). In mice, Mg2+ deficiency resulted in an increase in 
β3-adrenergic receptor expression in white adipose tissue (WAT), where it induces 
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Table 2 | Animal studies that have assessed the role of Mg2+ deficiency on body weight and/
or insulin sensitivity.
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(Chapter 3)
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 Plasma glucose
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IPGTT: intraperitoneal glucose tolerance test, IPITT: intraperitoneal insulin tolerance test, IVGTT: intravenous 
glucose tolerance test, IVITT: intravenous insulin tolerance test, OGTT: oral glucose tolerance test, OSTT: oral 
sucrose tolerance test, pIR: insulin receptor phosphorylation, pIRS: insulin receptor substrate phosphorylation.
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lipolysis (Chapter 3). In these hypomagnesemic mice the downstream effects of 
enhanced β3-adrenergic receptor signaling were also elevated, including lipolysis, 
brown adipose tissue activity, body temperature and gluconeogenesis (Chapter 3 
and 4). In this animal study it was not investigated whether the effects of Mg2+ were 
specific to the β3-adrenergic receptors, or if the β1 and β2 receptors were also 
affected. However, other studies indicated that Mg2+ suppresses β-adrenergic 
signaling in general, both in vitro and in vivo (89-91). In the heart, Mg2+ suppressed 
the β1-adrenergic receptor by inhibiting the Cav1.2 channel, thereby reducing the 
L-type Ca2+ current (91). In rats lower blood Mg2+ levels enhanced the effects of 
epinephrine on heart rate and cardiac output, which was mediated by the 
β1-adrenergic receptor (92). 
Figure 2 | Downstream effects of the activation of β-adrenergic receptors in different tissues 
In white adipose tissue, the β3R is dominant, whereas in kidney and heart the β1R is dominant. 
βnR: βn-adrenergic receptor.
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Besides suppressing β-adrenergic signaling, Mg2+ also reduced epinephrine secretion 
by blocking Ca2+ channels, and Mg2+ infusion in patients inhibited catecholamine 
release (93-95). Interestingly, supplying Mg2+ to animals before slaughter suppresses 
their stress levels (96, 97), whereas Mg2+ deficient animals have elevated serum and 
urine concentrations of catecholamines (80, 98). However, no significant differences 
in catecholamine levels were observed in our experiments (Chapter 3).   
  More mechanistic knowledge is required to understand how Mg2+ affects 
β-adrenergic receptor signaling and the secretion of catecholamines. Enhanced 
activation of the sympathetic nervous system is associated with obesity and insulin 
resistance, which are major risk factors for developing T2D (99-101). Could reduced 
blood Mg2+ levels increase the risk of T2D due to a higher activity of the sympathetic 
nervous system? 
Serum magnesium and complications of type 2 diabetes
Reduced blood Mg2+ levels in T2D patients have been associated with an increased 
prevalence of comorbidities, including diabetic nephropathy, retinopathy, neuropathy 
and micro- and macrovascular disease, (69, 102-104). It is, however, unclear whether 
the higher prevalence of T2D-related complications is a direct consequence of lower 
blood Mg2+ levels or whether they are merely mediated by increased T2D disease 
severity.  
  In T2D patients, lower serum Mg2+ levels are an independent predictor of 
increased renal function decline (105, 106). Moreover, the serum Mg2+ concentration 
has been inversely associated with albuminuria, a marker of kidney disease (104). 
Inducing hypomagnesemia in mice using a restricted Mg2+ diet resulted in 
HFD-induced renal phospholipidosis (Chapter 4). These massive accumulations 
can result in proximal tubular damage, which could be an explanation for the 
correlation between serum Mg2+ levels and renal function decline. The enzymes that 
break down charged lipids, such as phospholipases for phospholipid breakdown, 
and neutral sphingomyelinases for the hydrolysis of sphingolipids, require Mg2+ for 
their function (107-109). Mg2+ deficiency could thereby disrupt the breakdown of 
charged lipids, resulting in lysosomal accumulation. Interestingly, sphingolipid 
metabolism was also disturbed in transient receptor melastatin 6 (Trpm6) knockout 
mice, which have severe hypomagnesemia, and elevated serum and liver levels of 
sphingolipids (110). No research, either in vitro or in vivo, has yet focused on the role 
of Mg2+ in sphingolipid metabolism. 
Clinical implications 
The data presented in this thesis have further substantiated the high prevalence of 
hypomagnesemia in T2D patients. Hypomagnesemia was demonstrated to be 
intrinsic to T2D, and not merely a consequence of polypharmacy (Chapter 2). These 
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studies have expanded our knowledge on both the development and consequences 
of hypomagnesemia in T2D, which can have several important clinical implications.
  Multiple cohort studies have confirmed the importance of Mg2+ in the 
development of T2D. Increased dietary intake of Mg2+ was linked to a reduced risk of 
developing T2D in several large population-based cohort studies (111-113). 
Meta-analyses of these cohort studies demonstrated a relative risk for the 
development of T2D of 0.75-86 per increment of 100 mg/day Mg2+ intake (114-116). 
In addition, lower serum Mg2+ levels have been associated with an increased risk of 
developing T2D, with individuals in the lowest sextile of serum Mg2+ having a two-fold 
increased risk of developing T2D compared to patients in the highest sextile (117). 
Recently, a population-based study showed a hazard ratio of 1.18 for the development 
of T2D per 0.1 mmol/L decrease in serum Mg2+, which was partially attributed to 
SNPs in key magnesiotropic genes, including CNNM2 and TRPM6 (76). Interestingly, 
feeding a HFD to Mg2+-deficient mice reduced the expression of these genes 
(Chapter 4). Increasing the dietary intake of Mg2+-rich foods and correcting blood 
Mg2+ levels could reduce the incidence of T2D in the population. 
  Lowering blood lipid levels could be a novel method of improving blood ionized 
Mg2+ levels. Hypertriglyceridemia, which is a common lipid abnormality in T2D 
patients, reduced Mg2+ levels by direct binding of Mg2+ to FFA molecules (Chapter 6). 
As hypertriglyceridemia induces hypomagnesemia, Mg2+ levels should be more 
closely monitored in severely hypertriglyceridemic T2D patients. Combining Mg2+ 
supplementation with lipid-lowering medication could be a more effective strategy to 
restore blood Mg2+ levels in hypertriglyceridemic patients.
  The direct binding of Mg2+ to FFAs has implications for the calculation of the 
FEMg. The data presented in this thesis indicate that the fraction of ionized Mg2+ 
could fluctuate based on the lipid status of the patient. An increased blood FFA 
concentration could result in an erroneously calculated FEMg. Therefore, future 
clinical studies should investigate whether the lipid status of the patient has to be 
taken into consideration when calculating and interpreting the FEMg in hypertri-
glyceridemic T2D patients. Both clinicians and researchers have to be aware about 
these limitations when interpreting the FEMg in hypertriglyceridemic patients.
  The data from this thesis clearly show that hypertriglyceridemia induces 
hypomagnesemia and add FFA as a new player in Mg2+ homeostasis. This 
knowledge will open up new research directions and could explain the cause of 
hypomagnesemia in different diseases (e.g. asthma, alcohol addiction and metabolic 
disorders), which should be a major focus of further clinical investigations. Recent 
population studies have indicated an increased risk for developing T2D with 
decreasing serum Mg2+ levels; underlining the clinical necessity of maintaining 
physiological Mg2+ levels. However, the molecular mechanisms underlying this 
increased risk remain largely unknown. The results presented in this thesis identify 
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dyslipidemia as one of the potential contributing factors. Supplementing T2D patients 
with oral Mg2+ has yielded conflicting findings (Table 2 in Chapter 1). Intervention 
trials should focus on supplementing only the hypomagnesemic T2D patients, which 
could yield stronger positive effects. As the intervention studies have only been 
performed in small populations, large clinical trials are required to investigate the 
potential of Mg2+ to reduce T2D disease progression and complications. Mg2+ 
 supplementation would provide a cheap and safe treatment and prevention strategy. 
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“One of the principal functions of a friend is to suffer the punishments  
(in a milder and symbolic form) that we should like, but are unable,  
to inflict upon our enemies”
– Aldous Huxley | Brave New World
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Samenvatting
Magnesiumtekort bij diabetes mellitus type 2: oorzaak of gevolg?
Magnesium (Mg2+) is een mineraal dat essentieel is voor het functioneren van elke 
cel in het lichaam. Om een normale concentratie Mg2+ in het bloed te behouden 
werken drie organen nauw samen: de nieren, de darmen en de botten. Als er 
onvoldoende Mg2+ wordt opgenomen uit het voedsel door de darmen, of de nieren 
teveel Mg2+ verliezen via de urine, kan er een Mg2+-tekort in het lichaam ontstaan. 
Dit heet hypomagnesiëmie (Mg2+-concentratie in het bloed lager dan 0.7 mmol/L). 
De meest bekende symptomen van hypomagnesiëmie zijn spierkrampen, moeheid, 
hoofdpijn en hartritmestoornissen. Aangezien deze klachten vrij algemeen van aard 
zijn, worden de symptomen vaak niet toegeschreven aan een Mg2+-tekort. Mede 
hierdoor blijft een hypomagnesiëmie vaak onopgemerkt bij de patiënt. 
  Hypomagnesiëmie komt vaak voor bij patiënten met diabetes mellitus type 2 
(T2D), in de volksmond beter bekend als ‘ouderdomssuikerziekte’. Het is echter niet 
duidelijk wat de oorzaak hiervan is. Bovendien is het grotendeels onbekend wat de 
gevolgen van een Mg2+-tekort zijn voor het ziekteverloop en het ontstaan van comor-
biditeiten in T2D patiënten. Het doel van het onderzoek in dit proefschrift is om de 
oorzaak van hypomagnesiëmie bij patiënten met T2D op te helderen. Verder is in 
deze studies uitgezocht wat voor effecten dit Mg2+-tekort heeft op de energiehu-
ishouding en op de stofwisseling van vetten in de context van T2D. Beide aspecten 
zijn bestudeerd op het niveau van moleculen, cellen, muizen en patiënten. 
Welke factoren dragen bij aan de hypomagnesiëmie in type 2 
diabetes patiënten? 
  Om gericht vervolgonderzoek mogelijk te maken is eerst uitgezocht welke 
T2D-gerelateerde factoren bijdragen aan een verlaagde bloed Mg2+-concentratie. 
Aangezien T2D een complexe ziekte is met veel verschillende comorbiditeiten, komt 
polyfarmacie veel voor in de behandeling van T2D. Verschillende medicijnen kunnen 
de Mg2+-balans beïnvloeden en kunnen daardoor mogelijkerwijs het Mg2+-tekort in 
T2D patiënten verklaren. Om te onderzoeken welke factoren de Mg2+-balans 
beïnvloeden is in hoofdstuk 2 gebruik gemaakt van een observationeel cohort, het 
PARELSNOER cohort, bestaande uit 395 T2D patiënten met nauwkeurig beschreven 
kenmerken. Bij 31% van de patiënten werd een hypomagnesiëmie vastgesteld. 
Bovendien had meer dan 40% van de patiënten teveel Mg2+ in de urine (fractionele 
excretie van Mg2+ >4%), onafhankelijk van de concentratie van Mg2+ in het bloed.  
  Om te identificeren welke factoren bijdragen aan veranderingen in de bloed 
Mg2+-concentratie van de patiënten is gebruik gemaakt van multivariabele re-
gressieanalyses. Door middel van dit statistisch model kan worden achterhaald 
welke factoren het meest samenhangen met een verlaagde Mg2+-concentratie in het 
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bloed, en dat bleek de concentratie van glucose en triglyceriden (een soort 
vetmolecuul) in het bloed te zijn. Het gebruik van een aantal geneesmiddelen, namelijk 
metformine, een glucoseverlagend geneesmiddel bij T2D, maagzuur remmers uit 
de groep van protonpompremmers en geneesmiddelen die de β-adrenerge receptor 
stimuleren waren ook geassocieerd met een lagere bloed Mg2+-concentratie. 
De totale bijdrage van medicatie aan de hypomagnesiëmie in T2D was echter 
minimaal. Deze bevindingen tonen aan dat hypomagnesiëmie direct samenhangt 
met T2D, en dus niet verklaard kan worden door het gebruik van medicatie. 
Wat zijn de gevolgen van een magnesiumtekort?
Om te onderzoeken wat de rol van Mg2+ is in de energiehuishouding en het 
vetmetabolisme is in hoofdstuk 3 gebruik gemaakt van een muismodel representatief 
voor T2D. Muizen kregen gedurende 17 weken een dieet dat veel vet bevatte om de 
ontwikkeling van T2D na te bootsen. Het dieet werd gecombineerd met een lage of 
normale hoeveelheid Mg2+ in het voedsel om te onderzoeken wat de invloed is van 
een Mg2+-tekort op de stofwisseling en op het ontstaan van T2D. 
  De muizen op een Mg2+-beperkt dieet werden minder dik door het hoog vetdieet 
dan de muizen op een normaal Mg2+ dieet. Het lagere lichaamsgewicht ging gepaard 
met meerdere secundaire positieve aspecten, waaronder een verbeterde insuline-
gevoeligheid, verminderde leververvetting en een lager glucosegehalte van het 
bloed. De Mg2+-deficiënte muizen hadden echter een verhoogde triglyceriden-
concentratie in het bloed, dat een gevolg was van een versnelde afbraak van vet in 
het vetweefsel. De afbraak van het vetweefsel wordt voornamelijk gereguleerd door 
activatie van de β3-adrenerge receptor. De genexpressie van deze receptor was 
verhoogd in het vetweefsel van de Mg2+-deficiënte muizen op een hoog vetdieet. 
De β3-adrenerge receptor reguleert tevens de activiteit van het bruine vetweefsel, dat 
betrokken is bij de regulatie van de lichaamstemperatuur. Het bruine vet was actiever 
in de muizen, wat resulteerde in een verhoogde lichaamstemperatuur. Er was echter 
geen verschil in het energieverbruik tussen de muizen met een normale of lage 
hoeveelheid Mg2+ in het dieet.  
  Naast een verhoogde concentratie van vet in het bloed waren er ook uitgebreide 
stapelingen van vetten in de nier waarneembaar, hetgeen is beschreven in hoofdstuk 4. 
Deze vetzuurstapeling, genaamd fosfolipidose, kan een andere verklaring zijn 
waarom hypomagnesiëmie geassocieerd is met nierfalen in T2D. Deze bevindingen 
suggereren  dat T2D patiënten met een lage bloed Mg2+ waarde een extra risico 
hebben op het ontwikkelen van dyslipidemie en nierschade.
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Wat is het effect van type 2 diabetes op de magnesiumbalans?
Om het effect van T2D op de Mg2+-balans te onderzoeken zijn twee verschillende 
muismodellen gebruikt. In hoofdstuk 4 is er gebruik gemaakt van de hierboven 
beschreven muizen die een hoog vetdieet kregen. Al binnen vier weken daalde de 
bloed Mg2+-concentratie van de muizen op een hoog vet dieet. Als de bloed 
Mg2+-concentratie daalt kan de darm meer Mg2+ uit het dieet opnemen, en kan de 
nier meer Mg2+ uit de voorurine terugresorberen. Het belangrijkste kanaal voor 
gereguleerd Mg2+-(re)absorptie is Trpm6. Ondanks de hypomagnesiëmie van de 
muizen was de expressie van Trpm6 in de darm en nier niet verhoogd. Er werd echter 
geen verlies van Mg2+ waargenomen via de urine of de feces.  
  In hoofdstuk 5 is gebruik gemaakt van een genetisch muismodel voor T2D, 
de db/db muis. Ook in dit model voor T2D onwikkelden de muizen een verlaagd 
bloed Mg2+-niveau. De lagere bloed Mg2+-concentratie zorgde in de db/db muizen 
voor een compensatoire verhoging in de genexpressie van Trpm6 in zowel de darmen 
als nieren. Ook in deze muizen werd er geen groot verlies van Mg2+ in de urine 
geobserveerd, ondanks de hoge concentratie van glucose in de urine. Het behandelen 
van db/db muizen met metformine, dat geassocieerd was met lagere Mg2+-waardes 
in de T2D patiënten van het PARELSNOER cohort, had geen effect op de Mg2+-balans. 
Samenvattend laten de bevindingen zien dat hypomagnesiëmie een gevolg is van 
T2D, maar het blijft onduidelijk op welke wijze het Mg2+ exact verloren gaat.
De binding tussen magnesium en vrije vetzuren
De concentratie van triglyceriden in het bloed bepaalt voor een belangrijk deel de 
verlaagde bloed Mg2+-concentratie, zowel bij T2D patiënten (hoofdstuk 2) als bij 
mensen met overgewicht (hoofdstuk 6). In hoofdstuk 6 is aangetoond dat het 
induceren hoge vetwaardes in het bloed van muizen, door middel van een orale 
toediening van olijfolie, zorgde voor een directe daling van de concentratie Mg2+ in 
het bloed. Zodra de vetwaardes in het bloed weer daalden, herstelde de bloed 
Mg2+-concentratie weer naar het oorspronkelijke niveau. Om te laten zien dat deze 
resultaten ook relevant zijn voor mensen, hebben we de Mg2+-concentratie bepaald 
in het bloed van gezonde vrouwen die een portie slagroom hadden geconsumeerd. 
Hetzelfde fenomeen kon worden waargenomen: zodra het vetgehalte in het bloed 
steeg, daalde de concentratie Mg2+ in het bloed. In de muizen was een omgekeerd 
verband tussen de serumconcentraties van vrije vetzuren en Mg2+, hetgeen 
suggereert dat Mg2+ direct bindt aan de negatief geladen vrije vetzuren. Inderdaad, 
zodra toenemende hoeveelheden vrije vetzuren werden toegevoegd aan verschillende 
Mg2+-bevattende oplossingen, nam de concentratie vrij Mg2+ in deze oplossingen 
af. Deze resultaten maken duidelijk waarom er een negatieve correlatie bestaat 
tussen triglyceriden en Mg2+ in T2D patiënten en kunnen het vaak voorkomen van 
hypomagnesiëmie deels verklaren.
180 | Chapter 9
Perspectieven
Dit proefschrift heeft onze kennis over het ontstaan van hypomagnesiëmie, en de 
gevolgen hiervan, verbreed in de context van T2D. Het opent nieuwe wegen voor 
onderzoek naar de functie van Mg2+ in de fysiologie alsmede de pathofysiologie.  
  Analyses in het PARELSNOER cohort van T2D patiënten toonden aan dat hypo-
magnesiëmie intrinsiek is aan T2D, en niet enkel het gevolg van medicatiegebruik. 
Bij deze analyse zijn een aantal belangrijke elementen niet geïncludeerd, namelijk: 
genetische variatie, de aanwezigheid van comorbiditeiten en de hoeveelheid Mg2+ 
in het dieet. Ook zouden de bloed Mg2+-concentraties van de patiënten gemeten 
moeten worden gedurende meerdere jaren, zodat er conclusies kunnen worden 
getrokken aangaande causaliteit. Deze analyses zouden belangrijke inzichten geven 
over het ontstaan van hypomagnesiëmie, en de gevolgen hiervan op de stofwisseling, 
in T2D patiënten. 
  In dit cohort van T2D patiënten was er een sterk negatief verband tussen de 
concentratie van Mg2+ en triglyceriden in het bloed. De resultaten van dit proefschrift 
laten zien dat een Mg2+-tekort zorgt voor hoge triglyceridewaardes in muizen op een 
hoog vetdieet. Aan de andere kant leiden hoge triglyceride– en vrije vetzuurconcen-
traties ook tot een sterke verlaging van de bloed Mg2+-concentratie. Het zou 
interessant zijn om Mg2+-concentraties te meten in mensen zonder T2D maar met 
hoge triglyceridenconcentratie in het bloed, om de effecten van hoge triglyceriden op 
de Mg2+-balans te onderscheiden van insulineresistentie. Er zijn verschillende 
ziektebeelden en factoren die zorgen voor een verhoging in de vrije vetzuurconcen-
traties in het bloed, zoals overmatig alcoholgebruik, stress en medicijnen die de 
β-adrenerge receptoren stimuleren (behandeling voor astma). Een verlaagde bloed 
Mg2+-concentratie wordt vaak gezien bij de voorgenoemde factoren. De bevinding 
dat Mg2+ bindt aan vrije vetzuren zou een verklaring kunnen zijn voor de hypomag-
nesiëmie in verschillende ziektebeelden. In dit proefschrift zijn echter enkel de korte 
termijneffecten van hypertriglyceridemie op de Mg2+-concentratie bestudeerd. Of de 
binding van Mg2+ aan vrije vetzuren ook een verklaring vormt voor een chronische 
hypomagnesiëmie is in dit proefschrift niet onderzocht.
  Muizen op een Mg2+-beperkt dieet hadden een verhoogde genexpressie van de 
β3-adrenerge receptor in het vetweefsel, dat gepaard ging met een verhoogde 
vetafbraak en vetverbranding. We hebben echter niet bestudeerd of de effecten 
specifiek waren voor de β3-adrenerge receptor of dat het Mg2+-tekort ook invloed 
had op andere β-adrenerge receptoren (de β1 en β2 receptoren). In de literatuur is 
beschreven dat Mg2+ de effecten van adrenaline, een stimulator van β-adrenerge 
receptoren, onderdrukt. Het zal relevant zijn te bestuderen hoe Mg2+ het β-adrenerge 
systeem kan onderdrukken in zowel fysiologie als in verscheidene stress-gerela-
teerde omstandigheden. 
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De onderzoeken die worden beschreven in dit proefschrift laten zien dat een 
Mg2+-tekort zeer vaak voorkomt bij patiënten met T2D. In dit proefschrift zijn een 
aantal nieuwe factoren en mechanismen blootgelegd welke bijdragen aan de 
 hypomagnesiëmie in patiënten met T2D. Bovendien is duidelijk geworden dat een 
Mg2+-tekort diverse ingrijpende consequenties heeft op het metabolisme en de 
 lipidenhuishouding. Dit proefschrift benadrukt het belang van Mg2+ in de context van 
T2D.
“Yesterday I was clever, so I wanted to change the world.  
Today I am wise, so I am changing myself”
– Path of Exile | Rumi of the Vaal
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List of abbreviations 
A
ACE Angiotensin-converting enzyme
ADRB3 Adrenergic receptor beta 3
ANOVA Analysis of variance
AQP2 Aquaporin-2 
ATC Anatomic therapeutic chemical
ATGL Adipose triglyceride lipase 
ATP Adenosine triphosphate
APOA1  Apolipoprotein A1
APOB Apolipoprotein B
AUC Area under the curve
B
BAT Brown adipose tissue
BMI Body mass index
BSA Bovine serum albumin
C
Ca2+ Calcium ion 
CCD Central commission for animal experiments
cDNA  Complementary DNA
CKD Chronic kidney disease 
CLDN Claudin
CNNM2 Cyclin M2
CNNM4 Cyclin M4
CNT Connecting tubule
CPT1-L Carnitine palmitoyltransferase liver type
CPT1-M Carnitine palmitoyltransferase muscle type
D
DBP Diastolic blood pressure  
DCT  Distal convoluted tubule  
DKD Diabetic kidney disease
DMEM Dulbecco’s modified eagle’s medium
DNA Deoxyribonucleic acid   
E
EDTA Ethylene diamine tetraacetic acid 
EGF Epidermal growth factor
eGFR Estimated glomerular filtration rate
EGTA Ethylene glycol tetraacetic acid 
EL-VLDL Extra large VLDL
EM Electron microscopy 
ESRD End stage renal disease 
eWAT Epididymal white adipose tissue
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F
FABP1 Fatty acid binding protein 1
FBS Fetal bovine serum
FEMg Fractional excretion of magnesium
FA Fatty acid
FFA Free fatty acid
FF-BSA Free fatty acid-free bovine serum albumin
FPKM Fragments per kilobase million 
G
GFP Green fluorescent protein 
GFR Glomerular filtration rate 
GLA Alpha galactidose
GTT Glucose tolerance test 
GLUT Glucose transporter
GO-term Gene ontology term
H
HbA1c Glycated hemoglobin
HDL High-density lipoprotein
H&E Haematoxylin & eosin
HFD High fat diet
HNF1B Hepatocyte nuclear factor 1 homeobox B
HPLC High-performance liquid chromatography
HR Heart rate
HSL Hormone-sensitive lipase
I
IDL Intermediate-density lipoprotein
IHC Immunohistochemistry 
IPGTT Intraperitoneal glucose tolerance test
IPITT Intraperitoneal insulin tolerance test
ITT Insulin tolerance test
iWAT Inguinal white adipose tissue
K
K+ Potassium ion
KDa Kilo Dalton
KIM1 Kidney injury molecule
KLK1 Kallikrein 1
L
LCFA Long-chain fatty acid
L-HDL Large high-density lipoprotein
L-LDL Large low-density lipoprotein
L-VLDL Large very low-density lipoprotein
LDL Low-density lipoprotein
LFD Low fat diet
LPL Lipoprotein lipase
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M
MDRD Modification of diet in renal disease
Mg2+ Magnesium ion 
MgCl2 Magnesiumchloride
M-HDL Medium high-density lipoprotein
M-LDL Medium low-density lipoprotein
M-MLV Murine leukemia virus
MQ Milli-Q water 
mRNA Messenger ribonucleic acid 
MRS2 Magnesium transporter 2
M-VLDL Medium very-low density lipoprotein
N
Na+ Sodium ion
NCC  The thiazide-sensitive NaCl cotransporter
NKCC2 Sodium-potassium-chloride cotransporter
NMR Nuclear magnetic resonance
P
PAS Periodic acid-Schiff
PCR Polymerase chain reaction
PEPCK1 Phosphoenuylpyruvate carboxykinase 1
PK-M Pyruvate kinase muscle type 
PLIN2 Perilipin 2
PPAR Peroxisome proliferator-activated receptor
PPI Proton pump inhibitor
PT Proximal tubule
PVALB Parvalbumin
PLC Phospholipase C
R
RNA Ribonucleic acid
RNA-seq Ribonucleic acid sequencing
RAAS Renin-angiotensin-aldosterone system 
RER Respiratory exchange ratio
RPM Round per minute
RT Reverse transcriptase
RT-qPCR Real time quantitative PCR 
S
SBP Systolic blood pressure
SD Standard deviation
SEM Standard error of the mean
Screa Serum creatinine
SLC12A3 Solute carrier family 12 member 3
SLC41A1 Solute carrier family 41 member 1
S-HDL Small high-density lipoprotein
S-LDL Small low-density lipoprotein
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SMg Serum magnesium
SMPD Sphingomyelin phosphodiesterase
S-VLDL Small very low-density lipoprotein
T
T2D Type 2 diabetes
TAL Thick ascending limb
TRPM Transient receptor melastatin member
U
UCP1 Uncoupling protein 1
Ucrea Urinary creatinine
UMg Urinary magnesium
V
VLDL Very low-density lipoprotein
VL-HDL Very large high-density lipoprotein
VL-VLDL Very large very low-density lipoprotein
VS-VLDL Very small very low-density lipoprotein
W
WAT White adipose tissue
WHO World health organization
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Curriculum vitae
Steef Kurstjens was born in Nijmegen, the Netherlands, 
on 10 July 1991. After graduating from high school in 2009 
at the Stedelijk Gymnasium Nijmegen, he obtained his 
bachelor in Biomedical Sciences at the Radboud 
University Nijmegen in 2013. He then started his master 
Biomedical Sciences, majoring Human Pathobiology 
with a specialization-track Infectious Diseases. Steef 
performed his first master-internship at the department 
of Physiology at the Radboudumc, in the group of Prof. 
dr. P.M.T. Deen. Here, he investigated the molecular cause of diuresis and loss of 
aquaporin-2 expression in polycystic kidney disease and nephronophthisis. His second 
master- internship was based on a new collaboration between the department of 
Pediatric Infectious Disease, Radboudumc, group of Prof. dr. P.W.M. Hermans, and 
the department of Organic Chemistry, Radboud University, group of Prof. dr. ir. J.C.M. 
van Hest. Here, he focused on setting up a novel FACS-based method to isolate 
antigen- specific B-cells. After obtaining his master-degree in 2014, he joined the 
department of Physiology, Radboudumc, as a PhD candidate under the supervision 
of Prof. dr. J.G.J. Hoenderop, Prof. dr. C.J.J. Tack, Prof. dr. R.J.M. Bindels and 
dr. J.H.F. de Baaij. In his PhD project, he investigated the causal relationship between 
hypomagnesemia and type 2 diabetes mellitus. Steef presented his findings by oral 
and poster presentations at national conferences such as the Annual Dutch Diabetes 
Research Meeting in Oosterbeek, the Netherlands, and the New Frontiers Symposia 
of the Radboudumc in Nijmegen, the Netherlands. Moreover, he was awarded a 
travel grant by the RIMLS to attend and present a poster at the PhD symposium of the 
IRB institute of Barcelona. He also received an internalization grant by the Radboud 
University to attend and give a poster and oral presentation at the Experimental 
Biology meeting in Chicago, where he was nominated for the Campbell award in the 
Endocrinology and Metabolism section. He successfully completed the PhD training 
program of the RIMLS and supervised 9 undergraduate students from Biomedical 
Sciences, Medicine and Medical Biology studies. 
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Research data management
The data obtained in this thesis are archived according to the Findable, Accessible, 
Interoperable and Reusable (FAIR) principles.1 Both the raw and processed data that 
were generated during my PhD were stored on Labguru, a digital lab book, which is 
centrally stored and backed up daily. All data on Labguru are accessible by the 
associated senior staff members (view only). Moreover, the data were directly stored 
on servers of the Radboud University, which are also backed up daily. The animal 
studies described in Chapters 3,4, 5 and 6 were approved by the animal ethics 
board of the associated universities. The human studies presented in Chapters 2 
and 5 were conducted according to the principles expressed in the Declaration of 
Helsinki. The studies were approved by the Medical Ethics Committee of the 
Radboudumc and by the Institutional Review Board of the Franciscus Gasthuis & 
Vlietland Rotterdam and the regional independent medical ethics committee of the 
Maasstad Hospital Rotterdam. The RNA-SEQ data from Chapter 3 is available 
through the public functional genomics data repository GEO (gene expression 
omnibus). Data generated in this thesis are part of published articles and its materials 
and files are available from the corresponding authors upon reasonable request. To 
ensure general accessibility of the data, all filenames, primary and secondary data 
and descriptive files used to provide the final results are documented according to 
the protocol of the department of Physiology. 
1.  Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management 
and stewardship. Sci Data 2016; 3: 160018
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PhD portfolio
Radboud Institute for Molecular Life Sciences
Name PhD student:
Steef Kurstjens
Department:
Physiology
Research School:
Radboud Institute for Molecular Life Sciences
PhD period:
01-11-2014 – 01-11-2018
Promotors:
Prof. dr. J.G.J. Hoenderop
Prof. dr. C.J.J. Tack
Co-promotor:
Dr. J.H.F. de Baaij
Year(s) ECTS
TRAINING ACTIVITIES
a)  Courses & Workshops
 -  RIMLS Graduate Course
 -  Winterschool Nierstichting
 -  Scientific Integrity course 
b)  Seminars & lectures
 -  RIMLS Radboud Research Rounds / Lecture Series
 -  RIMLS Seminars
 -  RIMLS Spotlights / Kidney Theme Meetings
 -  RIMLS Technical Forum on statistics 
 -  RIMLS Meet the expert: Seahorse
c)  (Inter)national Symposia & Congresses
 -  RIMLS Radboud New Frontiers #
 -  RIMLS PhD retreat *#
 -  Radboud Science Day *
 -  Internal Medicine Science Day *
 -  Experimental Biology Meeting *# 
 -  Annual Dutch Diabetes Research Meeting *
d)  Other
 -  Peer review scientific articles
 -  Mentor/supervising of foreign PhD student
 -  Meeting international professors
2014
2014
2015
2015-2018
2015-2018
2015-2018
2016 
2018
2014-2017
2015-2018
2015
2015 
2017 
2016-2017
2015-2018
2016
2017
2
1
1
1.4
1.5
1.9
0.1 
0.2
2
4
0.7
0.5
2
1
0.3
0.5
0.5
TEACHING ACTIVITIES
e)  Lecturing
 -  Teaching Medical course: Capita Selecta
 -  Open House University: Biomedical Sciences study
 -  Open House RIMLS
 -  Mentor first year students
 -  Teaching Biomedical Science: Gordon Syndrome
 -  Teaching Biomedical Science: learning community
 -  Teaching Biomedical Science: supervise practical
2015
2016
2016 
2018
2016-2017
2016
2017
0.5
0.2 
0.2
0.1
0.4
0.2
0.2
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TEACHING ACTIVITIES
f)   Students
 -  Supervision Marlies Fennis (Master Medicine)
 -  Supervision Frank Krewinkel (Master Medicine)
 -  Supervision Mares Voet (Master Biomedical Sciences)
 -   Supervision Nikki van Hooft (Bachelor Biomedical Sciences)
 -   Supervision Veronica Garzero (Master Biomedical Sciences)
 -   Supervision Albert Ruiz Llombart (Master Biomedical Sciences)
 -   Supervision Olivier Schäffers, Joep van Walsum  
and Myrthe Swart
 -  Supervision of ‘meet-the-PhD’ -students
2015
2016
2016-2017
2017
2017-2018
2017-2018
2016-2017
2017
2
1
2
1
2
2
1.5
2
TOTAL 35.9
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“Our envy of others devours us most of all. 
Rub your eyes and purify your heart 
- and prize above all else in the world 
those who wish you well. 
Do not hurt them or scold them, 
and never part from any of them in anger”
– Aleksandr Solzhenitsyn | The Gulag Archipelago
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Dankwoord
Na vier jaar zwoegen, met pieken en dalen, kan ik terugkijken op een geweldige 
periode. Wat maakte deze periode zo geweldig? De mensen die ik heb leren kennen, 
de vele (veeeeele) borrels en het slap geouwehoer op het lab. Met trots kijk ik terug 
op wat ik bereikt heb, maar dit was niet mogelijk zonder alle mensen die mij hebben 
geholpen en die mij hebben moeten tolereren de afgelopen jaren.
 
Eerst wil ik graag mijn promotoren Prof. Dr. Joost Hoenderop en Prof. Dr. Cees Tack, 
en co-promotor Dr. Jeroen de Baaij bedanken. Joost, ik zal je eerste mailtje, waarin 
je me vroeg om te solliciteren, nooit vergeten! Voor mij is het onbegrijpelijk hoe 
iemand zoveel energie kan hebben als jij. Van ’s ochtends vroeg (eigenlijk nog ’s 
nachts) tot ’s avonds laat ben je hard aan het werk en ren je op en neer van je kantoor 
naar het koffiezetapparaat. Met (en om) jou viel altijd te lachen! Het was erg prettig 
dat je zo’n uitgesproken vertrouwen in mij had, waardoor ik vrij was om de 
onderzoekslijn te volgen die ik wilde. Cees, het is mooi om te zien hoe jij kliniek en 
onderzoek combineert (alhoewel niet altijd volledig stressloos). Terwijl ik gefocust 
was op mijn experimentjes zorgde jij ervoor dat we het grote plaatje van het onderzoek 
bleven zien (Wat betekent dit voor de patiënt? Hoe verkopen we deze data?), daar 
heb ik veel van geleerd! Bedankt voor al je vertrouwen in mij. Jeroen, ik zou pagina’s 
vol kunnen schrijven hier! Wat kijk ik naar jou op, de manier waarop je meer dan 10 
mensen begeleidt, en nog steeds tijd weet te vinden voor je eigen onderzoek is 
onvoorstelbaar! Mijn promotie was niet half zo goed geweest zonder jouw inzet, 
brainstormsessies, hulp bij dierenexperimenten en je hulp bij het schrijven van mijn 
manuscripten. Vreemd genoeg zijn toch mijn meeste herinneringen van afgelopen 
jaren niet gerelateerd aan werk, maar aan alcohol: tot diep in de nacht in de Kluizenaar, 
in de pub in Oxford, feestjes op congressen en samen whisky’s drinken. Onze ritmes 
waren niet altijd goed op elkaar afgestemd: ik viel in slaap om 10 uur op vrijdagavond 
in de kroeg en jij kon doordeweeks je bed niet uitkomen voor onze werkbespreking. 
Dank voor deze mooie tijd, en ik hoop dat we nog langer met elkaar kunnen 
samenwerken! René, de manier waarop je de afdeling Fysiologie runt is echt 
geweldig! Je hecht veel waarde aan een goede sfeer en je organiseert dus allerlei 
gezellige evenementen voor de afdeling. Het is wonderbaarlijk hoeveel taken jij op je 
bordje krijgt: de hele dag ren je van meeting naar meeting. Op de een of andere 
manier (waarschijnlijk door je waanzinnig goede gestructureerde manier van werken 
waar ik nog veel van kan leren) weet je daar nog alle werkbesprekingen en de rest 
van je onderzoekstaken in te combineren. 
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Collaborations with external research groups have been of great benefit for my work 
in the last few years. I am grateful to everyone who was involved in, and contributed 
to, my research.
Prof. Dr. Frances Ashcroft, thank you for your interest and involvement in my PhD 
project! It has been wonderful to work together with you during these past few years. 
I had a great time visiting your lab, sharing my data and having scientific discussions. 
Also many thanks to the people from your lab that helped me both with practical work 
and scientific input: Raúl Terron Exposito, Maria Rohm and Melissa Brereton. Also 
thanks to your collaboration with Heather Cater from the Harwell Institute, who 
performed the animal experiment in chapter 3.   
Bedankt Prof. Dr. Ewout Hoorn en Brenda Kieboom voor een mooie samenwerking, 
welke vast niet de laatste gaat zijn! 
Dr. Manuel Castro Cabezas, Benjamin Burggraaf en Marijke de Vries, jullie patiënten- 
 studie was een geweldige toevoeging aan hoofdstuk 6, wat een mooi artikel in Diabetologia 
heeft opgeleverd! Hopelijk zetten we deze lijn door in de toekomst. 
Natuurlijk weet iedereen dat de afdeling Fysiologie de leukste en gezelligste afdeling 
is. Hier hebben, door de jaren heen, veel mensen hun steentje aan bijdragen.
Natuurlijk begin ik met jou Caro, oftewel Bossie, mijn paranimf. Je hebt op zowel 
praktisch gebied als persoonlijk gebied veel voor mij betekend. Mijn dierexperimenten 
waren niet mogelijk geweest zonder jouw hulp (aangezien ik zelf niet altijd even 
bekwaam was op dit vlak). We hebben samen flink wat tripjes gemaakt naar Bilthoven, 
waar de spanning soms echt te snijden was! Uren waren we aan het wachten op het 
volgende tijdspunt…een goed moment om de laatste roddels van het lab even uit te 
wisselen! Verder heb je altijd voor me klaargestaan, zonder morren luisteren naar al 
mijn gezwets. Andreas, inmiddels ben jij al Dr. Eumel, en heb je een mooie baan 
gevonden als (zoals je het zelf noemt) sales-slet. Een lange tijd ben jij mijn buurman 
geweest, wat waren wij vervelend! Uren lang maakte wij goede grappen (andere 
mensen ervoeren dit onterecht al ‘slechte grappen’) op het lab, met het nodige lawaai 
(sorry Sander en Dirk!). Ik kan op elk moment nog in de lach schieten van de vertaling 
van het woord ‘slagboom’: ‘whipped beam’. Verder was jij mijn black metal buddy 
(lees: herrie-maatje). We reizen heel Nederland af naar alle concerten, en met jou aan 
mijn zijde heb ik al mijn favoriete bands gezien: Inquisition, Slayer, Mayhem, Archgoat, 
Ruins of Beverast en nog veel meer! Wat is er nou ontspannener dan dat? Anique, 
ik zal je al je bijnamen maar besparen, anders wordt het nog twee kantjes langer, en 
van bepaalde bijnamen zouden mensen misschien enigszins vreemd opkijken… 
Wat hebben we samen veel gelachen, en wat heb ik veel om jou moeten lachen :P 
(nee Israël ligt niet in Afrika, Bob Dylan zat niet in de Beatles en de Veluwe ligt niet in 
Limburg). Frietjes eten, bier drinken, hangen op het Waalstrandje, of dat allemaal 
tegelijk. Samen lekker ontspannen na een harde dag werk! Paco, oude man! 
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Tegenwoordig kan jij perfect Nederlands, dus is het Engels niet meer nodig. Elke dag 
trotseren wij weer de kantine van het Radboud. We klagen altijd dat het eten in de 
kantine er steeds meer uit gaat zien als gevangenis-voedsel, maar toch blijven we het 
eten. Doorzetters, dat zijn we! Je hebt het grootste hart van iedereen die ik ken en je 
ziet altijd het beste in iedereen, raak deze geweldige eigenschap nooit kwijt! Mark H., 
jij hebt me ingewerkt in mijn eerste paar maanden. Door jou ben ik weer eens goed 
in de magnesium-assay gedoken :P. Klopt die precinorm nou wel? Moet er misschien 
wat parafilm om mijn buffer? Ook zal ik de BBQ bij jou thuis nooit vergeten. Deze BBQ 
bracht je op temperatuur met een soort Flammenwerfer uit de Tweede Wereldoorlog 
(zeer effectief). Hacene, a hard worker and extremely motivated. Together we worked 
on multiple manuscripts. Thanks for the nice collaboration, and good luck with 
finishing your PhD in Algeria. Jenny, inmiddels hoor jij ook al wel bij het interieur van 
het lab. Bij jou kon ik altijd terecht met mijn kleine bullshit-vraagjes, maar ook voor 
een goed gesprek. Jojanneke, ook een metgezel bij de herrie-concerten. Altijd in 
voor een biertje, of twee, of drie…Het is onvoorstelbaar om te zien hoe je omgaat met 
de klappen die je te verduren hebt gekregen afgelopen jaren. Maar nog altijd tijd voor 
een praatje, een grapje en een lach. Mama Elja, als er geen initiatief wordt genomen 
door de groep dan spring jij naar voren! In ons achterhoofd weten we allemaal: Elja, 
die regelt het wel! Een echt gezelschapsdier en groot fan van lekker eten en een 
speciaalbiertje. Op vrijdagavond ben je altijd van de partij! Chao, my partner in crime 
in the metabolism-field. You were a great company on the lab in the weekends . 
Femke, altijd recht voor zijn raap en goudeerlijk, daar houd ik wel van! En dan plots 
een supermooie, onverwachte en ongepaste grap, geweldig! Lisanne, Gompie, jij 
bent de belichaming van een groen persoon. Wat je ook wordt gevraagd, je bent 
altijd bereid om te helpen. Ook al maken we hier altijd grappen over, raak deze 
eigenschap nooit kwijt! Excuses dat ik altijd tegen je aan kwam lullen met mijn laatste 
hersenspinsels. Eric V., jouw gefocuste manier van werken is echt wonderbaarlijk en 
maakt mij zeer jaloers! Altijd leuk om met jou over politiek(e correctheid) en het 
huidige nieuws te discussiëren. Gijs, vader Gans, mijn buurman. Wij staan, niet 
onterecht, bekend als de ‘negatieve unit’. Maar hé, als je geen verwachtingen hebt, 
wordt je ook niet teleurgesteld! Houd dit vast! (sorry Jeroen). Lotte, in het begin keek 
je nog een beetje de kat uit de boom en was je wat meer op de achtergrond. Dan 
hoorde ik je wel grinniken achter je computer als ik weer met Gijs aan het bullshitten 
was. Je bent ontzettend gedreven en leert graag nieuwe dingen, dus dat komt wel 
goed met je PhD . Irene, zonder jou zou het lab figuurlijk (of misschien wel letterlijk) 
in brand staan. Als er weer eens iets op was, dan had jij altijd nog een doosje achter 
de hand, en anders was er nog wel een secret-stock, of een secret-secret stock. 
Hoeveel labs hebben zo’n luxe? Lynette, jij neemt mijn stokje over in het magnesium- 
diabetes onderzoek. Maak er wat moois van! Omar, iedereen kan wat leren van de 
manier waarop jij in het leven staat. Jij zet alles weer even in perspectief. Onze 
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gesprekken in Chicago waren erg waardevol. Ik heb ook nog nooit in mijn leven zo 
hard gelachen als om jouw ‘foutje’ bij het Experimental Biology openingsfeest. Ellen, 
jij was de aanstichter van alle gezellige avonden: spelletjesavonden, drankje in de 
kroeg, dansen in Dollars, poolen en nog veel meer leuke dingen! Mohammad, 
samen hebben we stage gelopen en we zijn daarna allebei een PhD gaan doen bij 
Fysiologie. Jouw levensverhaal is echt wonderbaarlijk, heel veel respect. Je bent bij 
Fysiologie niet alleen weggegaan met een doctoraat, maar ook heb je hier je geluk 
gevonden bij Claudia: I will never forget your first bike-trip here, I feared for my life! 
It was an honor to be the first to show you around in the lab and in Nijmegen. Sjoerd, 
Short Verkort, als ik aan jou denk dan denk ik aan je practical jokes, die nog steeds 
gebruikt worden op het lab. Je had altijd heel erg veel goede ideeën en kwam 
enthousiast brainstormen na de FLMs. Peter, jij hebt mijn enthousiasme in onderzoek, 
en specifiek nieronderzoek, aangewakkerd. Ik ken niemand die zo gedreven en 
gepassioneerd is in kennis vergaren als jij. Ik vond het altijd erg leuk om met jou 
wetenschappelijke discussies te voeren! Martijn en Dick, bedankt voor jullie 
genereuze hulp bij de statistiek van hoofdstuk 2. Vincent, jaren hebben wij samen 
tennis-competitie gespeeld. Wat een toeval dat we elkaar hier weer tegen zijn 
gekomen! Volgens mij ga jij nog een mooie carrière tegenmoet! Furthermore, I would 
like to thank all the rest who bring/brought this department to the ‘next level’ (booooo 
cheesy!): Sami, Juan, Sara, Charlotte, Daan, Eric B, Lara, Niki, Valentina, Niky, 
Margo, Kim, Rachaël, Liz, Claudia, Lauriane, Theun, Eline, Anke L., Frans, 
Marjolein, Sabina, Fareeba, Milène, Michael, Wilco, Luke, Marco, Femke van der 
H, Anke van M, Nicolai, Seng, Selma, all the people from Integrative Physiology and 
anyone that I might have forgotten!
Toen ik begon aan mijn PhD was mijn kennis over metabolisme minimaal. Gelukkig 
had ik een enthousiaste groep mensen bij interne geneeskunde die altijd klaarstond 
om me te helpen. Janna, ik was compleet achterovergeslagen van de onbaatzuchtige 
manier waarop je mij hebt geholpen toen ik nog een groentje was. Je hebt vele dagen 
opgeofferd om mij te helpen met mijn experimenten, en je bent zelfs meegekomen 
naar Bilthoven. We hebben samen flink gelachen en ik hoop je in de toekomst zeker 
nog vaker te zien. Dit proefschrift was er niet zonder jou! Hanne, wat ben jij awesome! 
Bedankt dat je me betrok bij de groep. Ik heb zoveel respect voor jouw manier van 
werken, en ik ben ontzettend jaloers op jouw geweldige thesis! Bedankt Inge, Joost 
R, Niels en Mihai, voor het gebruik van jullie patiënten-samples en de wetenschap-
pelijke discussies over de resultaten. Dit heeft ervoor gezorgd dat mijn artikel bij 
Diabetologia terecht is gekomen! Kiki en Anneke, bedankt voor jullie zeer waardevolle 
praktische bijdrage aan mijn onderzoek! Kathrin, het was erg prettig om met je 
samen te werken! Veel succes met de laatste loodjes van je eigen PhD! Xanthe, 
bedankt voor de lekkere biertjes en de fijne openhartige gesprekken, dit was erg 
Dankwoord – Acknowledgments | 205
11
waardevol voor mij! Ik heb veel goede herinneringen aan de gezellige BBQs en dia-
betes-congressen samen met Lian, Jacqueline, Rinke, Evita, Bastiaan, Anouk en 
iedereen van de interne geneeskunde groep die ik eventueel ben vergeten! 
Ik heb hulp gekregen van verscheidene mensen in het Radboudumc, wat gezorgd 
heeft voor mooie samenwerkingen tussen verschillende disciplines! Bedankt Bart en 
Henry (afdeling Pathologie) voor de discussies over het nierfenotype en de mooie 
kleuringen in hoofdstuk 4. Marieke en Huib (afdeling Celbiologie), onvoorstelbaar 
hoe behulpzaam jullie zijn! Bedankt voor alle hulp bij de kleuringen en microscopie, 
hier was ik zelf meestal niet erg handig in... Wynand (CMBI), alle analyses van de 
RNA-Seq in hoofdstuk 3 heb ik aan jou te danken! Teun (afdeling Laboratorium-
geneeskunde), bedankt voor het meten van de metabolieten in hoofdstuk 3. Jan 
(afdeling Nierziekten), dank voor je hulp bij de statistiek in hoofdstuk 2!
Laura en Connie, de verhuizing van mijn experiment naar Bilthoven was een flinke 
klus, maar door jullie is het allemaal goed gekomen! En dank aan alle CDL-mede-
werkers die mij over de jaren geholpen hebben: Karin, Tim, Maikel, Helma, Saskia, 
Janneke en Jeroen. Jullie toewijding aan de experimenten en aan het dierenwelzijn 
is bewonderingswaardig (en essentieel), top!
Of course I did not have to do all this hard work on my own. I had the pleasure to 
receive the generous and tremendous help from many students. Hopefully, I have 
been able to return this favour by educating you as much as I could! Mares, Albert, 
Marlies, Veronica, Nikki and Frank, thanks for all your effort!  
Olivier, je begon als mijn minor-student maar eindigde als vriend! Je hebt waanzinnig 
veel drive en ik ben jaloers op hoe hard je kan werken. Veel succes met je toekomstig 
onderzoek, en ga vooral door waar je mee bezig bent, dan komt het wel goed! 
Rob, Thomas, Mark, Bram, Robin en Sanne, mijn meest hechte en nerdy vrienden-
groep. Onze vakanties, wekelijke etentjes, borrels, films en bordspelletjes zijn de 
meest waardevolle momenten van mijn week. Ik kan jullie niet genoeg bedanken voor 
de leuke tijden, de steun, het begrip (als ik weer eens moe en chagrijnig was na werk) 
en alle mooie herinneringen; hopelijk volgen er nog veel meer! Ook hebben jullie 
programmaatjes geschreven die me tientallen uren werk hebben bespaard, wat is 
het handig om computernerds als vrienden te hebben ! Matthijs, mijn game-buddy 
en mede MMA (mixed martial arts) fan. Lekker in het weekend samen op de bank 
voor de TV met een biertje in de hand de laatste UFC-event kijken, dat is pas relaxen! 
Door de jaren heen ben je er voor me geweest in goede tijden en in de zwaarste 
tijden. Ik heb ook erg genoten van de wandelingetjes tijdens de koffiepauzes! Daniel 
en Caspar, we waren al vrienden tijdens de basisschool en we hebben samen heel 
206 | Chapter 11
wat mooie momenten doorgemaakt! Hopelijk komen er nog vele mooie ervaringen 
bij! Ik begrijp trouwens nog steeds niet hoe wij niet moddervet zijn geworden met de 
lading chocopinda’s, ice-tea, en yoghurtsnoepjes die wij achterover sloegen! Mick, 
wij zijn al vrienden vanaf geboorte! Stoeien, Warhammeren, knikkerbanen van Knex 
bouwen en computeren. Ik heb je op zien groeien van een jongetje tot een man die 
zijn eigen bedrijf op een zeer professionele manier heeft opgezet. Ik bewonder je 
avontuurlijke manier van leven en de manier waarop je overal vol voor gaat. Ik weet 
zeker dat je bedrijf een groot succes gaat worden! Tonke, samen ijsjes eten, naar het 
strand, ijsjes eten, picknicken, ijsjes eten, koffie drinken en ijsjes eten! Bedankt voor 
alle leuke afleidingen tijdens werktijd en veel succes met het afronden van je eigen 
PhD! Shan, ik heb je leren kennen bij de studie, en samen hebben we stage gelopen 
bij Fysiologie. Het klikte gelijk tussen ons door onze gezamenlijke interesses voor 
broodjes kroket en Starcraft 2 / Diablo 3. Ik wens je alle geluk met je vrouw Joan en 
je mooie zoontje Cayden (toekomstig onderzoeker). Julie, ik ben je dankbaarder dan 
je je ooit kan voorstellen! Ik zal onze pool-avonden en ons paintball-avontuur niet 
gauw vergeten . Je harkt nu de prijzen en beurzen links en rechts binnen, succes 
met je PhD!
Jos, Marlies en Cas, en Hanny en Ben, jullie zijn mijn 2e familie! We hebben samen 
vele vakanties gevierd en mooie landen bezocht; huisje in Frankrijk, tentje in Italië 
(of tentje onderwater) en een memorabel appartement in Griekenland. Bij jullie kan 
ik altijd terecht voor een bakje koffie of een pilsje. Ik kan jullie niet genoeg bedanken 
voor de steun die jullie ons gezin hebben gegeven in het zware 2018. Ook dank aan 
de rest van de Brakse (brakke?) Club! Mijn lieve zus Roos, wat zou ik zonder jou 
moeten? Bij jou kan ik altijd terecht. Samen spelletjes doen, puzzelen, wandelen, 
ijsjes eten en altijd een luisterend oor voor mijn gezeur. Na wat lastige jaren heb je je 
geluk gevonden bij Luuk. Wat een respect heb ik voor jou kerel! Het is echt waanzinnig 
om te zien hoe jij jezelf en Roos staande houdt als de chaos (die jullie soms wel zelf 
creëren) maximaal is. Nu is jullie grootste droom uitgekomen met de geboorte van 
de liefste baby in de wereld: Juno ! Nu kan ik mezelf met trots Ome Steef noemen! 
Pa, bijna al mijn interesses en hobby’s heb ik aan jou te danken. Bedankt dat je me 
alle deze mooie dingen hebt bijgebracht! Ook mijn interesse in wetenschap heb ik 
aan jou te danken: je gaf me als kind een microscoop, een telescoop, een scheikunde- 
setje en nog veel meer. Jouw enthousiasme voor de natuur en voor het leren van 
nieuwe dingen werkt erg aanstekelijk. Ma, of eigenlijk Paula, aangezien je nooit 
reageert op ‘ma’. Het was niet makkelijk om mij aan het (huis)werk te krijgen als tiener 
(kom nou eens achter die computer vandaan!). Je hebt me vrij gelaten in wat ik wilde 
doen, maar me ook de nodige schoppen onder de kont gegeven op de juiste momenten. 
Van jou heb ik essentiële dingen geleerd: ambitie/hard werken, verantwoordelijkheid 
en het belang van op je eigen benen kunnen staan, maar ook relaxen, gezelligheid 
Dankwoord – Acknowledgments | 207
11
(lees: bier drinken) en reizen. Het is bewonderingswaardig hoe jij met de zwaarste 
klappen in het leven om gaat, je bent echt de sterkste vrouw die ik ken! Eric, een echt 
gezelschapsdier en ras-optimist. Op elk feestje zorgde jij ervoor dat iedereen voorzien 
was van een biertje, en je brullende lach klonk overal bovenuit. Ik blijf je eeuwig 
dankbaar voor het geluk dat je mijn moeder hebt gebracht, en hoe je mijn zus en mij 
opnam als je eigen kinderen. Helaas sloeg afgelopen jaar het noodlot toe… veels te 
vroeg. Het was een eer om zo nauw betrokken te zijn in de laatste maanden. Dit heeft 
een band geschept wat me nooit meer ontnomen kan worden. Ik denk nog elke dag 
aan je, rust zacht mijn vriend.
 

